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Abstract 
 
Dengue virus (DENV) is a rapidly emerging pathogen causing an estimated 100 million 
symptomatic infections annually. The clinical spectrum of dengue disease is broad ranging 
from asymptomatic to death. Factors contributing to differential outcome of DENV disease 
are not entirely understood. However, variation in host genetics and in the immune 
response are thought to play an important role in dengue pathogenesis. In this thesis, the 
influence of host genetics and of a recently discovered unconventional T cell, called 
Mucosal Associated Invariant T (MAIT) cell, on DENV infection were investigated.  
MAIT cells are abundant in humans and recognise bacterial ligands. For the first time, 
activation of MAIT cells was observed during a human viral infection in vivo and in vitro. 
This activation was TCR independent but dependent on IL-18. Furthermore, levels of IL-18 
and MAIT cell activation correlated with disease severity in DENV infected patients. Upon 
activation, MAIT cells were able to enhance or inhibit DENV infection of various target cells 
in vitro mediated by IFN-γ. These findings suggest a possible mechanism for how MAIT 
cell activation may contribute to both antiviral defence and immunopathology during DENV 
infection.  
As high viremia is associated with disease severity, the influence of host genetic variants 
on the susceptibility of two target cells – primary human DCs and macrophages - on DENV 
infection was investigated using a systems genetics approach. In DCs and macrophages, 
expression levels of 93 and 3 genes showed strong correlations with the inter-individual 
variation in infection rates, respectively. These results may lead to the discovery of 
unknown host genomic risk factors for DENV susceptibility.  
Overall, understanding the role of MAIT cells during DENV infection as well as identifying 
new host genomic risk factors for DENV susceptibility are crucial to better understand 
dengue pathogenesis and may help generate therapeutic agents in the future. 
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I.1 Dengue Disease 
 
1.1 Dengue Virus 
 
1.1.1 History 
 
Dengue is an old disease with case studies reporting dengue-like illnesses in Philadelphia 
back in the late 18th century (Rush, 1789). During this period of time, the virus as well as 
its mosquito vector, Aedes aegypti, were slowly distributed worldwide due to the growing 
shipping industry (Gubler, 2002). However because of the slow mode of transportation, 
epidemics were still infrequent at that time. This dramatically changed in Southeast Asia 
during World War II as troop movements accelerated the spread of viruses and vectors 
between populations causing the first recorded epidemics of severe dengue in the 
Philippines and Thailand in the 1950s (Gubler, 2002).  At that time, dengue virus (DENV) 
was isolated for the first time in 1944 by two independent research groups from Japan and 
the United States (Kimura and Hotta, 1944, Sabin and Schlesinger, 1945). With the 
worldwide economic boom, population growth, modern transportation and urbanisation 
after the war, epidemics of dengue and severe dengue spread to the Pacific and the 
American tropics (Gubler, 2002). To date, dengue is the most widespread and important 
arboviral disease of humans infecting around 390 million people annually of whom 96 
million manifest clinical symptoms and require hospitalization (Bhatt et al., 2013). These 
hospitalizations result in approximately 25,000 deaths. Dengue disease has been 
documented in all continents except Antarctica. Nevertheless, it is mostly found in tropical 
and subtropical areas of the globe, with more than 100 countries reporting endemic DENV 
infection (Gubler, 2002).  
 
Aedes aegypti and Aedes albopictus are urban mosquitoes carrying DENV that can readily 
enter into the urban cycle and transmit virus to humans (Simmons et al., 2012). In the 
1900s, the first mosquito vector Aedes aegypti was identified for DENV. Aedes aegypti 
originated from Africa and adapted to the peridomestic environment in West African 
Villages prior to the slave trade (Mousson et al., 2005). The slave trade led then to the 
introduction of Aedes aegypti to the New World and the following close adaptation to 
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humans and the urban environment. The second mosquito vector of DENV is Aedes 
albopictus, located predominantly in Asian villages and cities until the Second World War 
(Simmons et al., 2012)., Due to urbanisation and increased travelling both vectors have 
spread geographically around the world.  
 
 
 
 
 
Figure 1.1 Dengue viral genome and polyprotein (adapted from Whitehead et al., 2007 
and Perera & Kuhn, 2008). (a) The viral RNA genome. (b) Membrane topology of the viral 
polyprotein. The viral RNA genome is translated as a polyprotein and processed by cellular 
and viral proteases (denoted by arrows). 
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1.1.2 Infectious agent  
 
 1.1.2a Classification 
 
DENV belongs to the Flaviviridae family within the Flavivirus genus. This genus also 
includes West Nile, Japanese encephalitis, Yellow fever and Zika virus. There are four 
antigenically related but distinct DENV serotypes (DENV1/2/3/4) circulating around the 
globe. All four serotypes share around 70% homology at the nucleotide and amino acid 
level (Urcuqui-Inchima et al., 2010). Sequencing of dengue viral RNA has further 
demonstrated subtle antigenic differences within each serotype subdividing each serotype 
into genetically distinct groups, called genotypes. Recently a proposed new serotype 
(DENV5) has been described from Malaysia, which is most closely related to DENV4 but 
follows only the sylvatic cycle (Mustafa et al., 2015).   
 
 1.1.2b Virion structure and morphology 
 
DENV is a spherical, lipid enveloped virus containing a single-stranded positive sense 
RNA. The genome is around 11 kbp including a 5’ type I cap structure (m7GpppAmG) but 
no poly-A Tail at the 3’ terminus (Urcuqui-Inchima et al., 2010). It encodes a single open 
reading frame and acts directly as mRNA for the synthesis of the viral polyprotein. The viral 
polyprotein is composed of 3 structural proteins (capsid (C), precursor membrane (prM) 
and envelope (E)) as well as 7 non-structural (NS) proteins (NS1, NS2a, NS2b, NS3, NS4a, 
NS4b and NS5) and is subsequently cleaved by host and viral enzymes (Fig. 1.1) (Perera 
and Kuhn, 2008).    
 
The dengue virion carries all 3 structural proteins. However, prior to DENV exocytosis and 
release from the host cell, prM is proteolitically cleaved under acidic conditions (pH 5.8-
6.0) to pr and the membrane (M) proteins (Perera and Kuhn, 2008, Yu et al., 2008). This 
cleavage is part of the maturation process of DENV in the trans-Golgi network (TGN) and 
is driven by a host enzyme called furin. A virion containing only M protein on the surface is 
considered as mature. However due to insufficient furin activity some viral particles might 
be partially mature or immature containing either M and/or prM proteins on the virion 
surface, respectively (Fig. 1.2). 
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The virus particle is about 50 to 60 nm in diameter depending on its maturation state. E 
and prM proteins on an immature virion form 60 trimeric spikes protruding outward from 
the virion surface. In contrast the mature virion containing only M proteins, has a smooth 
surface with 90 homodimers of E proteins (Fig. 1.2b+c) (Yu et al., 2008).   
 
 1.1.2c Viral Proteins 
 
DENV encodes 3 structural and 7 NS viral proteins (Fig. 1.1). 
 
Structural proteins 
 
 Capsid protein (C): The C protein is 12 kDa in size and covers the viral genome to 
form the nucleocapsid. It is found in the cytoplasm and nucleus of infected cells but its role 
in the nucleus is still unknown. The capsid is required for viral assembly and may also take 
part in viral replication as well as induce apoptosis (Yang et al., 2002, Urcuqui-Inchima et 
al., 2010).    
 
 Precursor Membrane (prM) or Membrane (M) protein: Depending on the maturity of 
the virus either prM (25 kDa) and/or M (8 kDa) proteins will be expressed on the virion 
surface. Translation of the viral genome will generate prM molecules which interact with 
the E proteins. This interaction is required for proper folding, assembly and secretion of E 
protein (Li et al., 2008, Urcuqui-Inchima et al., 2010). Furthermore, pr molecule caps the 
fusion loop of the E protein to prevent its fusion to the cell membrane when moving through 
the acidic compartments of the TGN. During virus release, prM is cleaved by furin 
generating M protein. Once viral particle are secreted and exposed to neutral pH, pr is 
removed from the virion (Urcuqui-Inchima et al., 2010). The function of the M protein 
remains largely unknown.   
 
 Envelope protein (E): The E protein (50 kDa) is crucial for viral attachment to the 
host cell as well as fusion of the virus to the endosomal membrane during cell entry. It is 
also a major target for neutralizing antibodies (Urcuqui-Inchima et al., 2010, Rey et al., 
1995). On a mature virion, E proteins are arranged as dimers in a head to tail format. Upon 
exposure to low pH, E dimers re-arrange to form trimers exposing the fusion loop outwards 
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(Urcuqui-Inchima et al., 2010). The E protein is composed of three domains; the central 
domain I, the dimerization domain II and the Ig-like domain III (Urcuqui-Inchima et al., 
2010). 
 
 
 
Figure 1.2 Dengue structures (adapted from Perera and Kuhn, 2008 and I-Mei Yu et al., 
2008). (a) The structure of Dengue virus while being transported through the host cell. In 
the endoplasmic reticulum (ER), a 60 prM-E trimeric virion is generated at neutral pH. 
Following transportation through the acidic TGN, prM-E is dissociated and changed to 90 
dimers that lie flat on the virion. Following furin cleavage, the mature virion is secreted into 
the extracellular milleu and the pr peptide is released from mature particle. (b) The cartoon 
shows the arrangement of prM and E on an immature and mature virion at different 
locations in its life cycle. (c) The cryo-EM reconstruction of the immature virion at neutral 
and acidic pH as well as the mature virion.  
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Non-Structural proteins 
 
 NS1 protein (46-50 kDa) is a glycosylated protein that shares a high degree of 
homology with all flavivirus NS1 proteins. During synthesis of the viral polyprotein, NS1 is 
translocated into the ER lumen where it forms hydrophobic dimers and associates with the 
membrane. Cellular NS1 plays an important role in early viral replication (Muller and Young, 
2013). Furthermore, NS1 also exists in a hexameric form which is soluble and secreted 
from the cell. Soluble NS1 (sNS1) can bind to the surface of infected and uninfected cells 
through the association with glycosaminoglycans (Muller and Young, 2013). The role of 
sNS1 is still elusive but it is thought to play a number of roles in the pathogenesis of dengue, 
including stimulation and inhibition of complement pathways as well as damage to platelets 
and endothelial cells by cross-reactive anti-NS1 antibodies (Muller and Young, 2013, 
Avirutnan et al., 2006, Cheng et al., 2009). A recent study has also observed that sNS1 
can bind to Toll-like receptor (TLR) 4 on immune cells, leading to pro-inflammatory 
cytokines and chemokines secretion, which is thought to alter the endothelial monolayer 
integrity and induce capillary leakage (Modhiran et al., 2015). Eva Harris et al. supported 
this hypothesis by demonstrating that sNS1 can directly disrupt the endothelial glycocalyx 
layer which has a key role in regulating the endothelial barrier function (Puerta-Guardo et 
al., 2016).   
 
 NS2A/B proteins (22/14 kDA) are small hydrophobic proteins that mainly play a role 
in viral replication by associating with other molecules to form a viral replication complex 
(Urcuqui-Inchima et al., 2010). In addition, NS2A is thought to have a suppressive effect 
on the Type I interferon (IFN) host response when associated with NS4A/B. NS2B is also 
a cofactor of the NS3 protein and is essential for its serine-like protease activity (Urcuqui-
Inchima et al., 2010).   
 
 NS3 protein (70 kDa) is a multifunctional protein with two distinct functional domains. 
The N terminal protease is involved in the cleavage of the polyprotein upon interaction with 
its cofactor NS2B whereas the C terminal helicase of NS3 interacts with NS5 facilitating 
viral replication and formation of the 5’ cap (Perera and Kuhn, 2008). 
 
 NS4A/B proteins (16/27 kDa) are small hydrophobic proteins which are involved in 
the viral replication process. NS4A has been suggested to play a role in the rearrangement 
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of the host cell membranes (Urcuqui-Inchima et al., 2010). Furthermore, NS4B has been 
shown to inhibit the host Type I IFN response whilst inducing pro-inflammatory mediators 
such as TNF-α, IFN-γ and CXCL10 (Munoz-Jordan et al., 2005, Chappell and Young, 
2014). 
 
 NS5 protein (103 kDa) is the largest and most conserved NS proteins across the 
flaviviruses. NS5 has two distinct functional domains with an N and C terminus involved in 
the 5’ RNA cap formation and viral replication, respectively (Perera and Kuhn, 2008, 
Urcuqui-Inchima et al., 2010).   
  
1.1.3 Life cycle of Dengue Virus  
 
DENV attaches to receptors on the surface of permissive cells to allow viral entry via 
receptor mediated endocytosis. There are mainly two types of cell receptors enabling 
DENV entry via interaction with domain III of the E protein: glycosaminoglycans (e.g. 
heparin sulfate) and lectin receptors (e.g. dendritic cell specific ICAM-3 grabbing 
nonintegrin (DC-SIGN)) (Germi et al., 2002, Tassaneetrithep et al., 2003). However, these 
receptors are only the initial step of viral entry as other receptors, such as heat shock 
proteins (HSP) 70 and 90, might also contribute in this process via the formation of receptor 
complexes and the induction of endosomal formation in macrophages and monocytes 
(Reyes-Del Valle et al., 2005). In addition, virus-antibody complexes can enter host cells 
following binding to Fc receptors (FcR) on their cell surface. This phenomenon is called 
antibody dependent enhancement (ADE) (Halstead, 2003). 
Upon clathrin-mediated entry, DENV particles are transported through the early and then 
late endosome (van der Schaar et al., 2008). At low pH, E homodimers on the virion re-
arrange to form homotrimers exposing the fusion loop outwards. The association of the 
fusion loop to the endosomal membrane provokes the release of the nucleocapsid into the 
cytoplasma (Mukhopadhyay et al., 2005).  
After uncoating, viral RNA is translated at the endoplasmic reticulum (ER) membrane into 
a single polyprotein using the host translational machinery (Urcuqui-Inchima et al., 2010). 
The ER membrane bound polyprotein is then cleaved by proteases to produce structural 
and NS viral proteins. Following translation, viral NS proteins together with host factors 
form a replication complex responsible for the synthesis of negative sense RNA which 
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results in an intermediate double stranded RNA. The new synthesis of positive sense RNA 
functions as mRNA and as genomic RNA to form new virus progeny.  
Following polyprotein translation and genomic replication, assembly of the virus occurs on 
membranes derived from the ER. Capsid proteins associate with the viral genome to form 
the NC and bud into the lumen of the ER, becoming enveloped by a lipid membrane 
containing prM and E. The immature virion is subsequently transported through the TGN, 
where the prM protein is cleaved by the protease furin. To prevent premature binding of 
the E protein to the exosomal membrane, pr proteins continue to be associated with the 
virion until it is released from the cell. Mature virions are transported to the outer cell 
membrane by exocytosis and released into the extracellular medium. The life cycle of 
DENV is summarised in Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Dengue virus life cycle (Pierson and Diamond, 2014). 
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1.1.4 Clinical features of dengue disease 
 
The clinical spectrum of dengue disease is broad, ranging from asymptomatic to death. 
The disease outcome is influenced by a variety of factors including the immune status and 
age of the individual, the strain of infecting virus and the previous history of DENV 
exposure.  Most patients infected with DENV remain asymptomatic and recover without 
severe clinical presentation. Nevertheless, a small percentage of patients (~25% of infected 
individual (Bhatt et al., 2013)) will present with clinical symptoms ranging from mild febrile 
illness to severe and fatal disease due to high plasma leakage. Even though only a small 
proportion of those cases (5-30% (WHO, 2002)) will develop severe dengue, the number 
of cases of dengue and severe dengue increase every year resulting in a health, economic 
and social burden on the populations of endemic areas.     
 
 1.1.4a The course of infection 
 
Dengue disease is a systemic infection which is caused following a bite from an infected 
mosquito. The incubation period can be up to 2 weeks (commonly 5-7 days), after which 
patients will develop symptoms. Dengue illness can be divided into three phases: an initial 
febrile phase, a critical phase around the time of defervescence and a spontaneous 
recovery phase (Fig. 1.4).   
 
Febrile phase (3-7 days): Patients experience a sudden onset of high fever around 40°C 
accompanied by myalgia, headache, nausea, vomiting and joint pain. In addition the liver 
is often palpable, although rarely markedly enlarged. The predominant laboratory findings 
are leukopenia, thrombocytopenia and a mild to moderate increase of transaminase levels 
in the serum. The high fever persists for 3 to 7 days and terminates abruptly. The symptoms 
at the early stage are difficult to discriminate from other febrile diseases and are also 
identical between dengue and severe dengue.        
 
Critical phase (48-72 hours):  This phase usually occurs on day 3-7 of illness and starts 
with the fever dropping back to 37°C – called defervescence. A small proportion of patients 
will develop a systemic vascular leak syndrome due to an increase in capillary permeability 
(~15% in primary and ~30% in secondary infections (Fox et al., 2011)). An increase in 
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haematocrit, pleural effusions and ascites can also be observed as well as a progressive 
decline in platelet and white blood cell counts. In addition, haemorrhagic manifestations 
are most common during this critical period. When loss of plasma volume becomes critical, 
peripheral vascular collapse can occur, leading to shock and organ impairment, which can 
result to death (1-2.5% of cases (Back and Lundkvist, 2013)). 
 
Recovery phase: Rapid improvement occurs 24-48 hours after the critical period. The 
altered vascular permeability and abnormal haemostasis recover to normal levels and 
patients return to good health. The white blood cell and platelet count start to increase and 
recover to normal levels.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Course of Dengue infection (WHO, 2009) 
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Figure 1.5 Dengue case classification and levels of severity (WHO, 2009). 
 
1.1.4b Classification of Dengue severity 
 
In 1970s, the World Health Organisation (WHO) classified patients as having either 
undifferentiated fever, dengue fever (DF) or dengue haemorrhagic fever (DHF) (WHO, 
1997). DHF can be further divided into 4 severity grades with DHF3 and DHF4 representing 
dengue shock syndrome (DSS). However, increasing concern have been voiced regarding 
the usefulness and complexity of this system as some patients with clinically severe 
disease were categorised inappropriately. As a result in 2009 the WHO revised the 
classification of dengue disease based on the overall level of clinical severity – separating 
patients in two groups: dengue or severe dengue (WHO, 2009) (Fig. 1.5).  
 
Dengue (previously Dengue Fever) 
Patients recovering without major complications are classified as having dengue. With the 
new classification dengue is subdivided into two groups; patients with or without warning 
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signs. Criteria required for patients to be diagnosed for dengue with or without warning 
signs are indicated in Figure 1.5.  
 
  Severe dengue (previously Dengue Haemorrhagic Fever 1-4) 
Patients with dengue can progress to severe dengue if they develop any of the three broad 
categories: severe plasma leakage, severe haemorrhage or organ impairment. Any other 
criteria resulting from those complications are indicated in Figure 1.5.  
 
1.1.5 Treatment, vaccines, prevention and control 
 
1.1.5a Diagnostic test  
 
Diagnostic tools take advantage of the characteristics of the virus, the humoral immune 
response to the virus and viral replication. Diagnosis is important for surveillance support, 
clinical care and vaccine and drug development. So far, there are direct (virus isolation, 
RNA and antigen detection) and indirect methods (serological detection) to confirm dengue 
infection (WHO, 2009, Peeling et al., 2010a).  
Direct methods show the highest confidence. However, tests often take several days and 
require expensive equipment and reagents. Recently, NS1 antigen detection via ELISA 
has been developed and is a promising tool since it is rapid and relatively cheap (Roberts 
et al., 2012). However, the sensitivity and accuracy of this test are lower during a secondary 
infection most likely due to the interference of the antibody response to previous infection. 
Indirect methods, such as IgM and IgG ELISAs, are cheap and quick but are only useful at 
the end of the acute phase of illness as DENV specific antibodies are detectable 5-6 days 
after onset of fever (Roberts et al., 2012). Furthermore, the antibody response against 
DENV will depend on the number of infections that the patient has previously received. IgM 
titers are higher in the primary than in the secondary infection. The opposite can be 
observed for IgG titers. Therefore, distinguishing primary versus secondary infections can 
also be determined by these IgM and IgG ELISAs. However recent vaccination/infection 
with related flaviviruses might interfere with the diagnosis. The diagnostic tests for DENV 
infection are depicted in Figure 1.6. 
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Figure 1.6 Diagnostic tests for dengue infection (Peeling et al., 2010). 
 
1.1.5b Treatment of the disease 
 
To date, there is no specific treatment for dengue disease. Fluid replacement and 
supportive care are suggested. In addition, colloidal solutions might be used when patients 
show signs of fluid overload. Finally, blood or platelet transfusions may be required if 
patients have severe bleeding. To reduce fever, paracetamol is sufficient. However, the 
use of non-steroidal anti-inflammatory agents, such as aspirin and ibuprofen, should be 
avoided (Roberts et al., 2012).  
In the past few years, investigations in antiviral (e.g. balapiravir and celgosivir) and 
adjunctive therapies (e.g. chloroquine and corticosteroid) failed to demonstrate any 
beneficial effects on disease outcome or viremia (Yacoub et al., 2016). Furthermore, the 
use of Lovastatin which reduces fatty acids during DENV infection, inhibited viral assembly 
in vitro as well as increased the survival rate in mice in vivo. However, no beneficial impact 
on disease outcome was observed in humans (Martinez-Gutierrez et al., 2014, Whitehorn 
et al., 2016).    
 
1.1.5c Vaccines 
 
A good dengue vaccine should provide long-term protection for homo- and heterotypic 
infections, require minimal booster immunisation and be low cost.  
In 2015, the first licensed vaccine (Dengvaxia; CYD-TDV) in the world for dengue was 
authorised for use in clinical practice in two countries - Mexico and the Philippines. 
Dengvaxia was developed by Sanofi-Pasteur and is a tetravalent live attenuated vaccine 
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(Guy et al., 2010). The DENV proteins prM and E for each of the four serotypes were 
inserted into the backbone of the yellow fever virus 17D vaccine strain. A tetravalent 
mixture of all four monovalent chimeric viruses was used for clinical assessments. 
Recently, two large-scale phase III vaccine trails have been completed in Asia and Latin 
America (Capeding et al., 2014, Villar et al., 2015). The overall vaccine efficacy was 56.5% 
and 64.7% in Asian and Latin American children, respectively. However, the serotype-
specific efficacy of the vaccine for DENV2 was poor and not statistically significant with 
only 35% in the Asian study and 42.3% in Latin America. In addition, a recent long-term 
follow-up study (3 years post vaccination) of the CYD-TDV vaccine in 35,000 children 
reported an unexplained increase in hospitalization for severe dengue among children 
younger than 9 years old when compared to unvaccinated subjects (Hadinegoro et al., 
2015). These results indicate that the efficacy and safety of Dengvaxia vaccine require 
further investigation and the need to improve our understanding of the immune response 
to DENV as neutralising antibodies were detected for all four serotypes in an earlier study. 
In addition to the licensed Dengvaxia vaccine, other vaccine candidates are in the early 
phase of vaccine development and some show promising results. These vaccines include 
two live attenuated dengue vaccines from Takeda and the Butantan Institute, an inactivated 
dengue vaccine from Glaxo Smith Kline and a recombinant subunit vaccine from Merck 
(Liu et al., 2016). 
Finally several novel concepts such as the mosquito-based and DENV NS1-based 
immunisation strategies are under investigation as potential candidates for dengue 
prevention in the future (Liu et al., 2016). 
 
1.1.5d Prevention and Control 
 
Due to the fact that DENV is primarily transmitted via two day biting mosquitoes, preventing 
dengue transmission depends also on controlling those vectors. Aedes albopictus and 
aegypti are highly adapted to the urban life and breed mainly in man-made containers. 
Thus water storage containers should be emptied regularly or covered to prevent mosquito 
breeding. The use of insecticides and larvicides are used to kill adult mosquitos or larva 
but have many limitations including resistance (Luz et al., 2011).  
Recently, there are new attempts to control the vector using biologic and genetic 
approaches. For example, the introduction of intracellular bacterium Wolbachia spp. can 
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limit DENV replication in the mosquito and compete with the natural mosquito population 
(Moreira et al., 2009). First results were obtained from two field trials in Vietnam and 
Australia demonstrating a successful invasion of this bacteria into the mosquito population 
(Hoffmann et al., 2011).  
Promising results were also obtained using genetically modified sterile male mosquitoes in 
order to reduce the number of eggs (Harris et al., 2011).  
 
1.1.6 Pathogenesis of the disease 
 
Insights into the pathogenesis of severe dengue are hampered due to the lack of an 
appropriate animal model which recreates the transient vascular permeability with a 
decrease in viral load as observed in patients. However, epidemiological studies have 
observed that severe dengue occurs 80% of the time during a secondary infection with a 
heterologous serotype (Kouri et al., 1989). Mechanistically, the increased risk during a 
secondary infection is thought to be linked to a pre-existing cross-reactive adaptive immune 
response (Halstead, 2003). In addition plasma leakage, a hallmark of severe dengue, 
occurs when viremia is declined suggesting that the main force driving dengue 
pathogenesis is an aberrant immune response. However it is important to keep in mind that 
no single host or viral factor should be considered as the only mechanistic cause for severe 
dengue. Instead, an interplay between various virological and host variables will determine 
the outcome of the disease. Furthermore, as those risk factors were identified based on 
population-wide scale studies, they might not necessarily be risk factors in individual 
patients.   
 
1.1.6a Viral factors  
 
In addition to the increased risk to develop severe dengue during a secondary DENV 
infection with a heterologous serotype, epidemiological studies have also shown that some 
DENV serotypes cause more severe disease than others. DENV2 and DENV3 have been 
associated with outbreaks of severe dengue, whereas DENV1 and DENV4 are often linked 
to a more mild disease phenotype (Fried et al., 2010). Furthermore, different viral 
genotypes may also determine dengue severity. A well-established example of this has 
been the introduction of the Asian DENV2 strain in Latin America where previously the 
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more benign American DENV2 strain circulated. This was accompanied with the 
occurrence of an increase in severe cases (Rico-Hesse et al., 1997). Sequence analysis 
of these two genotypes revealed that six different amino acids were found, contributing to 
structural changes and differences in virulence (Yacoub et al., 2013). 
 
1.1.6b Host factors 
 
Genetic Factors  
A genetic component to dengue susceptibility was first indirectly suggested by Agramonte 
in 1906 when he observed that ‘Black people seem to have remarkable degree of 
resistance to dengue disease’ (Agramonte, 1906). This observation has been supported 
by epidemiological studies in Cuba and Haiti suggesting that people with African ancestry 
have reduced risk to develop severe dengue than people with European ancestry (de la et 
al., 2007). However, interpretation of these findings must be done with caution since other 
factors, such as viral genotype and vector transmission, could also be determinants of 
disease outcome.   
Genetic studies have identified a number of candidate genes associated with disease 
susceptibility. Human Leukocyte Antigens (HLAs) show great variability and some of them 
were linked to disease severity (Stephens, 2010). Furthermore, other gene variants have 
also been associated with disease severity such as FcR, vitamin D receptor, TNF-α and 
DC-SIGN (Coffey et al., 2009). Recently, a large human genome wide association study 
(GWAS) in Vietnam has identified two new distinct loci associated with DSS, MHC class I 
polypeptide-related sequence B (MICB) and phospholipase C, epsilon 1 (PLCE1) (Khor et 
al., 2011).  
Host genetic factors are important determinants of resistance or susceptibility to severe 
dengue. This will be discussed in more detail in section 1.2 of this introduction ‘Host genetic 
determinants’.  
 
Immunological Factors 
The immune response in DENV infected patients may develop in two directions – protective 
or pathogenic. Several immune mechanisms promoting dengue pathogenesis have been 
proposed. This will be discussed in more detail in section 1.3 ‘Immune responses to 
Dengue Infection’.   
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Humoral immune response: Immune enhancement of DENV infection was initially 
proposed in 1977 and was supported by epidemiological studies, observing that patients 
with secondary infections are at greater risk of developing severe dengue (Whitehorn and 
Simmons, 2011). Halstead et al. demonstrated that pre-existing cross-reactive antibodies 
elicited by a primary infection are unsuccessful at neutralising the currently infecting virus, 
but instead enhance viral entry into FcR-bearing cells through the process of ADE 
(Halstead and O'Rourke, 1977b, Halstead and O'Rourke, 1977a). In particular, cells of the 
monocyte-macrophage lineage are believed to be a major site of DENV infection under 
those conditions (Halstead et al., 1977). The resulting increase in viral replication and 
infection has been linked to disease severity, with viral loads 1-2 logs higher in patients 
with severe dengue (Vaughn et al., 2000). Most neutralising monoclonal antibodies have 
the potential to be enhancing at sub-neutralising concentrations. However, recently a 
monoclonal antibody against the structural viral protein prM (anti-prM) has been discovered 
that failed to fully neutralise the virus even at high titers (Dejnirattisai et al., 2010). In 
general, prM proteins are cleaved during the maturation process in a host cell, implying 
that anti-prM are not able to bind infectious mature virions. However partially or immature 
dengue virions which otherwise are less- or non-infectious, can be detected by anti-prM, 
resulting in ADE (Dejnirattisai et al., 2010). 
Another important component of the antibody response contributing to dengue 
pathogenesis are monoclonal antibodies against NS1 (anti-NS1). Anti-NS1 form immune 
complexes with sNS1 activating complement which has been proposed to promote 
vascular leak (Avirutnan et al., 2006). Finally, anti-NS1 can bind to the endothelium and 
platelets leading to cell damage and inflammatory activation (Lin et al., 2006). 
 
Cellular immune response: Cross-reactive T cells have been proposed to contribute to 
dengue pathogenesis during secondary infection. In general, activated CD8 T cells play an 
important role in clearing virus infection via the recognition of viral peptides presented on 
DENV infected cells. The efficiency of eradicating infected cells depends on the avidity of 
activated T cells. Interestingly, Mongkolsapaya et al. demonstrated that T cells during 
severe dengue infection have a relatively low avidity for the current infecting serotype but 
a high avidity for a past infection with a different serotype (Mongkolsapaya et al., 2003). 
Furthermore, more IFN-γ and/or TNF-α were produced by those cross-reactive memory T 
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cells. Thus, cross-reactive memory T cells might out-compete naïve T cells contributing to 
incomplete viral elimination and the production of high levels of pro-inflammatory cytokines 
leading to apoptosis and inflammation (Mongkolsapaya et al., 2003).  
 
Cytokines: It is believed that high viremia as well as the innate and adaptive immune 
response trigger expression of a wave of cytokines and other inflammatory molecules. This 
cytokine storm is thought to be responsible for the increased permeability in the vascular 
endothelium leading to plasma leakage (Whitehorn and Simmons, 2011, Basu and 
Chaturvedi, 2008, Appanna et al., 2012). Increased levels of many different cytokines have 
been observed in patients suffering from severe dengue during the acute phase of infection, 
such as IFN-γ, TNF-α and IL-10 (Chakravarti and Kumaria, 2006, Perez et al., 2004). 
Furthermore, TNF-α has been shown to promote increased endothelial permeability in vitro 
and it is plausible that an increase in this cytokine could result in a more severe disease 
course (Anderson et al., 1997).  
 
Complement: Imbalance of complement activation has been observed during DENV 
infection. Increased levels of some complement components such as C3a and C5a have 
been described in patients with severe dengue, suggesting that complement activation may 
have a role in the pathogenesis (Nascimento et al., 2009). It has been suggested that 
DENV infected endothelial cells can activate human complement in the presence of 
antibodies resulting in the membrane attack complex (MAC) formation and cell death, 
which may contribute to the vascular leakage observed in severe dengue (Avirutnan et al., 
2006). Furthermore, levels of NS1 which are secreted by infected cells positively correlate 
with disease severity and are believed to be an important modulator of the complement 
pathway. NS1 can function in immune evasion as it attenuates the classical and lectin 
pathways by interacting with C4 (Avirutnan et al., 2010). This leads to a decrease in the 
formation of MAC on infected cells and an increase in viral replication.  
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1.1.6c Other Factors 
 
Other possible risk factors for severe dengue include age, gender and comorbidities such 
as diabetes and hypertension. A retrospective study in Vietnam identified that the likelihood 
of a child less than 5 years old dying of dengue was four times higher than a child aged 
above 10 years (Anders et al., 2011). In addition, a number of cases suggested that gender 
might also be a risk factor for severe dengue and death, due to the fact that females were 
over-represented in both cases (Anders et al., 2011, Halstead et al., 1970). However, some 
authors speculated that this might only reflect a different health-seeking behaviour of males 
and females rather than the possibility that women have a higher susceptibility to capillary 
leakage. 
Two recent studies also identified an increased risk of severe dengue in people with 
diabetes and hypertension (Pang et al., 2012). The reason for this may be due to the 
underlying endothelial injury and dysfunction that already occur in these conditions. 
However further studies are required to confirm these observations.   
 
1.2 Host Genetic Determinants 
 
Most studies exploring genetic association in dengue are case-control association studies. 
A panel of single nucleotide polymorphisms (SNPs) has been identified as being 
associated with both protection and vulnerability to dengue. However the validity of many 
of these associations has yet to be tested in independent cohorts. Nevertheless, with the 
completion of sequencing for the human genome project in 2003 and the international 
HapMap project in 2005, a set of new research tools have emerged that make it possible 
to find the genetic contributions to diseases, including infectious diseases.  
 
1.2.1 Case Control Studies 
 
1.2.1a HLA genotype  
 
Due to the fact that the immune response is strongly implicated in the pathogenesis of 
dengue, many studies have investigated genes involved in its regulation. Previous studies 
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showed that the nature and magnitude of T cell responses generated by antigen-MHC 
complexes contribute to dengue pathogenesis. Therefore, polymorphism in HLA genes 
were analysed by various groups using different geographical and ethnical settings. 
Overall, some highly polymorphic HLA alleles have been proposed to have an association 
with either disease susceptibility or protection (Coffey et al., 2009). However, no single HLA 
allele has been consistently associated with dengue disease and most studies were 
compromised by small sample sizes. Nevertheless, a study conducted in Thailand showed 
various HLA class I alleles associated with disease outcome depending on the infecting 
DENV serotype (Stephens et al., 2002). For example, HLA-A*0207 and HLA-B*52 have 
been associated with more or less severe disease only in patients with secondary DENV1 
and DENV2. In contrast other HLA alleles, such as HLA-A*0203 and HLA-A*B51, were 
linked to less or more severe disease regardless of serotype. Furthermore, Stephens et al. 
also reported that various HLA-B alleles (B44, B62, B76 and B77) appeared to protect 
against severe dengue from secondary infections (Stephens et al., 2002). However, as 
mentioned above, these results should be interpreted with caution due to the lack of 
replications in independent cohorts and the use of small sample sizes.  
 
 1.2.1b Cytokines 
 
In 2004, Fernandez-Mestre et al. examined SNPs in TNF-α, IFN-γ, IL-6, TGF-β and IL-10 
for associations with disease development (Fernandez-Mestre et al., 2004). Only one 
polymorphism in the TNF-α promoter region (TNF-308) was significantly associated with 
severe dengue. An A allele at this position has been shown to be a stronger transcriptional 
activator, leading to higher TNF-α levels (Fernandez-Mestre et al., 2004). Elevated levels 
of TNF-α can be observed in plasma of patient with severe dengue and previous reports 
suggested that TNF-α contributes to vascular permeability, thus, genetic determination of 
high TNF-α levels may contribute to dengue pathogenesis (Anderson et al., 1997, 
Chakravarti and Kumaria, 2006).  
Another case control study showed an increased frequency of a polymorphism in the TGF-
β1 gene at position 509 in cases of severe dengue as compared to DF (Chen et al., 2009).  
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 1.2.1c DC-SIGN 
 
DC-SIGN is an important receptor for DENV attachment which enables the virus to enter 
host cells (Tassaneetrithep et al., 2003). The G allele in the promoter region at position 336 
was associated with protection against DF but showed no effect for DHF (Sakuntabhai et 
al., 2005). Another study in 2011 showed that this variant is associated with higher DC-
SIGN expression but lower DENV replication in DCs (Wang et al., 2011). The observation 
that the DC-SIGN variant protects DF but not DHF suggest that the two disease phenotypes 
may involve distinct pathophysiological processes with different levels of DC-SIGN 
involvement (Tassaneetrithep et al., 2003).   
 
 1.2.1d Others 
 
The vitamin D receptor is expressed on all cells of the immune system and activation of the 
receptor modulates the immune response by triggering cell mediated immunity and 
inhibiting the proliferation of lymphocytes (Baeke et al., 2010). The tt genotype of a SNP at 
position 352 of this gene was linked with protection from severe dengue (Loke et al., 2002). 
This variant has also been associated with tuberculoid leprosy, enhanced clearance of 
hepatitis B infection and resistance to pulmonary tuberculosis, supporting the role of 
enhanced cell mediated immunity in controlling DENV infection (Roy et al., 1999, Bellamy 
et al., 1999). 
ADE requires FcR to mediate entry of immune complexes into target cells. While all FcγRs 
are expressed on the cell surface of DCs, FcγRII (CD32) is the predominant molecule 
(Halstead, 2003). Loke et al. showed that homozygotes for the arginine variant at position 
131 of the FcγRII gene appeared to protect in the development of severe dengue (Loke et 
al., 2002). However, whether this association reflects reduced ADE dependent infection in 
cells has yet to be tested.    
Immune complexes have been detected on platelets in patients with severe dengue and 
evidence suggests that viral binding to platelets via human platelet antigens (HPA) may 
result in thrombocytopenia, which is observed in severe infection. A study in India showed 
that the frequency of HPA-1a and HPA-2b alleles was higher in patients with DHF 
compared to DF or controls (Soundravally and Hoti, 2007).  
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1.2.2 Genome wide association study  
 
So far the vast majority of examined polymorphisms in candidate genes was selected upon 
pre-analysis justification for an association. The limited strength of case control study 
design is illustrated by the fact that no associations have been replicated in an independent 
cohort or study, with the exception of DC-SIGN. As GWAS are becoming more accessible 
due to reduced costs and the development of high throughput sequencing, a more 
comprehensive approach to understanding the genetic factors that drive disease severity 
is possible. GWAS is an examination of a genome-wide set of genetic variants in different 
individuals to see if any SNP is associated with a trait. Recently, a human GWAS was 
performed on a large cohort of 2000 paediatric cases for DSS in Vietnam. Two new distinct 
loci were identified that associate with DSS, MICB and PLCE1 (Khor et al., 2011).  
MICB encodes an activating ligand for the NKG2D receptor present on NK cells and CD8 
T cells. Upon ligation a range of antiviral effector functions including cytokine expression 
and cytotoxic activity are induced. Thus, this SNP in MICB might induce an altered or 
dysfunctional natural killer (NK) and/or CD8 T cell activation early in the disease, allowing 
higher viral load which is associated with disease severity (Khor et al., 2011).  
Mutations in PLCE1 may play a role in the vascular endothelial dysfunction seen in DSS 
(Khor et al., 2011).   
 
1.3 Immune Responses to Dengue Infection 
 
Following viral infection, the initial response is mediated by the innate immune response 
followed by an acquired immune response, called adaptive immune response, which 
develops 4-7 days after infection.  
The innate immune response refers to a non-pathogen specific response which develops 
rapidly after the initial infection and does not require previous antigenic exposure. It is 
composed by non-specific barriers (e.g. skin), phagocytic cells, innate leukocytes (e.g. NK 
cell), complement system and cytokines (e.g. IFN). The adaptive immune response, 
comprising T and B cells, is pathogen specific and is characterised by genomic 
rearrangements in the T cell receptor (TCR) or antibody genes. This event gives rise to a 
vast repertoire of receptors that can subsequently expand following the exposure of an 
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antigen. In contrast to the innate immune response, the adaptive immune response 
develops slower but is more specific and effective.   
 
1.3.1 Innate immunity  
 
1.3.1a Phagocytic cells  
 
  Dendritic cells 
DCs are potent antigen presenting cells (APCs) and play a critical role in the induction of 
the adaptive immune response. Once infected with pathogen, DCs process and present 
antigens on their cell surface as well as migrate from peripheral tissues to secondary 
lymphoid tissues where they efficiently activate T and B cells. DCs are a heterogenous 
group of cells and based on their location, two subsets of DCs can be described – 
plasmacytoid (pDCs) and myeloid DCs. pDCs are mostly found in the blood and lymphoid 
tissues whereas myeloid DCs populate most lymphoid and non-lymphoid tissues.  
 
Following the bite of an infected mosquito, myeloid DCs in the dermis and epidermis are 
the first targets who become infected through DC-SIGN (Wu et al., 2000, Tassaneetrithep 
et al., 2003). Once infected, DCs sense viral RNA by the endosomal TLRs 3 and 7 as well 
as the cytoplasmic RNA helicases RIG-I and MDA5 (Santos Souza et al., 2016). This leads 
to the secretion of type I IFNs and other inflammatory cytokines, inducing an anti-viral 
response. In addition, DCs in response to DENV recruit other immune cells (e.g. 
unconventional T cells, NK cells, monocytes) to the site of infection (Dejnirattisai et al., 
2008). Recruited monocytes have been shown to differentiate into DCs in the dermis 
thereby increasing target cells for DENV (Schmid and Harris, 2014). Furthermore, 
unconventional T, NK and T cells become activated by infected or non-infected bystander 
DCs, creating an inflammatory environment (Dejnirattisai et al., 2008, Tsai et al., 2015, Lim 
et al., 2014, van Wilgenburg et al., 2016, Semino et al., 2005). Finally, DENV infected DCs 
migrate to secondary lymphoid organs where naïve T and B cells are primed against DENV. 
However to reduce the induction of the adaptive immune response, DENV maintain 
infected DCs in an immature state with low levels of antigen presentation and co-
stimulatory molecule expression (Dejnirattisai et al., 2008). However, an inflammatory 
environment can reverse this blockade (Dejnirattisai et al., 2008).   
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pDCs recognise DENV via TLR7 and rapidly produce high quantities of IFN-α (Sun et al., 
2009). In contrast to myeloid DCs, pDCs do not support a robust DENV infection in vitro 
and IFN-α production appears independent of active viral replication (Sun et al., 2009). 
Dreux et al. demonstrated that pDCs sense immature DENV particles as well as DENV 
infected cells by direct cell-to-cell contact, triggering higher IFN responses (Decembre et 
al., 2014). This suggests that pDCs combat DENV without being susceptible to infection or 
to immune evasion mediated by viral proteins. 
 
  Macrophages/Monocytes 
Monocytes circulate in steady-state blood, patrol lymphoid and non-lymphoid organs and 
are recruited to inflamed tissues. During inflammation, monocytes can differentiate into 
DCs and macrophages. In contrast to monocytes, macrophages reside within tissues and 
have limited ability to migrate and prime naïve T cells. However, both cells are able to 
phagocytise pathogens and infected or damaged cells as well as secrete cytokines and 
present antigens. Depending on the cell type and subset, monocytes and macrophages 
can express C-type lectin domain family 5 member A (CLEC5A), mannose receptor (MR; 
CD206) and DC-SIGN or L-SIGN; all of which are involved in DENV recognition and binding 
(Wu et al., 2013a, Santos Souza et al., 2016).  
 
Macrophages are heterogeneous throughout the body and distinct environmental 
conditions will influence macrophage polarisation. GM-CSF and M-CSF are the most 
important factors contributing to the differentiation towards either an inflammatory or a 
resting macrophage, respectively (Wu et al., 2013a). While resting macrophages are less 
susceptible to DENV infection and do not produce IL-1β and IL-18, inflammatory 
macrophages are highly sensitive to DENV infection and release high levels of TNF-α (Wu 
et al., 2013b). In addition, DENV triggers CLEC5A on inflammatory macrophages, 
activating the NLR family PYD-containing protein 3 (NLRP3) inflammasome which in turn 
releases IL-1β and IL-18 (Wu et al., 2013b). These findings suggest that inflammatory 
macrophages play a more important role than resting macrophages in the context of 
dengue pathogenesis.   
Human blood monocytes are also heterogeneous and can be divided into CD16+ and 
CD16- subsets. Both subsets are equally susceptible to DENV infection and capable of 
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producing anti-viral factors (e.g. CXCL10 and IFN-α) in vitro. Nevertheless, only CD16+ 
monocytes produce inflammatory cytokines (e.g. TNF-α) and chemokines as well as 
stimulate plasmablast differentiation (Kwissa et al., 2014, Wong et al., 2012). Interestingly, 
DENV infection of CD16- monocytes promotes CD16 upregulation (Kwissa et al., 2014). 
This is in line with human studies revealing a positive correlation between high viral load 
and percentage of CD16+ monocytes in the blood (Kwissa et al., 2014). Even though both 
monocytes subsets can potentially contribute to the anti-viral response against DENV, 
CD16+ monocytes could also influence the immune pathogenesis through inflammatory 
mechanisms.  
 
During a secondary DENV infection with a heterologous serotype, cross-reactive 
antibodies at subneutralising concentrations lead to ADE by enhancing DENV entry of FcR-
bearing cells (Halstead and O'Rourke, 1977b). The primary target cells for ADE dependent 
infection are monocytes and macrophages. Upon ADE dependent infection, a 2 to 10 fold 
increase in infection rate can be observed as well as an increase in cytokine production 
(TNF-α, IL-6 and IFN-α) and costimulatory marker expression (CD86 and CD40) (Boonnak 
et al., 2011, Sun et al., 2009).  
 
1.3.1b Innate leukocytes 
 
  NK cells 
NK cells are capable of killing virus infected cells within an hour via the release of cytotoxic 
granules. Target cells are recognised by a variety of receptors and the absence of MHC 
molecules. In addition, NK cells can kill antibody coated DENV infected cells through 
antibody dependent cell mediated cytotoxicity (ADCC) (Beltran and Lopez-Verges, 2014). 
Activation of NK cells has been reported during the acute phase of infection and activation 
correlated with disease severity (Green et al., 1999a). Further, liver cell damage during 
DENV infection in mice was associated with the infiltration of NK cells in the liver (Sung et 
al., 2012). The mechanism of NK cell activation is still not well understood. However, an in 
vitro study demonstrated a rapid activation of NK cells via the combination of type I IFN, 
TNF-α and cell surface receptor engagement with DENV infected DCs (Lim et al., 2014).   
 
41 | P a g e  
 
1.3.1c Soluble factors 
 
  Interferons 
The interferon (IFN) dependent innate immune response is necessary for protection 
against dengue infection. Type I IFNs (IFN-α/β) are rapidly produced after infection and 
induce an antiviral activity in an auto- and paracrine manner (Kurane and Ennis, 1988). 
Pre-treatment with IFN has been shown to control DENV infection in vitro (Diamond et al., 
2000). In addition, IFN receptor knock-out mice are susceptible to DENV infection in 
contrast to wild-type mice, suggesting a strong anti-viral effect of IFN in vivo (Shresta et al., 
2004). The mechanism by which IFN blocks dengue infection is thought to involve inhibition 
of the RNA replication step (Diamond and Harris, 2001). 
However, DENV has evolved mechanisms to evade this immune response through 
suppression of type I IFN signalling and production. DENV can inhibit the production of 
type I IFN via the active viral protease complex NS2B3 (consisting of the last 40 and first 
180 amino acids of NS2B and NS3, respectively), which targets a key host factor called 
STING (Aguirre et al., 2012). In addition, other viral proteins have been shown to attenuate 
IFN-mediated activation such as NS2A, NS4A, NS4B and NS5 (Jones et al., 2005). For 
example, NS5 mediates the degradation of human STAT2, which is essential for type I IFN 
signalling (Ashour et al., 2009). A restricted IFN response could enhance infection which 
might lead to disease severity.     
 
Type II IFN (IFN-γ) is mainly produced by activated T cells, NK cells and unconventional T 
cells with previous studies reporting production of IFN-γ upon interaction with DENV 
infected APCs (van Wilgenburg et al., 2016, Tsai et al., 2015, Lim et al., 2014, Kurane et 
al., 1989). The receptor for IFN-γ is highly expressed on APCs and endothelial cells. Upon 
IFN-γ stimulation, DENV infected APCs increase activation and maturation as well as 
amplify the production of cytokines (IL-12 and IL-18) and IFN-γ inducible chemokines 
(CXCL9/10/11) (Dejnirattisai et al., 2008, Libraty et al., 2001). 
The effect of IFN-γ on DENV infection in vitro is still inconclusive since both stimulatory and 
inhibitory consequences have been reported. Pre-treatment of IFN-γ inhibits infection in 
HepG2, monocytes and human foreskin fibroblasts whereas IFN-γ enhances infection in 
mononuclear cells in the presence of DENV specific antibodies (Diamond et al., 2000, 
Kontny et al., 1988). In addition, the role of IFN-γ in vivo during DENV infection is also 
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controversial with some studies showing both high and low levels of IFN-γ during severe 
dengue (Bozza et al., 2008, Priyadarshini et al., 2010, Chakravarti and Kumaria, 2006). 
This discrepancy is probably due to the timing of sample collection during the acute phase 
of infection. However, time course studies show that IFN-γ level peaks at an early time 
point and this increased level was observed in patients with severe dengue having plasma 
leakage (Libraty et al., 2002). 
 
  Nitric Oxide (NO) 
Nitric oxide (NO) is an important paracrine and autocrine signal used and produced by 
many cells. NO has a wide range of functions from dilating blood vessels, aggregation of 
platelets, fighting infections and a mediator of inflammation (Chaturvedi and Nagar, 2009). 
NO may have a dual role during DENV infection depending on the cell population involved 
in its production and on the presence of additional inflammatory mediators. Production of 
NO during DENV infection has been shown to depend on IFN-γ in vivo and in vitro 
(Fagundes et al., 2011).   
 
1.3.2 Adaptive Immunity 
 
1.3.2a T lymphocytes 
 
T cells recognise short antigenic peptides bound to the MHC class I and II molecules. As a 
result T cells become activated, proliferate, produce cytokines and kill infected target cells. 
Dengue specific T cells were first reported 20 years ago and are present during primary 
and secondary infection in humans and murine models of DENV infection (Kurane et al., 
1989, Rothman, 2011). T cell responses against DENV can be found across the whole 
virus polyprotein but the most immunodominant region resides on the NS3 protein 
(Rothman, 2011).  
 
In primary infection, T cells become activated and specifically respond towards the infecting 
DENV serotype. However, some cross-reactive T cell responses can also be identified. 
Upon activation, DENV specific T cells proliferate, produce cytokines and lyse infected 
target cells suggesting that serotype specific T cells are functional and may contribute to 
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protection in humans with primary DENV infection (Kurane et al., 1989, Gagnon et al., 
1999, Livingston et al., 1995).  
In contrast, T cell responses during a secondary infection with another serotype are highly 
cross-reactive (Rothman, 2011). These cross-reactive T cells have been shown to produce 
predominantly IFN-γ when exposed to the homologous serotype but more TNF-α when 
exposed to a heterologous serotype (Mangada and Rothman, 2005). Also, the response of 
individual DENV specific T cells upon recognition of a heterologous serotype will depend 
on its functional avidity towards the peptide, resulting in different levels of cytotoxicity and 
cytokine production (Kurane et al., 1989, Rothman, 2011, Dong et al., 2007). Recently, it 
has been proposed that during a secondary DENV infection, expansion of pre-existing 
lower avidity cross-reactive memory T cells dominate the response over that of naïve T 
cells, which have a higher avidity for the current DENV serotype (Mongkolsapaya et al., 
2003). This phenomenon is called original antigenic sin and was also observed in CD8 T 
cell responses against lymphocytic choriomeningitis virus (LCMV) (Klenerman and 
Zinkernagel, 1998). Phenotypic analysis of the cross-reactive T cell response during DENV 
infection revealed suboptimal degranulation but high cytokine production, which may 
contribute to the development of the vascular leak and increase viral load (Mongkolsapaya 
et al., 2006, Duangchinda et al., 2010). This is in line with clinical observations seen in 
patients with severe dengue, which show increased T cell activation and cytokine 
production during the course of infection (Green et al., 1999a, Chau et al., 2008).  
 
Studies in murine models of DENV infection have demonstrated that T cells contribute to 
the protection against lethal infection. This observation was accomplished either by 
adaptive transfer of T cells or by immunisation to selectively expand T cell responses in 
absence of antibodies (Yauch et al., 2009, Yauch et al., 2010, Zompi et al., 2012). 
Furthermore, a recent study examining DENV specific memory CD8 T cell responses from 
healthy individuals reported that HLA alleles associated with increased risk of severe 
dengue are linked with weak and mono-functional CD8 T cell responses (Weiskopf et al., 
2013). In contrast, a strong and multi-functional T cell response was observed in individuals 
carrying alleles associated with protection from severe disease. These data suggest a 
protective role of CD8 T cells against severe DENV disease in humans.     
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1.3.2b Antibody responses  
 
The kinetic of antibody responses to DENV infection depends on the previous history of 
DENV exposure. During a primary infection, level of IgM antibodies rise during the acute 
phase of infection (Peeling et al., 2010b). Over the next 2-3 months IgM levels fall and are 
replaced by IgG. Following a secondary infection, IgG antibodies exceed IgM production 
and rapidly rise (Peeling et al., 2010b). The role of antibodies during DENV infection has 
been demonstrated in several mechanisms such as neutralisation, ADE, ADCC and 
opsonisation.  
 
In neutralisation, antibodies interact with the viral structural E proteins, inhibiting viral entry 
and uncoating of the viral genome (Halstead, 2003). Recently, a new class of antibodies 
capable of potently neutralising all four serotypes has been discovered. These antibodies 
recognise a novel epitope which is spread across two E monomers called E dimer epitope 
(EDE) (Dejnirattisai et al., 2015). Neutralising antibodies can be long lived and are 
proposed to provide protection against re-infection with the same serotype. However, non-
neutralising antibodies, such as anti-prM, are responsible for immune enhancement of 
DENV via ADE (Dejnirattisai et al., 2010). Virions which are marked with antibodies can 
also be opsonised and killed by phagocytic cells. Furthermore, antibodies can bind on viral 
antigens exposed on DENV infected cells and mediate recruitment and killing by Fc-
receptor bearing cells via ADCC. One of the viral antigens exposed on infected cells can 
be NS1. Antibodies specific for this viral protein have been shown to trigger complement 
lysis of target cells upon binding to NS1 (Muller and Young, 2013).     
 
1.3.3 The in-betweeners: Unconventional T cells  
 
Most T cells will be reactive to complexes of peptide and MHC proteins. However, not all T 
cells fit this paradigm. These cells include CD1-restricted T cells (e.g. NKT cells), MR1-
restricted mucosal associated invariant T (MAIT) cells and γδ T cells. Collectively, these T 
cells are called ‘unconventional’ due to the fact that they do not recognise classical peptide 
antigens but rather lipids, vitamin metabolites or modified peptides. In general, 
unconventional T cells show simplified patterns of TCR receptor expression and are able 
to rapidly respond to stimulus. Furthermore, they circulate as abundant populations 
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throughout the body and have a tendency to localise in non-lymphoid tissues. Therefore, 
unconventional T cells might be one of the first cells responding towards an external stimuli. 
A comparison of unconventional and MHC-restricted T cell responses is summarized in 
Figure 1.7.    
 
 
 
 
 
Figure 1.7 Comparison of unconventional and MHC-restricted T cell responses 
(Godfrey et al., 2015). (a) A schematic of the MHC-restricted and unconventional T cell 
responses upon initial infection (left half of the graph) and reinfection (right half of the graph) 
(b) Table showing characteristics of MHC-restricted as compared to unconventional T cell 
responses. 
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1.3.3a γδ T cells 
 
γδ T cells constitute 1-10% of T cells in human and mouse peripheral blood (Godfrey et al., 
2015). Like conventional T cells, γδ T cells generate TCR heterodimers through somatic 
recombination of genes. However, the number of gene segments is much more limited than 
for αβ T cells. In healthy adults, 50-95% of γδ T cells express the Vδ2 and Vγ9 chains 
(Godfrey et al., 2015). Those γδ T cells are activated by phosphoantigen metabolites of the 
isoprenoid biosynthetic pathway, which are mainly synthesised by bacterial and protozoan 
cells but not by mammalian cells (Puan et al., 2007). Therefore, only microbial reactivity 
has been postulated for γδ T cells. It has become clear that γδ T cells also respond to viral 
infections and can influence the disease outcome via a rapid production of IFN-γ as well 
as Fas-Fas ligand and perforin/granzyme B dependent cytotoxicity against virally infected 
cells (Poccia et al., 2005). In addition to their direct antiviral properties, activation of γδ T 
cells can play a crucial immunoregulatory role for the subsequent immune response 
(Ferrick et al., 1995).  
 
The role of γδ T cells during DENV infection is still not fully understood. It was reported that 
γδ T cells become activated during the acute phase of infection (Green et al., 1999a, Tsai 
et al., 2015). Another study investigating the mechanism of γδ T cell activation in vitro, 
demonstrated a rapid cytokine-dependent activation regulated by type I IFN and IL-18 
derived from DENV infected DCs (Tsai et al., 2015). Upon activation, γδ T cells secret IFN-
γ as well as lyse autologous DENV infected DCs (Tsai et al., 2015). These data indicate 
that γδ T cells may contribute to the immune response during DENV infection by providing 
an early source of IFN-γ and reducing viral production.    
 
1.3.3b Natural Killer T cells  
 
NKT cells recognise lipid antigens presented by the CD1d molecule. Two broad types of 
NKT cells exist: type I and type II NKT cells (Diana and Lehuen, 2009). 
Type I NKT cells, also known as invariant NKT (iNKT) cells, express an invariant TCRα 
chain (Vα24 (human) or Vα14 (mice)-Jα18) and a limited range of TCRβ chains (Diana and 
Lehuen, 2009). Like unconventional T cells, iNKT cells rapidly become effector cells upon 
stimulation and produce a wide range of cytokines as well as have the potential to kill target 
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cells (Godfrey et al., 2015). iNKT cells can be activated by exogenous or endogenous lipid 
antigens (Mattner et al., 2005). The latter is dependent on TLR mediated activation of APCs 
and IL-12 secretion (Salio et al., 2007, Brigl et al., 2003). Exogenous lipids are mostly α-
linked glycolipids such as the potent agonist α-galactosylceramide (α-GalCer) (Godfrey et 
al., 2015). In addition to CD1d dependent activation, iNKT cells can be activated indirectly 
by the stimulatory cytokines IL-12 and IL-18 which are released by DCs following TLR 
signalling (Nagarajan and Kronenberg, 2007). 
Type II NKT cells are also CD1d restricted but express more diverse TCRα chain and do 
not react towards α-GalCer. However as type II NKT cells lack any defining markers, 
analysis of these cells is hampered.    
 
Even though viruses do not express glycolipids, NKT cells are nevertheless involved in 
antiviral responses, contributing to innate responses and regulating the adaptive immune 
response (Diana and Lehuen, 2009). Studies performed with NKT deficient mice have 
shown that these cells are critical for the clearance of various pathogens, such as influenza 
virus (De Santo et al., 2008). Furthermore the combination of α-GalCer with an influenza 
virus vaccine promoted an enhanced CD8 T cell memory response (Guillonneau et al., 
2009).  
A detrimental role for NKT cells has been observed during DENV infection. DENV infected 
mice lacking NKT cells were more resistant to lethal infection than wild-type mice 
(Renneson et al., 2011). This phenotype was reversed following adoptive transfer of NKT 
cells. Furthermore, activation level of NKT cells in DENV infected patients correlated with 
disease severity (Matangkasombut et al., 2014). These data suggest that NKT cells may 
play a critical role in the pathogenesis of dengue in mice and potentially in humans.    
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I.2 A Recently Discovered Unconventional T Cell: MAIT Cell 
 
2.1 Mucosal Associated Invariant T cell 
 
2.1.1 MAIT cell at a glance 
 
MAIT cells belong to the family of unconventional T cells and express a semi-invariant TCR 
comprising of a semi-invariant TCRα chain (Vα7.2 (human) or Vα19 (mice)-Jα33) with a 
limited number of TCRβ chains. In 1993, Porcelli et al. noted that a high proportion of T 
cells in human blood contain a unique TCR sequence (Vα7.2) (Porcelli et al., 1993). Six 
years later this unique TCRα rearrangement was ascribed to a new subset of T cells (Tilloy 
et al., 1999). The name MAIT cells originated because of their abundance in the gut lamina 
propria (Treiner et al., 2003). However, human MAIT cells are also very abundant in blood 
and liver, representing up to 10 and 45% of T cells, respectively (Martin et al., 2009, Tang 
et al., 2013). Furthermore, MAIT cells can also be found in human and mouse lungs, skin, 
thymus and lymph nodes (Martin et al., 2009, Rahimpour et al., 2015, Teunissen et al., 
2014, Dusseaux et al., 2011, Gold et al., 2010). In contrast to humans, MAIT cells are 
generally low in frequency in mice (Rahimpour et al., 2015).  
MAIT cells recognise vitamin metabolites presented on the MHC class I-like protein (MR1) 
(Treiner et al., 2003, Kjer-Nielsen et al., 2012). Ligands for MAIT cells are mainly derived 
from the riboflavin (vitamin B2) and folate (vitamin B9) biosynthesis pathway (Kjer-Nielsen 
et al., 2012). Due to the fact that both pathways are synthesised in microbes but not in 
viruses or mammalian cells, studies suggested that MAIT cells respond only to bacteria 
and yeast but not viruses (Gold et al., 2010, Le Bourhis et al., 2010). Upon activation, MAIT 
cells are able to rapidly produce a diverse range of cytokines such as IFN-γ, IL-2, TNF-α 
and IL-17 as well as kill infected target cells via granzyme B and perforin (Dusseaux et al., 
2011, Le Bourhis et al., 2013, Kurioka et al., 2014). The development, phenotype and 
effector activities of MAIT cells are summarised in Figure 2.1.  
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Figure 2.1 Development, phenotype, specificity and effector activities of MAIT cells. 
(adapted from Le Bourhis et al., 2013) 
 
2.1.2 MAIT cell development and phenotype  
 
 2.1.2a MAIT cell development 
 
  Thymus 
MAIT cell development is still not fully understood. Nevertheless like other T cells, MAIT 
cells depend on the thymus for their development. In the thymus, MAIT cells undergo TCR 
rearrangement through somatic recombination followed by positive selection. Using a TCR-
transgenic mouse, it has been shown that MAIT cells are selected by CD4+CD8+ double 
positive (DP) thymocytes rather than thymic epithelial cells. In humans, DP thymocytes 
also express MR1 suggesting that human MAIT cells might be selected in a similar manner. 
The nature of ligands presented on DP thymocytes remains unknown. MAIT cells might 
recognise self-ligands on DP thymocytes as demonstrated for iNKT cell (Gold et al., 2015). 
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After undergoing positive selection, MAIT cells develop in three phenotypically and 
functional distinct stages (Koay et al., 2016). MAIT cells in stage 1 and 2 are predominate 
in the thymus and are regulated by MR1. In contrast, transition through stage 3 is controlled 
by multiple factors (e.g. the TF PLZF) and generates mature functional MAIT cells. While 
stage 3 cells are rare in the thymus, they progressively increase in abundance 
extrathymically. In line with the expression of PLZF, only stage 3 MAIT cells were able to 
produce TNF-α and IFN-γ in response to PMA/Ionomycin stimulation (Koay et al., 2016).  
 
  Peripheral expansion and maturation 
One to two years after birth, MAIT cell numbers gradually increase and acquire an effector 
memory phenotype (CD45RO+, CCR7-, CD62L-, CD27+, CD28+) in peripheral blood of 
infants until adult levels are reached (Dusseaux et al., 2011). This was confirmed in another 
study, which observed a substantial expansion in the frequency of Mycobacterium 
tuberculosis-reactive MAIT cells in blood of naïve adult as compared to cord blood 
indicating that MAIT cells undergo a population expansion shortly after birth (Gold et al., 
2013).   
Initial studies in mice demonstrated that maturation and expansion of MAIT cells in the 
periphery require B cells and a commensal microflora as MAIT cells were absent in B cell 
deficient or germ free mice (Treiner et al., 2003, Le Bourhis et al., 2010). However, a recent 
study of Leeansyah et al. reported that MAIT cells in the intestine, lung and liver of human 
foetuses already expressed a memory phenotype (Leeansyah et al., 2014). These data 
suggest that MAIT cell maturation occur prior the establishment of commensal microflora 
in humans. B cells, however, also appear to be critical for MAIT cell selection and/or 
expansion in humans as MAIT cells were absent in B cell deficient patients (Treiner et al., 
2003). Thus the precise signals that drive maturation and expansion of MAIT cells in the 
periphery of humans remain unclear.    
 
 2.1.2b MAIT cell phenotype  
 
In addition to possessing an invariant TCRα chain, MAIT cells can be identified by the 
expression of a number of additional surface and transcription markers.  
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Transcription Factors 
Promyelocytic leukemia zing finger (PLZF): Peripheral human and mouse MAIT cells 
express the transcription factor (TF) PLZF, which has been associated with ‘innate’ effector 
function for iNKT cells (Martin et al., 2009, Rahimpour et al., 2015, Savage et al., 2008, 
Kovalovsky et al., 2008). The expression of PLZF in MAIT cells is in line with their naïve or 
effector memory phenotype (Leeansyah et al., 2014, Koay et al., 2016).    
 
Retinoic acid-related orphan receptor γt (RORγt): Another important TF of MAIT cells is the 
TF RORγt, which has been shown to induce IL-17 production as well as CD161 expression 
(Maggi et al., 2010, Cosmi et al., 2008, Ivanov et al., 2006).  
 
Co-receptor usage 
MAIT cells can either express CD8, CD4 or neither on their cell surface. However in 
humans the CD8 population is the most abundant comprising 90% of all MAIT cells 
(Reantragoon et al., 2013). The opposite can be observed in mice where DN MAIT cells 
represent the most abundant population (Rahimpour et al., 2015). The CD4+ MAIT cell 
population exist in both species but are rare, especially in humans. To date, the functional 
differences between CD8, CD4 or DN MAIT cells are unclear. 
 
CD161 
CD161 is a C-type lectin receptor that is expressed on NK, T cells and other unconventional 
T cells (Lanier et al., 1994, Battistini et al., 1997). The majority of NK cells express CD161, 
while on T cells CD161 expression is limited to around 25% of cells (Ussher et al., 2014b). 
Recent findings showed that T cells expressing CD161 shared a common transcriptional 
and innate-like functional profile across distinct T cell population (Fergusson et al., 2014).  
The function of CD161 on MAIT cells is not fully understood. CD161 interaction with its 
ligand lectin-like transcript (LLT1) leads to the inhibition of NK cell cytotoxicity, whereas on 
T cells, studies reported opposite findings with some showing enhancing or inhibitory 
effects on cytokine production upon CD161 crosslinking (Aldemir et al., 2005, Rosen et al., 
2005). Recently, Le Bourhis et al. reported that ligation of CD161 in the presence of TCR 
stimuli on MAIT cells inhibited cytokine production but had no effect on cytotoxicity (Le 
Bourhis et al., 2013). Again, this stands in contrast to another study demonstrating that 
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CD161 function as a co-stimulatory receptor on MAIT cells in the context of TCR stimulation 
(Fergusson et al., 2014).    
 
 
 
Figure 2.2. MAIT cell activation to bacteria infected cells. (adapted from Usher et al., 
2014) (1) Bacteria enters an APC either through infection or phagocytosis (2) Lysis of the 
bacteria within endocytic compartments releases microbial vitamin B derivatives which bind 
and stabilize MR1. (3) The stable MR1 translocates to the cell surface, where it is 
presented along with other co-stimulatory molecules (CD80 or CD86) (4) Bacterial 
components trigger TLRs. (5) TLR stimulation triggers cytokine expression (IL-12) and the 
activation of the inflammasome, resulting in the release of active-IL-18. (6) MAIT cells are 
activated either by TCR recognition of MR1 in combination with co-stimulatory receptors 
and/or by cytokines (IL-12 and IL-18). (7-9) Activated MAIT cells express pro-inflammatory 
cytokines (IFN-γ, TNF-α, and IL-17) as well as upregulate perforin and granzyme B 
expression. These cytokines can directly act anti-bacterially, or recruit and stimulate other 
immune cells. Degranulation of cytotoxic granules allows MAIT cells to kill infected cells 
(target cells), via recognition of MR1. 
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Interleukin and chemokine receptors 
Interleukin Receptors: MAIT cells express the highest level of IL-18 receptor alpha (IL-
18Rα) of all human T cells (Billerbeck et al., 2010). Recent observations demonstrated that 
levels of IL-18Rα on thymic MAIT cells are low but increase as MAIT cells egress from the 
thymus and mature in tissues and the periphery (Leeansyah et al., 2014). In addition MAIT 
cells also express the receptors for IL-7 (CD127), IL-12 and IL-23 (Gapin, 2014, Tang et 
al., 2013). 
 
Chemokine Receptors: MAIT cells express a range of chemokine receptors (CCR5, CCR6, 
CCR9 and CXCR6) that localise them to the gut but more prominently to the lungs and liver 
(Ussher et al., 2014b, Billerbeck et al., 2010). Furthermore, under inflammatory conditions 
MAIT cells also express CXCR3, which recruits cells to inflamed tissues (Jeffery et al., 
2016).   
 
2.1.3 MAIT cell activation  
 
 2.1.3a TCR dependent activation 
 
TCR dependent activation of MAIT cells requires cognate interaction between the TCR and 
MR1, which presents bacteria derived ligands. Upon TCR recognition of the antigen-MR1 
complex, MAIT cells become activated, secrete cytokines and are able to kill bacteria 
infected cells via granzyme B and perforin (Le Bourhis et al., 2010, Le Bourhis et al., 2013). 
Activation of MAIT cells following bacterial infections is represented in Figure 2.2. 
 
A semi-invariant TCR 
As mentioned above, MAIT cells express an invariant TCRα chain consisting of Vα7.2 
joined to Jα33 in humans and Vα19 joined to Jα33 in mice. The α chain is paired with a 
limited number of TCRβ chains (Vβ2 and Vβ13 in humans and Vβ6 and Vβ8 in mice) 
(Lepore et al., 2014). In addition to the typical Vα7.2-Jα33 TCRα chain, 5-15% of human 
MAIT cells express two other J segments, Jα12 and Jα20 (Lepore et al., 2014, 
Reantragoon et al., 2013).The functional relevance of these ‘alternative’ MAIT cells 
remains unknown however it is clear that different MAIT cell subsets are differentially 
represented in the tissues of individuals (Lepore et al., 2014).  
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Figure 2.3 Recognition by the MAIT TCR of vitamin metabolites presented by MR1 
molecules. (Adapted from Gapin et al., 2014 and Patel et al. 2013) (a) Comparisons of 
antigen display and docking mode by MAIT TCR–MR1–RL-6-Me-7-OH complex (left); NKT 
TCR–CD1d–lipid complex (middle) and conventional Vα7.2 TCR–MHC–peptide complex 
(right) viewed down into the antigen-binding cleft. Black-filled circles indicate the centre of 
mass for the Vα and Vβ domains (b) Chemical structures of 3 vitamin metabolites, 6-formyl 
pterin (6-FP), 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH) and reduced 6-
hydroxymethyl-8-D-ribityllumazine (RL-6-CH2OH) and their antigenic potency for MAIT cell 
activation. (c) The interaction between the MAIT TCR and MR1 molecules presenting the 
vitamin metabolites. They key role of CDR3α-encoded Tyr95 in interacting with the ribityl 
moiety found on stimulatory antigen is depicted. 
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Furthermore, the TCRα chain increases its heterogeneity via the addition of N-nucleotides 
within the Vα and Jα junctional region (Patel et al., 2013, Reantragoon et al., 2012). 
Recent studies also demonstrated a wider and more distinct range of TCRβ chain usage 
than previously thought, reflecting differences in the MAIT TCR response to different 
microbes both within and between individuals (Gold et al., 2014, Eckle et al., 2014). These 
data suggest that MAIT cells may have an adaptive capacity and could be selectively 
expanded in response to distinct microbial ligands. Thus, an individual’s MAIT TCR 
repertoire may reflect previous or ongoing microbial exposures. Furthermore, Eckle et al. 
reported differences in the binding affinity of distinct TCRs to the same MR1-antigen 
complexes as the hypervariable CDR3β loop of the TCR interacts with the antigen 
presented on MR1 (Fig. 2.3a) (Eckle et al., 2014). This interaction in combination with the 
conserved interaction of the CDR3α residue Tyr95α, allows MAIT cells to recognise 
antigens from distinct microorganism like an innate pattern recognition receptor as well as 
allowing binding variation depending on the TCRβ chain usage.   
 
MHC related Protein 1: MR1 
Human MR1 is encoded by a single gene with limited polymorphism (Riegert et al., 1998, 
Tsukamoto et al., 2013). It is closely related to the classical class I MHC, HLA-A2, as it is 
formed by the MR1 heavy chain associated to β2m. However, the antigen presenting 
groove of MR1 has a number of distinct features. The MR1 cavity is smaller, lined with 
hydrophobic and basic residues and includes two pockets. The first one, which is a small 
positively charged cavity at similar location as the A’ tunnels in CD1 molecules. The other 
pocket termed F’ is shallower and can vary in size depending on the structure of the α2 
helix of MR1 (Kjer-Nielsen et al., 2012, Napier et al., 2015). So far, only antigens located 
in the A’ pocket have been identified and whether there are other ligands potentially being 
presented in the F’ pocket is unclear.    
MR1 proteins are ubiquitously expressed in a wide variety of mammalian cells and resides 
primarily in the ER and in intracellular endocytic compartments (Riegert et al., 1998, Huang 
et al., 2008, McWilliam et al., 2016). Thus, MR1 proteins are often undetectable on the cell 
surface. To activate MAIT cells in a TCR dependent manner, MR1 has to bind ligands to 
allow presentation on the cell surface (Huang et al., 2008, McWilliam et al., 2016). This 
process is dependent on proper MR1 folding after binding to a ligand (McWilliam et al., 
2016). Recent findings demonstrated that MR1 accumulates in the ER in an incompletely 
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folded conformation and captures vitamin B related antigens, which triggers a molecular 
switch that allows the complex to traffic to the plasma membrane (McWilliam et al., 2016). 
Following endocytosis, complexes are either degraded or recycled back to the cell surface. 
Nevertheless, the precise mechanism by which antigens are processed and presented on 
MR1 remain largely unknown.   
 
Ligands recognised by MAIT cells 
Using protein chemistry and mass spectrometry, ligands for MR1 were identified being 
vitamin B metabolites namely riboflavin and folic acid derivatives (Fig. 2.3b) (Kjer-Nielsen 
et al., 2012). Riboflavin (vitamin B2) is an essential micronutrient of human diet. However, 
humans cannot synthesize riboflavin de novo. In contrast, most microbes and all plants 
produce riboflavin but the biosynthetic pathway and physiological by-products are markedly 
different between species and microbes (Gold et al., 2015). Kjer-Nielson et al. showed that 
riboflavin derivatives bind to MR1 but induce different levels of MAIT cell activation (Fig. 
2.3b+c) (Kjer-Nielsen et al., 2012). In addition, MR1 presenting the folic acid (vitamin B9) 
derivative, 6-formyl pterin, was unable to activate MAIT cells. These data indicate that 
distinct antigens can induce different levels of MAIT cell activation depending on the 
structure of the presented antigen (Fig. 2.3b+c) (Patel et al., 2013). 
To date, known MR1 ligands do not completely fill the MR1 pocket, which suggest that 
other antigens for MAIT cells may exist (Kjer-Nielsen et al., 2012, Corbett et al., 2014). 
Finally, several evidences indicate that MR1 may also be able to present endogenous 
ligands. However, they remain to be discovered (Huang et al., 2005, Huang et al., 2008).  
 
2.1.3b Cytokine dependent activation 
 
Like other unconventional T cells, such as iNKT cells, MAIT cells can respond to infection 
in a MR1 independent manner. Due to the fact that MAIT cells express high amount of IL-
18R, Usher et al. investigated the possibility of cytokine mediated activation and 
demonstrated MAIT cell activation upon IL-12 and IL-18 treatment (Billerbeck et al., 2010, 
Ussher et al., 2013). In addition, using a bacteria which lacks the riboflavin biosynthesis 
pathway, they could show a MR1 independent but IL-12 and IL-18 dependent activation of 
MAIT cells via TLR stimulation (Ussher et al., 2013). A cytokine dependent activation was 
also observed in a murine model using Mycobacterium bovis BCG, as bacterial growth in 
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macrophages was inhibited by MAIT cells in an almost entirely IL-12 dependent and MR1 
independent manner (Chua et al., 2012).  
Other studies also reported that IL-7 can synergise with TCR stimulation to enhance MAIT 
cell activation in inflamed liver as well as arm resting MAIT cells into granzyme B effector 
cells and enhance the sensitivity of MAIT cells to detect low levels of bacteria (Tang et al., 
2013, Leeansyah et al., 2015). Furthermore, IL-15 and IFN-α in combination with IL-18 
have been reported to induce production of IFN-γ in MAIT cells (Sattler et al., 2015, Spaan 
et al., 2016, van Wilgenburg et al., 2016). IL-15 also affects TCR mediated MAIT cell 
function since it dramatically amplifies cytokine and granzyme production (Sattler et al., 
2015).  
 
2.2 MAIT Cells in Clinical Diseases 
 
2.2.1 Microbial infection 
 
A role for MAIT cells in antimicrobial immunity was first described by Le Bourhis et al. and 
Gold et al. demonstrating MAIT cell activation by microbial infected cells in vitro as well as 
a protective role against bacterial infections - Mycobacterium abscessus or Escherichia coli 
(E.coli) -  in vivo (Le Bourhis et al., 2010, Gold et al., 2010).  
 
Several in vitro studies have demonstrated that MAIT cells are activated by a wide variety 
of microorganisms including several bacteria (e.g. Lactobacillus acidophilus, Klebsiella 
pneumonia, Pseudomonas aeruginosa, Staphylococcus aureus and epidermidis) and 
yeast (e.g. Saccaromyces cerivisae, Candida albicans and galbrata) (Le Bourhis et al., 
2010). Upon activation, MAIT cells secrete a range of cytokines (IFN-γ, TNF-α and IL-17A) 
and are able to kill bacteria infected cells (Kurioka et al., 2014, Le Bourhis et al., 2013). 
Furthermore, activated MAIT cells are able to inhibit bacterial growth in Mycobacterium 
bovis or Francisella infected macrophages in vitro (Chua et al., 2012, Meierovics et al., 
2013).  
In addition to in vitro studies, murine models were used to investigate the role of MAIT cells 
during Francisella, Klebsiella, E.coli or Mycobacterium bovis BCG infection (Meierovics et 
al., 2013, Georgel et al., 2011, Chua et al., 2012, Le Bourhis et al., 2010). Studies of all 
four pathogens reported an increase in bacterial load as well as a delayed bacterial 
58 | P a g e  
 
clearance in mice lacking MAIT cells compared with wild-type mice. Together these studies 
indicate that the role of MAIT cells in controlling bacterial infections is not redundant and is 
vital for efficient clearance of microbial pathogens. 
 
In humans, studies have reported only observed correlation of disease with MAIT cell 
frequencies. A lower MAIT cell frequency in patients with active tuberculosis was reported 
compared with healthy individuals (Le Bourhis et al., 2010, Gold et al., 2010, Jiang et al., 
2014). This decrease in blood MAIT cell frequency has been proposed to be driven by the 
accumulation of MAIT cells to infected sites, as observed in mycobacterial infected mice 
(Sakala et al., 2015). Decreased numbers of circulating MAIT cells have also been 
demonstrated in individuals with cystic fibrosis with development of Pseudomonas 
aeruginosa (Smith et al., 2014). In this study, the reduction of MAIT cell frequency 
correlated with the severity of the lung disease. However, the reason for the decline in 
MAIT cell numbers was not addressed.   
 
Human MAIT cells were also examined during gastrointestinal bacterial infections such as 
Helicobacter pylori, Vibrio cholera and Shigella dysenteriae-1 infections (Booth et al., 2015, 
Le Bourhis et al., 2013, Leung et al., 2014). In all three cases, MAIT cell frequencies in 
peripheral blood declined in patients compared to healthy controls. Furthermore, MAIT cell 
activation as judged by the activation markers CD38 or HLA-DR, could be detected upon 
Vibrio cholera and Shigella dysenteriae-1 infections in vivo. The impact of MAIT cell 
activation and depletion from the periphery on the disease outcome is not understood. Of 
note, Leung et al. observed a positive correlation between the MAIT cell response and the 
antibody response to Vibrio cholera lipopolysaccharide, which has been shown to be an 
important determinant of protection (Leung et al., 2014).    
 
A specific decrease in MAIT cell counts was also observed in patients with severe bacterial 
infections (Grimaldi et al., 2014). This reduction was not detected in other unconventional 
T cells, such as NKT or γδ T cells. Critically ill patients admitted to the intensive care unit 
with sepsis showed the lowest circulating levels of MAIT cells compared to healthy controls 
and non-septic critically ill individuals. Furthermore, patients with lower MAIT cell numbers 
were more susceptible to hospital acquired infections.   
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2.2.2 Autoimmune diseases 
 
Many autoimmune conditions have been studied in the context of MAIT cells. These include 
multiple sclerosis (MS), systemic lupus erythematosus (SLE), psoriasis, type I diabetes 
mellitus, inflammatory bowel disease and rheumatoid arthritis (RA) (Reantragoon et al., 
2016).  
 
Multiple sclerosis: MAIT cell TCRs were first identified in central nervous system MS lesions 
using single-strand conformation polymorphism analysis (Illes et al., 2004). Recent studies 
reported that MAIT cells infiltrate MS lesions in the brain in an IL-18 dependent manner 
which results in a reduction of MAIT cell numbers in peripheral blood of MS patients (Willing 
et al., 2014, Miyazaki et al., 2011). Using a mouse model for MS revealed a protective role 
for MAIT cells against MS through suppression of T helper 1 cytokine production and 
increased production of IL-10 by B cells (Croxford et al., 2006). Furthermore, mice lacking 
MAIT cells showed an exacerbating disease development, suggesting a new regulatory 
role for MAIT cells. Of note, the distribution of MAIT cells in peripheral blood of MS patients 
is still unclear as conflicting results have emerged from different groups (Illes et al., 2004, 
Miyazaki et al., 2011, Annibali et al., 2011).  
 
Rheumatic Diseases: In SLE and RA patients, MAIT cells were reduced in numbers and 
were functionally impaired, as they had lower IFN-γ production when challenged with 
bacteria or with phorbol 12-myristate 13-acetate and ionomycin (PMA/Iono) compared to 
healthy individuals and patients controls (Cho et al., 2014). In addition, MAIT cells in SLE 
patients expressed higher levels of the inhibitory molecule PD-1 compared to RA patients 
or healthy controls. However, MAIT cell dysfunction was not fully recovered by blockade of 
PD-1, indicating other negative regulation mechanisms may contribute to MAIT cell 
dysfunction in rheumatic diseases. Furthermore, MAIT cell deficiency correlated with 
disease activity. 
 
Psoriasis: Two studies investigated the role of MAIT cells in psoriasis lesions and 
demonstrated the presence of MAIT cells in psoriatic lesional and healthy skin (Teunissen 
et al., 2014, Li et al., 2016). Skin MAIT cells express the skin-homing marker cutaneous 
lymphocyte-associated antigen (CLA) and the α-chain (CD103) of the integrin αEβ7, which 
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is a known surface marker for lymphocytes embedded in non-lymphoid tissues. 
Furthermore Teunissen et al. showed that MAIT cells participate in the production of IL-
17A in psoriasis lesions and might therefore contribute in the pathogenesis of psoriasis 
(Teunissen et al., 2014).  
 
2.2.3 Viral infection 
 
Le Bourhis et al. reported that virally infected cells do not activate MAIT cells (Le Bourhis 
et al., 2010). Nevertheless, the fact that MAIT cells are able to become activated in a 
cytokine dependent manner, raises the question of their contribution during viral infections 
(Ussher et al., 2013). Several publications have investigated the numbers and activation 
status of MAIT cells during human immunodeficiency virus (HIV) and hepatitis B and C 
(HBV/HCV) virus infections. 
 
2.2.3a Human Immunodeficiency Virus 
 
HIV infection leads to an increase in the permeability of the intestinal epithelia which causes 
translocation of microbial products from the gastrointestinal tract resulting in a systemic 
immune activation. Due to the fact that MAIT cells are very abundant in the intestinal 
mucosa as well as react to microbial antigens, this field has been intensely studied.  
 
Several groups reported a reduction in numbers of circulating MAIT cells in patients with 
early or chronic stage HIV infection compared to healthy controls (Leeansyah et al., 2013, 
Cosgrove et al., 2013, Fernandez et al., 2014). Furthermore, the decrease of MAIT cells 
was nonreversible as anti-retroviral therapy was unable to restore MAIT cell counts 
(Cosgrove et al., 2013, Leeansyah et al., 2013). The reason for this MAIT cell depletion is 
still unclear. Cosgrove et al. suggested that depletion might be induced due to an 
enrichment of MAIT cells in tissues (Cosgrove et al., 2013). To date, accumulation of MAIT 
cells in tissues such as colon or rectal mucosa remains unobserved (Leeansyah et al., 
2013, Greathead et al., 2014, Cosgrove et al., 2013). Also, a decrease in the tissue-homing 
chemokine receptor CCR6 was reported on MAIT cells from HIV infected patients 
compared to healthy donors, suggesting that recruitment of MAIT cells to tissues might be 
impaired (Fernandez et al., 2014). These findings are in line with a recent study in simian 
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immunodeficiency virus (SIV) infected rhesus macaques which reported a systemic 
depletion of MAIT cells (Vinton et al., 2016).  
Another explanation for the loss of MAIT cells is activation-induced cell death (AICD) as 
previous work demonstrated that bacterially stimulated MAIT cells were more susceptible 
to apoptosis in vitro (Cosgrove et al., 2013). Given the amount of microbial translocation 
into the gut lamina propria in HIV infection, AICD would be a plausible explanation for MAIT 
loss (Saeidi et al., 2016). 
 
Activation and function of circulating MAIT cells in HIV were also assessed in several 
studies. MAIT cells from early and chronic HIV infected patients expressed an activation 
phenotype as judged by the expression of two activation markers CD38 and HLA-DR 
(Fernandez et al., 2014, Leeansyah et al., 2013). Even though MAIT cells were activated, 
ex vivo stimulation of PBMC from HIV infected patients resulted in reduce IFN-γ, IL-17 and 
TNF-α production in MAIT cells compared to healthy controls (Leeansyah et al., 2013, 
Cosgrove et al., 2013). Cytokine production of MAIT cells was partially restored after anti-
retroviral therapy (Leeansyah et al., 2013). However, this functional impairment of MAIT 
cells was not confirmed in a separate study (Fernandez et al., 2014). Of note, this study 
used recently infected patients (median, 4 months) whereas patients in the other two 
studies had been infected for a minimum of 2 years. Thus, functional impairment of MAIT 
cells might occur at a late stage in HIV infection. In addition, a recent study showed a crucial 
role of IL-7 in arming MAIT cell effector function and demonstrated its defect in HIV infected 
patients, supporting the idea of functional impairment of MAIT cells in HIV (Leeansyah et 
al., 2015).      
 
The decline and possible impaired activation of MAIT cells in patients infected with HIV 
may affect the ability of MAIT cells to control microbial infection and as a result increase 
the susceptibility of patients and contribute to disease severity.  
 
  2.2.3b Hepatitis B or C virus 
 
HBV and HCV infect liver cells and can establish a persistent infection. Due to the fact that 
a large proportion of liver resident T cells are MAIT cells, Jo et al. investigated the role of 
liver MAIT cells during HBV and HCV infections (Jo et al., 2014). As both viruses contain a 
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single stranded RNA (ssRNA), TLR8 agonist ssRNA40 was used to stimulate intra-
sinusoidal cells in presence of MAIT cells, resulting in MAIT cell activation as judged by 
IFN-γ expression (Jo et al., 2014). Activation occurred in a MR1-independent but IL-12 and 
IL-18 dependent manner. IFN-γ production by hepatic MAIT cells could also be observed 
in HBV and HCV infected livers. However, whether both viruses are able to induce MAIT 
cell activation in the same way as ssRNA40 was not investigated in this study.   
 
 
I.3 Aims Of The Thesis 
 
To find new host factors which influence the acute phase of DENV infection. 
 
1. Investigate the role of MAIT cells during DENV infection in vivo and in vitro.  
 
 An aberrant immune response is responsible for dengue pathogenesis.  
 Elevated cytokine levels are a hallmark of severe dengue and can be detected 2-3 
days after onset of fever.  
- DENV specific CD8 T cells are not detectable during the acute phase of 
infection. 
- Unconventional T cells respond quickly to infections and secrete high amounts 
of pro-inflammatory cytokines.  
 iNKT cells have been shown to play a detrimental role during DENV infection. 
However in contrast to MAIT cells, the frequency of iNKT cells is very low in humans.   
 
2. Identify new host genomic risk factors which influence the susceptibility of two 
main target cells (DCs and macrophages) to DENV infection. 
 
 High viremia is associated with disease severity.  
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II.1 Buffers and reagents 
 
3% carboxymethylcellulose (CMC; Sigma –Aldrich) 
3 gram of carboxymethylcellulose in 100 ml water 
 
1.5% CMC 
3% CMC 50 ml, 2x MEM (Invitrogen) 45 ml, Fetal Calf Serum (FCS; Gibco) 3 ml, 10x 
streptomycin and penicillin 1 ml  
 
RBC lysis buffer 
0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA in PBS – Filtered and LPS free 
 
MACS Buffer  
0.5% FCS, 2mM EDTA (Sigma-Aldrich) in PBS – Filtered and LPS free 
 
Freezing medium 
90% FCS in DMSO (Sigma-Aldrich)   
 
Cell sorting buffer 
1% FCS, 25 mM HEPES pH 7.0 (Sigma-Aldrich) in PBS – Filtered  
 
FACS Wash 
1% FCS, 0.5% Human Serum (PAA), 2mM EDTA (Sigma-Aldrich) in PBS 
 
FACS fix solution 
4% formaldehyde in PBS 
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II.2 Patients and control samples 
 
All samples were collected with appropriate patient consent and local research ethics 
committee approval. PBMC samples were frozen and stored at −80°C until examined. 
Healthy donors were supplied by the NHS blood service without any further donor 
information.   
The study on DENV patient samples was approved by the Scientific and Ethical Committee 
of the Khon Kaen Hospital in Thailand and the Riverside Ethics Committee in the UK 
(06/Q0401/22). Patients with dengue disease were children admitted during acute febrile 
illness and recruited from Khon Kaen Hospital in Thailand during 2001-2008. Laboratory 
confirmation of DENV infection was determined by RT-PCR detection of DENV nucleic acid 
(which also confirmed the infecting serotype) or seroconversion in an ELISA of IgM. 
Secondary infection was defined based on the ratio of DENV specific IgM to IgG <1.2 on 
or after day 6 of illness. Disease severity was classified according to 1997 World Health 
Organization criteria. Of the patients enrolled in the study, ten patients were classified with 
DF, and ten patients were classified with the severe form of dengue including DHF and 
DSS (Supplementary Table 1). The day of defervescence was defined as day 0, the day 
before defervescence as day −1, the day after defervescence as day +1, and so forth. 
Peripheral blood mononuclear cells were isolated from whole blood by Ficoll-Hypaque 
density-gradient centrifugation at various time points during hospitalization and 
cryopreserved until further use. 
Heparin plasma samples were collected from DENV infected patients (Supplementary 
Table 2) at different phases of illness or from healthy donors and were stored at −80°C until 
further use. 
 
II.3 Cell lines 
 
All cell lines were tested for mycoplasma before use and stored in freezing medium in a 
liquid nitrogen tank if not needed.  
 
Vero cell line, isolated from kidney epithelial cells extracted from an African green 
monkey, was cultured in MEM medium (Gibco) with L-glutamine and supplemented with 
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10% FCS at 37 °C in a 5% CO2 incubator. Cells were cultured in T75 flasks until 90 % 
confluent (107 cells/flask) and subcultured at a 1:10 ratio using Trypsin-EDTA (Sigma-
Aldrich).   
C6/36 cells, an Aedes albopictus mosquito cell line, were cultured in Leibovitz’s L-
15 medium (Gibco) with L-glutamine and supplemented with 10% FCS at 28 °C with no air 
exchange. Cells were cultured in T75 flasks until 100 % confluent (3x107 cells/flask) and 
subcultured at a 1:10 ratio using a cell scraper (TPP).      
HepG2 cells, a human liver carcinoma cell line, were cultured in DMEM medium 
(Gibco) with L-glutamine and supplemented with 10% FCS and 1 mM non-essential amino 
acids (Sigma-Aldrich) at 37 °C in a 5% CO2 incubator. Cells were cultured in T75 flasks 
until 100 % confluent (3x107 cells/flask) and subcultured at a 1:4 ratio using Trypsin-EDTA 
(Sigma-Aldrich).    
U937 cells, a human monocytic cell line isolated from the histiocytic lymphoma of a 
male patient, were cultured in RPMI 1640 (Sigma Aldrich) with L-glutamine supplemented 
with 10% FCS (R10) at 37 °C in a 5% CO2 incubator. Cells were kept in suspension in 
standing T75 flasks and subcultured at a 1:5 to 1:10 ratio. Maximal cell concentration did 
not exceed 2x106 cells/ml.      
 
II.4 Dengue virus 
 
DENV serotype 2, strain 16681, was grown in C6/36 cells in Leibovitz’s L-15 medium with 
L-glutamine and supplemented with 10% FCS. C6/36 cells were plated for 2 days in 96 flat 
bottom well plate until 80% confluent. At the day of infection, cell culture media was 
replaced to Leibovitz’s L-15 medium with L-glutamine and supplemented with 1.5% FCS 
and cells were infected with the virus at a multiplicity of infection (MOI) of 0.001 FFU/cell 
for 3 hours, then topped up to 15 ml for T75 flask. DENV infected cells were incubated at 
28°C until 80-90 % of cytopathic effect (CPE) could be seen. Culture medium was 
centrifuged at 3000 rpm for 10 min and stored at −80 °C. C6/36 cells without the virus were 
cultured in parallel and used to generate Mock supernatant. Mock treated cells were used 
as a negative control.  
 
For UV-irradiated virus, DENV was exposed to 3 J/cm2 UV light for 5 min. 
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Infection rates of DENV infected cells were assessed using a monoclonal antibody E1D8 
(Gift from E. Harris) against the non-structural DENV protein NS3 by flow cytometry. Viral 
production of DENV infected cells was assessed by focus forming assay.  
 
All experiments with live DENV were performed in the Biosafety level 3 facility.   
 
II.5 Focus forming assay – Titration of dengue virus 
 
The titres of virus in the supernatants were determined by a focus forming assay on Vero 
cells and expressed as focus-forming units (FFU) per ml. Vero cells were plated at 2.5x104 
cells/well in a 96 well plate at a final volume of 125 µl. After 2 days incubation at 37 °C/5% 
CO2, 70 µl of media was discarded from the cells.  Supernatants containing DENV were 
10-fold serially diluted using MEM supplemented with 3% FCS and added to each well in 
a volume of 50 µl for 2 hours at 37 °C. The infected cells were then overlaid with 125 µl of 
1.5% CMC (Sigma-Aldrich) and incubated for a further 3 days. To detect virus infected foci, 
monolayers were first washed three times with PBS, fixed and permeabilised with 100 µl 
of 3.7% formaldehyde (Sigma-Aldrich) and 2% triton-X 100, respectively for 10 min at room 
temperature. Following washing three times with PBS, virus foci were stained with 50 µl of 
a monoclonal antibody 4G2 against the DENV envelope protein (Gift from AFRIMS) for 2 
hours at 37 °C. Unbound antibodies were washed away with PBS before adding 50 µl of 
peroxidase-conjugated anti-mouse Ig (1:1000; DAKO) for 1 hour at  37 °C followed by the 
addition of 50 µl DAB substrate (Sigma-Aldrich) for 5-10 minutes in the dark or until the 
infectious foci were clearly visible. The reaction was stopped by discarding the solution and 
washing with distilled water.  The number of foci was counted by ELISpot reader (AID 
ELISpot Reader Systems) and viral titers were calculated using the following formula:  
(number of foci x 10 x 2)/dilution of virus = virus titer (FFU/ml) 
 
II.6 Peripheral blood mononuclear cells (PBMCs) isolation 
 
10 ml concentrated blood supplied by the NHS blood was diluted with RPMI 1640 (PAA) in 
a 1:7 ratio. Blood collected from healthy donors was diluted in a 1:1 ratio. In a 50 ml falcon 
tube, 35ml diluted blood was gently overlaid on top of 15 ml lymphoprep (Nycomed), before 
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centrifuging at 2000 rpm for 20 minutes at room temperature with no break. PBMCs were 
collected at the interface between serum and lymphoprep using a pastette and washed 
three times with RPMI 1640 at 1500 rpm for 5 minutes. After the last wash, red blood cells 
were lysed with RBC lysis buffer for 5 minutes at room temperature and cells were washed 
one more time and resuspended in R10. 
 
II.7 Primary human monocyte, macrophage and dendritic cell 
preparations 
 
CD14+ cells were isolated by positive selection from PBMCs using MACS CD14 
microbeads (Miltenyi Biotec). PBMCs were centrifuged at 1500 rpm for 5 minutes and cell 
pellet was resuspended in 80 µl of MACS buffer + 10 µl CD14 microbeads per 107 total 
cells. Cells were incubated at 4 °C for 30 minutes on the rotar before washing with MACS 
buffer. Labelled cells were resuspended in 12 ml MACS buffer and applied onto a LS 
column (Miltenyi Biotec) followed by three times 5 ml MACS buffer. Cells were flushed out 
mechanically by adding 5 ml of R10, centrifuged and resuspended in R10. The purity of 
CD14+ cells was determined with an anti CD14-APC antibody (BD Biosciences) by flow 
cytometry. 
Monocytes, CD14+ cells, were cultured at 5x105 cells/ml in 24 or 48 well plate or stored in 
freezing medium in a liquid nitrogen tank until further use.  
 
To generate monocyte derived macrophages, 7x106 CD14+ cells were plated in a 60mm 
dish and cultured in 5 ml R10 with 50 ng/ml recombinant human GM-CSF (First Link) or 
100 ng/ml recombinant human M-CSF (Peprotech) for M1 or M2, respectively. After 5 days, 
adherent cells were gently washed with RPMI 1640 and detached with cell dissociation 
solution non-enzymatic (Sigma-Aldrich). Cells were resuspended in R10 and cultured at 
5x105 cells/ml in 24 or 48 well plate for 24 hours at 37 °C in a 5% CO2 incubator. 
To generate monocyte derived dendritic cells (DCs), CD14+ cells at 5x105 cells/ml were 
cultured in R10 with 20 ng/ml human recombinant GM-CSF (First Link) and 25 ng/ml human 
recombinant IL-4 (eBioscience) for 5 to 6 days at 37 °C in a 5% CO2 incubator. On day 3, 
half of the culture media was carefully replaced with fresh media containing 40 ng/ml 
human recombinant GM-CSF and 50 ng/ml human recombinant IL-4. Immature DCs were 
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harvested and confirmed with anti CD14-APC (BD Biosciences) and anti CD209-PE 
(Miltenyi Biotec) by flow cytometry.    
 
II.8 Dengue virus infection 
 
Primary human APCs or cell lines were collected in 50 ml falcon tubes, centrifuged and 
infected with DENV at a MOI of 1 or 5 FFU/cell, as determined based on the viral titre and 
number of cells, for 2 hours at 37 °C in a 5% CO2 incubator. Excess DENV was washed 
off three times with RPMI 1640. Cells were resuspended in R10 at 5x105 cells/ml and plated 
in 24 or 48 well plate at 37 °C, overnight. 
 
The antibody dependent enhancement (ADE) assay was performed using a monoclonal 
antibody against the DENV precursor membrane protein prM (1H10; produced in house 
(Dejnirattisai et al., 2010)). Anti-prM antibody was diluted to a final concentration of 0.2 
µg/ml in R10 in a volume of 100 µl. DENV, at a MOI of 1 or 5 FFU/cell, was mixed with the 
diluted antibody in a final volume of 200 µl for 1 hour at 37 °C to allow immune complex 
formation. After incubation, the antibody-virus mixture was added to the cells in a 50 ml 
falcon tube and incubated for 2 hours at 37 °C in a 5% CO2 incubator. To remove excess 
IC, cells were washed three times with RPMI 1640 before plating cells in 24 or 48 well plate 
(5x105 cells/ml) in R10 at 37 °C, overnight. 
 
For adherent cells (macrophages or HepG2 cells), DENV alone or ICs were overlaid on the 
cell monolayer and incubated for 2 hours at 37 °C. To remove residual ICs or DENV, 
supernatants were discarded from the monolayer and cells were carefully rinsed 3 times 
with RPMI 1640 before incubating cells in R10 at 37 °C, overnight.  
   
II.9 MAIT cell isolation and expansion 
 
Freshly isolated or thawed PBMCs were washed with PBS and stained with antibodies 
against anti-CD3 PE-Cy7 (1:50; Biolegend), anti-CD161 PE (1:50; Miltenyi Biotec) and anti-
Vα7.2 FITC (1:50; Biolegend) for 10 min at 4 °C. Cells were washed with PBS and 
resuspended in cell sorting buffer to 106-107 cells/ml. Cells were flushed through a 40 µm 
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filter before sorting MAIT cells by CD3+Vα7.2+CD161++ marker expression using a BD 
FACS Aria II (BD Bioscience) with an 85 µm nozzle size. Sorted MAIT cells were collected 
in R10, washed in RPMI 1640 and resuspended in RPMI 1640 with L-glutamine 
supplemented with 10% human AB serum (Invitrogen; H10).  
Sorted MAIT cells were expanded using irradiated allogeneic PBMCs at a final 
concentration of 2*106 cells/ml in H10 containing 40 µg/ml phytohemagglutinin (Sigma-
Aldrich). On day 3 post stimulation, human recombinant IL-2 (R&D) at a final concentration 
of 200 U/ml was added to the culture media. Sorted MAIT cells were used after day 10 post 
stimulation and were re-stimulated periodically after 3-4 weeks. 
 
II.10 In vitro stimulation 
 
After DENV infection of APCs and overnight incubation, autologous PBMCs or sorted MAIT 
cells were added to the infected cells at an E/T ratio of 2 for an additional 6 or 24 hours. As 
a negative control, effector cells were added to mock treated cells. 
For blocking experiments, neutralising agents were added into the culture 1 hour prior the 
addition of PBMCs or sorted MAIT cells. Blocking antibodies against IL-2Rα (Biolegend), 
IL-12p70 (R&D), IL-15 (R&D), IL-18 (MBL International), IFN-γ (eBioscience), MR1 
(Biolegend), PD-1 (Biolegend) or NKG2D (Biolegend) were used at 10 µg/ml. Type I IFN 
was blocked using either 1 µg/ml B18R (eBioscience), 10 µg/ml IFNAR1 (Stratech 
Scientific Ltd) or 4 µM of Ruxolitinib (Stratech Scientific Ltd). 
PBMCs or sorted MAIT cells were also stimulated using either 100 ng/ml PMA (Sigma-
Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) or 50 ng/ml recombinant human IL-12 
(Miltenyi Biotec) and IL-18 (R&D) in R10 for 6 or 24 hours.  
Activated PBMCs or MAIT cells were confirmed using intracellular staining against IFN-γ 
by flow cytometry. 
  
II.11 Cytokine measurements 
 
Cytokines levels were measured from cell culture supernatants or heparin plasma samples. 
Cell culture supernatants from cell lines or primary human cells treated with DENV or mock 
were collected at 24 or 42 hours post infection.  
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11.1 Multiplex bead assay 
Cytokines (IFN-α2, IL-18, IL-2, IL-12p70, IL-15 and TNF-α) were measured according to 
the manufacturer’s protocol Bio-PlexTM Cytokine Assay (Bio-Rad). Cell culture 
supernatants and heparin plasma samples were thawed on ice and diluted as 
recommended. Multiplex beads were added to the filter plate and incubated with samples, 
controls or standards for 30 minutes on a microplate shaker. After washing with washing 
buffer, biotin-labelled detection antibodies against individual multiplex beads were added 
to each well and incubated for 30 minutes on a microplate shaker before removing unbound 
antibodies with washing buffer. After that, Streptavidin conjugated with phycoerythrin was 
added for 10 min and analytes were measured by Bioplex 200 (Bio-Rad). Data were 
analysed by Bioplex manager 4.1.1 software (Bio-Rad).        
 
 11.2 IL-18 ELISA 
The concentration of IL-18 in culture medium was assessed using the human IL-18 ELISA 
Kit (Medical & Biological Laboratories Co., LTD.) according to the instructions provided by 
the manufacturer. Briefly, cell culture medium was thawed on ice and added directly in the 
microwells coated with anti-human IL-18 monoclonal antibody. After washing 4 times with 
washing buffer, the peroxidase conjugated anti-human IL-18 monoclonal antibody was 
added into the microwells and incubated for 60 min at room temperature. After another 
washing step, the substrate reagent is mixed with the chromogen before stopping the 
enzyme reaction with an acid solution. The optical density of each microwell is measured 
at 450 nm using a microplate reader (TECAN). The concentration of human IL-18 is 
calculated from a standard curve.   
 
II.12 Flow cytometry 
 
If intracellular staining was required, 10 µg/ml brefeldin A (Sigma-Aldrich) was added to the 
culture 5 hours prior harvesting cells for flow cytometry staining. In the case of CD107a 
staining, 200 ng/ml monensin (BD Bioscience) was added together with brefeldin A. 
 
Cells were harvest and transferred into FACS tubes before centrifuging at 1500 rpm for 5 
min to remove supernatant. Following washing with FACS wash, antibodies against surface 
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receptors were added directly to the cells for 20 min at 4 °C. Unbound antibodies were 
removed and cells were fixed and permeabilised using Cytofix/Cytoperm buffer (BD 
Bioscience) according to the manufacturer’s protocol. Cells were washed with FACS wash 
and incubated with antibodies against intracellular cytokines or granules for 20 min at 4 °C. 
Cells were washed and fixed with 120 µl of FACS fix solution before acquiring data on a 
BD FACSVerse (BD Bioscience) and analyzing them on FlowJo (Tree Star Inc.). 
 
Antibodies/dyes used were: viability dye Live/Dead fixable-Near-IR (Invitrogen), viability 
dye Live/Dead fixable-violet (Invitrogen), CD3-PECy7 (eBioscience), CD3-FITC (Dako), 
CD4-VioGreen (Miltenyi Biotec), CD8-PerCP.Cy5.5/PerCP (Biolegend), CD14-APC/FITC 
(BD Bioscience), CD16-FITC (BD Bioscience), CD38-APC (BD Bioscience), CD80-PE (BD 
Bioscience), CD86-FITC (BD Bioscience), CD107a-FITC (BD Bioscience), CD107a-
PECy7 (Biolegend), CD161-APC/PE (Miltenyi Biotec), CD163-FITC (BD Bioscience), 
CD206-FITC (Biolegend), Vα7.2-PE/FITC (Biolegend), HLA-DR-BV421 (Biolegend),  IFN-
γ-APC (BD Bioscience), IFN-γ-APCCy7 (Biolegend), Granzyme B-APC (Invitrogen), 
Perforin-PB (Bioegend), IL-18Rα-APC (eBioscience), TNF-α-PeCy7 (Biolegend), PD-1-
BV421 (Biolegend), NS3-E1D8 (Gift from E.Harris).  
 
II.13 RNA isolation from primary human cells 
 
Primary human DCs and M-CSF derived macrophages were infected with DENV or IC for 
6 or 24 hours as previously described. As a control, cells were treated with mock or mock 
with anti-prM for DCs and macrophages, respectively. After incubation time, cells were 
carefully washed with warm PBS before lysing cells with 500 µl TRIzol® reagent 
(Invitrogen). Cell lysates were kept at -80 °C until further use.  
Samples were thawed on ice and 100 µl chloroform was added to each condition. After 
centrifuging at 14000 rpm for 150 at 4 °C, the top aqueous layer was gently transferred to 
a fresh eppendorf before adding 70% ethanol at a 1:1 ratio.  
RNA was isolated using the RNeasy mini Kit (Qiagen) according to the manufacturer’s 
protocol. Briefly, the RNA mixture was transferred to a RNeasy mini column, centrifuged 
and washed with buffer RW1 to remove any non-specifically bound molecules on the silica 
membrane. DNA was digested by applying DNAse onto the membrane for 15 min at room 
temperature before washing with buffer RW1 followed by buffer RPE to remove traces of 
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salts. Filter columns were placed on clean eppendorfs and RNAs were eluted with RNAse 
free water. RNA quantification and quality were assessed using NanoDrop 2000 and stored 
at -80 °C until further use.  
 
II.14 RNA sequencing 
 
RNA samples were thawed on ice and the cDNA synthesis, labelling and subsequent 
hybridization was performed according to the manufacturer’s protocol using the TruSeq® 
Stranded mRNA Low Sample Preparation Guide (Illumina). Briefly, 500 ng total RNA was 
purified to obtain polyA containing mRNA using poly-T oligo attached magnetic beads. 
PolyA RNA was fragmented and primed with random hexamers for cDNA synthesis. After 
synthesis of the first strand cDNA, remaining RNA was removed and a second strand cDNA 
was synthesised to obtain blunt-ended double stranded cDNA. A single A nucleotide was 
added to the 3’ ends of each fragment to prevent them from ligating to one another and to 
facilitate ligation of the adaptor to the fragment. Following ligation of RNA adaptor indices 
to each sample, DNA fragments with adaptor molecules on both ends were enriched and 
amplified using a PCR primer cocktail that anneals to the ends of the adapters.    
The quality and quantification of the cDNA libraries were assessed using Agilent 2100 
Bioanalyzer (Agilent Technologies). Following validation, indexed DNA libraries were 
normalized to 5 ng/ml and pooled together in equal volumes. RNA sequencing was 
performed using an ultra-high-throughput sequencing system HiSeq 2500 (Illumina). Read 
counts per gene were calculated for each sample using HTseq-count version 0.6.1 with 
union mode and expression levels (in Fragments Per Kilobase of transcript per Million 
mapped reads (FPKM)) for each transcript were measured with Cufflinks 2.1.1. Raw reads 
were mapped to the reference human genome (hg19_ens_GRCh37) using tophat 2.0.11. 
The average mapping percentage was >80%. Sequencing and mapping were controlled 
for quality using standard tools provided in the FastQC software.   
 
II.15 Statistical analysis 
 
Statistical analysis was carried out with GraphPad Prism software. Statistical significance 
was reported as ns P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001. Error 
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bars on graphs represent SEM. Mann Whitney test was used to calculate significance 
levels between two groups. Wilcoxon matched-paired test was used to calculate 
significance levels between two paired groups. For comparisons of means from multiple 
groups against one control group the Kruskal–Wallis with Dunn’s multiple comparison post-
test analysis was performed. Spearman rank correlation analysis was used to calculate 
correlations. Sample sizes were adequate to detect large effects between groups, as 
determined by the reproducibility and variability of each particular experiment and limited 
by the availability of patient samples. No randomization or blinding was used. 
Statistical analysis for genes transcripts obtain by the RNA sequencing (RNA-seq) dataset 
were analysed using Pearson correlation.   
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Chapter III 
 
RESULTS PART 1  
Human MAIT Cell Activation In Response To 
Dengue Virus 
 
 
This Chapter is part of the paper ‘MAIT cells are activated during human viral infections’ 
published in Nature Communication in June 2016. 
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AIM: To investigate if and how MAIT cells become activated during the acute phase 
of DENV infection and their contribution to dengue pathogenesis.  
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III.1 Introduction 
 
DENV is the most significant and widespread mosquito borne viral illness worldwide. 
Current estimates suggest there are around 390 million people infected each year of which 
100 million will have an apparent infection (Bhatt et al., 2013). The clinical manifestation 
varies widely from asymptomatic to death. DENV is a ssRNA virus which is transmitted via 
the day biting mosquito Aedes aegyptis. Four serotypes are currently circulating in tropical 
and subtropical countries. Most individuals infected with DENV will be asymptomatic or 
experience high fever, called dengue fever (DF). Once fever remits (day of defervescence), 
a small percentage of patients develop a more severe disease; dengue haemorrhagic fever 
(DHF). The hallmarks of severe dengue are haemorrhage, cytokine storm and plasma 
leakage which can lead to shock and death. Dengue pathogenesis is still not fully 
understood. However, an aberrant immune response before and around the day of 
defervescence is thought to play an important role (Green and Rothman, 2006).  
 
So far, most investigations focused on the detrimental effects of cross-reactive adaptive 
immune responses known as antibody dependent enhancement (ADE) and T cell antigenic 
sin (Yacoub et al., 2013). ADE is thought to be the leading force driving high viral load in 
patients with severe dengue (Halstead, 2003). Although high viremia is associated with 
dengue severity, viral loads at the time of vascular leakage are falling steeply, implying that 
severe dengue is not a direct consequence of the virus (Vaughn et al., 2000). In addition, 
some patients experience high viremia but do not develop plasma leakage (Libraty et al., 
2002, Vaughn et al., 2000). These findings suggest that other mechanisms may contribute 
to dengue pathogenesis. 
Cytokine storm, a hallmark of severe dengue, is thought to induce vascular permeability 
(Appanna et al., 2012). Elevated cytokine levels (e.g.  IFN-γ and TNF-α) are detected few 
days after infection and most of them peak before or on the day of defervescence (Green 
et al., 1999b, Libraty et al., 2002). Activated CD8 T cells produce most of these cytokines 
and previous studies reported that cross-reactive CD8 T cells show suboptimal 
degranulation but high cytokine production upon DENV infection (Mongkolsapaya et al., 
2006, Duangchinda et al., 2010). However, it is questionable whether high cytokine levels 
observed in the acute phase of infection originated from T cells as DENV specific CD8 T 
cells are almost undetectable in the periphery during acute infection (Mongkolsapaya et al., 
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2003). Furthermore, a temporal mismatch between CD8 T cell responses and 
commencement of capillary leakage was observed, suggesting that T cells are probably 
not responsible for the early triggering of vascular leakage in patients with severe dengue 
(Dung et al., 2010).  
 
Studies on the innate immune response during DENV infection are still very limited. ‘Innate-
like’ or unconventional T cells are able to rapidly respond to infection, secrete a vast amount 
of cytokines and kill infected cells (Godfrey et al., 2015). Thus, unconventional T cells could 
initiate or even dictate the subsequent immune response against DENV and may contribute 
to the pathogenesis of dengue. Recently a novel type of unconventional T cell, called 
mucosal associated invariant T (MAIT) cells, has been discovered (Porcelli et al., 1993). 
MAIT cells are very abundant in humans and express a semi-invariant TCR composed of 
the invariant TCRα chain Vα7.2-Jα33 (Tilloy et al., 1999, Treiner et al., 2003). MAIT cells 
comprise up to 10% of T cells within the periphery and are found enriched in both gut and 
liver, where they represent up to 45% of T lymphocytes (Martin et al., 2009, Tang et al., 
2013). MAIT cells are restricted to microbial vitamin derivatives which are presented by the 
MHC class I like molecule, MR1 (Kjer-Nielsen et al., 2012, Patel et al., 2013). The anti-
microbial role of MAIT cells has been confirmed in several in vivo and in vitro studies 
(Napier et al., 2015). Upon activation, MAIT cells rapidly secrete various pro-inflammatory 
cytokines (IFN-γ, TNF-α and IL-17) and are able to kill infected target cells in an MR1 
dependent manner (Le Bourhis et al., 2013, Dusseaux et al., 2011).  
 
So far no viral activity has been reported and viral infected cells failed to activate MAIT cells 
in vitro (Le Bourhis et al., 2010). However, recent findings observed a TCR independent 
activation of MAIT cells via the cytokines IL-12 and IL-18 (Ussher et al., 2013). Furthermore 
stimulation of TLR8, which recognises viral ssRNA, induces IL-12 and IL-18 production in 
APCs (Jo et al., 2014). Given that MAIT cells are very abundant in humans and secrete 
high amounts of pro-inflammatory cytokines, early activation of these cells might potentially 
have an important impact during the early phase of the disease and perhaps influence the 
subsequent immune response during DENV infection. 
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III.2 Result  
 
2.1 MAIT Cell Activation during Acute DENV Infection in vivo 
 
The role of MAIT cells during DENV infection or any acute viral infection remains unclear. 
To address this, MAIT cell activation was analysed in a longitudinal study of PBMCs from 
a cohort of patients suffering from severe dengue (DHF) or dengue (DF) (Supplementary 
Table. 1). Blood was collected at consecutive days during the acute phase of infection and 
once at the end of illness, the convalescent phase. Dates were named in relation to the 
day fever subsided (day of defervescence; day 0) and samples taken ten or more days 
after the day of defervescence (day>10) were considered convalescent. The phenotype of 
MAIT cells in patient samples were analysed by gating on live CD3+CD161++Vα7.2+ cells 
using flow cytometry (Fig. 3a). 
 
A small but significant reduction was found in MAIT cell frequencies between the acute 
phase (acute, day 0) and the convalescent phase (conv, day>10) of DENV infection (Fig. 
3b+c). MAIT cell frequencies in DENV infected patients were compared to healthy donors, 
which were supplied by the NHS blood service without any further donor information. As 
previously reported, MAIT cell frequencies in healthy controls (HCs) varied among donors 
from 1 to 10% (Dusseaux et al., 2011, Martin et al., 2009), however no differences in MAIT 
cell frequency was observed between HCs and the acute phase of DENV infected patients 
as well as between DHF and DF patients over the course of infection (Fig. 3c+d).   
MAIT cell activation was assessed by measuring the percentage of expression and the 
expression level of two activation markers, CD38 and PD-1 (Fig. 3e-j and Supplementary 
Fig. 1). Analysis of CD38 and PD-1 revealed marked in vivo activation of MAIT cells during 
the acute phase of infection compared to the convalescent phase (Fig. 3e+f, h+i and 
Supplementary Fig. 1 a+c). Both activation markers increased over the course of infection 
and peaked at a critical moment for DENV infected patients – the day of defervescence. 
Interestingly, patients with the severe form of dengue had higher MAIT cell activation as 
judged by CD38 and PD-1 expression compared to DF patients over the course of infection 
(Fig. 3g+j and Supplementary Fig. 1 b+d). In both patient groups, CD38 expression on 
MAIT cells resolved to HC levels in the convalescent sample. In contrast, PD-1 expression  
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Figure 3 MAIT cell activation during acute DENV infection in vivo. PBMC’s from 
healthy controls (n=5-10), patients suffering from severe dengue (DHF, n=2-10), dengue 
(DF, n=4-10) were analysed by flow cytometry. (a, b, e, h) Representative flow cytometry 
plots. (c, f, i) Comparison between acute (day 0) and convalescent (day>10) phase of 
infection. (d, g, j) Comparison between DHF and DF patients. (a) Gating strategy to identify 
live CD3+CD161++Vα7.2+ (MAIT) cells in PBMCs from a representative patient. (b-d) MAIT 
cell frequency as a proportion of the T cell population. (e-g) Percentage of CD38 expression 
by MAIT cells. (h-j) Percentage of PD-1 expression by MAIT cells. Statistical significance 
was determined with a Kruskal-Wallis test followed by Dunns’ test and a Wilcoxon signed-
ranks test between matched samples of the acute and conv phase (c, f, i). A Mann-Whitney 
test was applied to compare DHF and DF samples (d, g, j). Bars represent means. ns > 
0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Abbreviations: HC, healthy 
controls; conv, convalescent; DENV, dengue virus. 
80 | P a g e  
 
on MAIT cells showed reduced levels in those samples, however a difference in expression 
level could still be observed between DHF and DF patients. 
Granzyme B and perforin expression were also assessed due to their tight regulation in 
MAIT cells and their absence in HCs (Kurioka et al., 2014). Furthermore, upregulation of 
granzyme B is associated with the acquisition of cytotoxic function by MAIT cells (Le 
Bourhis et al., 2013, Kurioka et al., 2014). Granzyme B and perforin were upregulated 
during the acute phase of infection and followed the same time course as that of the 
activation markers, CD38 and PD-1 (Fig. 4). However, no differences in expression levels 
could be observed between patients suffering from severe dengue and patients with DF 
(Fig. 4c+f). At the end of the illness, granzyme B and perforin expression by MAIT cells in 
DENV infected patients reduced back to the same level as HCs.  
To identify whether activation of MAIT cells during DENV infection is specific to those cells, 
total CD8 T cells were examined in patient samples and healthy adults (Supplementary 
Fig. 2). Interestingly, expression of granzyme B and perforin did not change during the 
course of infection in DHF and DF patients (Supplementary Fig. 2c-f). However, CD8 T 
cells showed marked activation during the acute phase of infection compared to the 
convalescent phase and HCs as judged by CD38 expression (Supplementary Fig. 2a+b). 
In contrast to MAIT cells, activation of CD8 T cells peaked at a later stage during DENV 
infection, a day after defervescence, and no difference in the expression of CD38 was 
observed between DHF and DF patients. This was also observed for CD161++ T cells 
lacking the invariant TCRα chain Vα7.2 (data not shown). 
 
Taken together, MAIT cells are activated during acute dengue infection and patients 
suffering from severe dengue showed higher MAIT cell activation compared to patients 
with DF. Furthermore, MAIT cell activation peaked at a critical moment in disease 
development – the day of defervescence. Increase in activation was also linked with an 
upregulation of cytolytic granules. These data suggest a possible role of MAIT cells during 
the early events of infection and a potential influence on dengue pathogenesis depending 
on the degree of MAIT cell activation.    
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Figure 4 Expression of Granzyme B and Perforin in MAIT cells during DENV infection 
in vivo. PBMC’s from healthy controls (n=10), patients suffering from severe dengue (DHF, 
n=2-10), dengue (DF, n=4-10) were analysed by flow cytometry by gating on live 
CD3+CD161++Vα7.2+ (MAIT) cells. (a, d) Representative flow cytometry plots. (b, e) 
Comparison between acute (day 0) and convalescent (day>10) phase of infection. (c, f) 
Comparison between DHF and DF patients. (a-c) Percentage of Granzyme B expression 
by MAIT cells. (d-f) Percentage of Perforin expression by MAIT cells. Statistical significance 
was determined with a Kruskal-Wallis test followed by Dunns’ test and a Wilcoxon signed-
ranks test between matched samples of the acute and convalescent phase (b, e). Bars 
represent means. ns > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
Abbreviations: HC, healthy controls; conv, convalescent; DENV, dengue virus; DF, dengue 
fever; DHF, dengue haemorrhagic fever; GrB, Granzyme B. 
  
82 | P a g e  
 
2.2 In vitro MAIT Cell Activation 
 
An immune response involves a complex interplay between many components. To study 
responses against DENV infection, most research has focused on clinical experiments due 
to the lack of appropriate animal models. However, even though in vitro studies cannot fully 
mimic all aspect of dengue pathogenesis they can be a powerful tool to better understand 
the molecular mechanisms at work during an infection. Having observed MAIT cell 
activation in vivo, an in vitro model was established to co-culture primary human APCs - 
DCs, macrophages or monocytes - which are the primary targets of DENV in vivo, with 
autologous PBMCs.   
 
2.2.1 Co-culture with primary human dendritic cells 
 
First, activation of MAIT cells was assessed in a co-culture experiment with DCs. Primary 
human DCs from healthy donors were differentiated from monocytes and either infected 
with DENV or left uninfected (=mock), as a negative control. Autologous PBMCs were 
added to the cells and incubated for 6 or 24 hours. PBMCs were stimulated with 
PMA/Ionomycin as a positive control.  
MAIT cells were readily activated as judged by IFN-γ expression in response to DENV 
infected DCs after 24 hours co-culture. This activation could not be observed after 6 hours 
co-culture or when PBMCs were incubated with mock treated DCs (Fig. 5a+b). After 24 
hours co-culture with DENV infected DCs, activation markers CD38 and PD-1 were also 
upregulated on MAIT cells (Fig. 5e and Supplementary Fig. 3. a+b). In addition, cytokine 
production was mainly skewed towards IFN-γ with little to no TNF-α production (Fig. 5c+d). 
As observed in patient samples, MAIT cells showed increased granzyme B expression and 
were able to degranulate upon co-culture with DENV infected DCs (Fig. 5f+g and 
Supplementary Fig. 3 c+d). Furthermore, expression of IFN-γ and granzyme B correlated 
with MAIT cell activation as judged by CD38 expression level (Fig. 5i+j). Finally, this 
activation was specific to MAIT cells as other T cell subsets, CD161+Vα7.2- and CD161- T 
cells, showed low expression levels of IFN-γ in response to DENV infected DCs (Fig. 5h).  
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Figure 5 Activation of MAIT cells by DENV infected DCs in vitro. MAIT cells from 
healthy individuals were analysed by flow cytometry, gated on live CD3+CD161++Vα7.2+ 
cells. PBMCs were co-cultured for 24 hours with DENV infected (MOI of 1 FFU/cell) or 
mock treated autologous monocyte derived DCs. As a positive control, PBMCs were 
stimulated with PMA/Ionomycin. (a, b) Proportion of MAIT cells (n=6) producing IFN-γ after 
6 and 24 hours co-culture. (b) Representative flow cytometry plots. (c-g) Proportion of 
MAIT cells producing or expressing IFN-γ (c, n=9), TNF-α (d, n=8), CD38 (e, n=10), 
Granzyme B (f, n=10), and CD107a (g, n=6) after co-culture with DCs. (h) Percentage of 
indicated cell population (n=8) expressing IFN-γ. (i, j) Correlation of percentage of 
Granzyme B (i) or IFN-γ (j) positive MAIT cells against CD38 expression on MAIT cells by 
Spearman rank correlation test. All data are representative from at least two independent 
experiments. Bars represent means ± s.e.m. (a, c-h) Statistical significance was 
determined with a Mann-Whitney test.  
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2.2.2 Co-culture with primary human monocytes and 
macrophages 
 
Antibody dependent enhancement (ADE) is an important mechanism for DENV to enhance 
infection of host cells and previous studies have shown that ADE plays a key role in dengue 
pathogenesis (Halstead, 2003). The main targets of ADE infection by DENV are monocytes 
and macrophages. Thus, MAIT cell activation was assessed upon co-culture with both 
primary human cells in the presence of DENV with or without antibodies.  
 
Macrophages from healthy donors were differentiated from monocytes using two distinct 
cytokines, GM-CSF and M-CSF, to generate M1-like macrophages (M1) and M2-like 
macrophages (M2), respectively (Verreck et al., 2006). The phenotype of both macrophage 
subsets was confirmed by flow cytometry using a panel of antibodies against cell surface 
receptors specific for M1 or M2 (Fig. 6a). M1, also known as classically activated 
macrophages, express high levels of MHC II (HLA-DR) and co-stimulatory molecules 
(CD80 and CD86), whereas M2 known as alternatively activated macrophages have 
increased expression of scavenger and mannose receptors, such as CD163 and CD206 
(Mantovani et al., 2005, Verreck et al., 2006).  
First, DENV infection of M1 and M2 was confirmed using a fluorochrome labelled antibody 
against the DENV protein NS3 (Fig. 6b). Infection of DENV without antibodies resulted in 
a weak infection rate in M1 and M2 with 7 to 12 % infected cells, respectively. In the 
presence of antibodies, infection rate of M1 doubled whereas M2 had a 7 fold increase 
showing up to 80% infected cells. Mock treated M1 or M2 in the presence of antibodies 
were used as a negative control.   
Autologous PBMCs were co-cultured with M1 (Fig. 6c+d) or M2 (Fig. 6e+f) for 24 hours 
and MAIT cell activation, judged by IFN-γ expression, was assessed by flow cytometry. As 
a positive control, PBMCs were co-cultured with DENV infected DCs derived from the same 
donor. In contrast to DENV infected DCs, MAIT cell activation was not induced by DENV 
infected M1 or M2 in presence or absence of antibodies.  
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Figure 6 MAIT cells are not activated upon co-culture with DENV infected 
macrophage subsets M1 or M2. (a) Expression of surface markers on lymphocytes, 
monocytes, M1 and M2. (b) Representative flow cytometry plots of M1 and M2 infection 
rates after 24 hours DENV infection (MOI of 1 FFU/cell) in presence or absence of 
antibodies. M1 and M2 were analysed by flow cytometry and infection rates were assessed 
by intracellular staining of the DENV non-structural protein NS3. (c-f) Percentage of IFN-γ 
expressing MAIT cells from healthy individuals was analysed by flow cytometry. As a 
positive control, PBMCs were stimulated with PMA/Ionomycin. PBMCs (n=3) were co-
cultured for 24 hours with DENV infected or mock treated autologous monocyte derived 
M1 (c) or M2 (e). (d, f) Representative flow cytometry plots. Bars represent means ± s.e.m. 
Statistical significance was determined with a Mann-Whitney test. ns > 0.05. Abbreviations: 
DENV, dengue virus; Iono, ionomycin; Ab, antibody.  
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Similar findings were observed when co-culturing PBMCs with autologous DENV infected 
monocytes with or without ADE (Fig. 7b+c). In contrast to macrophages, monocytes 
showed a weak infection rate in the presence of antibodies and remained uninfected when 
treated with DENV or antibody alone (Fig. 7a).  
 
  
Figure 7 MAIT cells are not activated upon co-culture with DENV infected monocytes. 
(a) Representative flow cytometry plots of DENV infection in monocytes after 24 hours at 
an MOI of 5 FFU/cell in presence or absence of antibodies or antibodies alone. Monocytes 
were analysed by flow cytometry and infection rate was assessed by intracellular staining 
of the DENV non-structural protein NS3. (b, c) Percentage of IFN-γ expressing MAIT cells 
from healthy individuals (n=5) after 24 hours co-culture with DENV infected or mock treated 
autologous monocytes. MAIT cells were analysed by flow cytometry, gated on live 
CD3+CD161++Vα7.2+ cells. As a positive control, PBMCs were stimulated with 
PMA/Ionomycin. (b) Representative flow cytometry plots. Data is representative from at 
least two independent experiments. Bars represent means ± s.e.m. Statistical significance 
was determined with a Mann-Whitney test. ns > 0.05. Abbreviations: DENV, dengue virus; 
Iono, ionomycin; IFN, interferon; Ab, antibody. 
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2.2.3 Co-culture with a liver carcinoma cell line: HepG2 cell 
line 
 
Hepatic dysfunction is a crucial feature of severe dengue and the spectrum of involvement 
ranges from asymptomatic elevation of hepatic transaminases to acute liver failure 
(Seneviratne et al., 2006). In addition, hepatocytes have been shown in in vitro studies to 
be important targets for DENV infection, which was confirmed in biopsies and autopsies of 
fatal cases (Huerre et al., 2001, Thongtan et al., 2004).  
Since liver dysfunction is frequent in dengue, activation of MAIT cell was assessed upon 
co-culture with a human liver cell line, HepG2 cells. HepG2 cells were infected with DENV 
or treated with mock, as a negative control. DENV infected up to 70% of HepG2 cells as 
measured by intracellular staining against NS3 (Fig. 8a). PBMCs were added to the 
infected or mock treated HepG2 cells for 24 hours. When measuring the percentage of 
IFN-γ positive cells, MAIT cells did not produce IFN-γ following 24 hours incubation with 
DENV infected HepG2 cells. However, PBMCs from the same donor become activated and 
expressed IFN-γ after 24 hours co-culture with autologous DENV infected DCs (Fig. 8b+c).  
 
 
Taken together, MAIT cells become activated in vitro upon 24 hours co-culture with DENV 
infected DCs. Activation of MAIT cells leads to IFN-γ and granzyme B production as well 
as upregulation of CD38 and PD-1 expression on their cell surface. Interestingly, activation 
of MAIT cells could only be observed when co-cultured with DCs. Other primary human 
APCs, such as macrophages or monocytes, as well as a liver cell line did not induce MAIT 
cell activation.  
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Figure 8 MAIT cells are not activated upon co-culture with DENV infected HepG2 
cells. (a) Representative flow cytometry plots of HepG2 infection rates after 24 hours 
DENV infection (MOI of 1 FFU/cell) or mock treatment. HepG2 cells were analysed by flow 
cytometry and infection rate was assessed by intracellular staining of the DENV non-
structural protein NS3. (b, c) Percentage of IFN-γ expressing MAIT cells from healthy 
individuals (n=4) after 24 hours co-culture with DENV infected or mock treated HepG2 cells. 
MAIT cells were analysed by flow cytometry, gated on live CD3+CD161++Vα7.2+ cells. As 
a positive control, PBMCs were stimulated with PMA/Ionomycin. (b) Representative flow 
cytometry plots. Data is representative from at least two independent experiments. Bars 
represent means ± s.e.m. Statistical significance was determined with a Mann-Whitney 
test. ns > 0.05. Abbreviations: DENV, dengue virus; Iono, ionomycin; IFN, interferon. 
  
89 | P a g e  
 
2.3 The Mechanism behind MAIT Cell Activation in Response 
to DENV 
 
Having observed MAIT cell activation upon co-culture with DENV infected DCs in vitro, the 
mechanism behind this activation was examined.  
 
2.3.1 MAIT cell activation is dependent on DENV infected 
dendritic cells 
 
First, the ability of DCs to activate MAIT cells was examined. To do so, PBMCs were 
cultured with DENV alone or with DENV infected DCs and IFN-γ expression was analysed 
after 24 hours by flow cytometry (Fig. 9a+b). In the absence of DCs, DENV did not induce 
MAIT cell activation as judged by IFN-γ expression. Thus, DCs are required for MAIT cell 
activation. To assess the requirement of viral replication in DENV infected DCs for MAIT 
cell activation, DCs were infected with UV-irradiated DENV (UV-DENV). UV-DENV 
prevents transcription or replication in the host cell but does not inhibit viral entry. After 24 
hours co-culture with autologous PBMCs, MAIT cells did not produce IFN-γ in contrast to 
MAIT cells incubated with DENV infected DCs (Fig. 9a+b). Additionally, activation of MAIT 
cells was not induced when DCs were treated with mock or UV-irradiated mock (UV-mock). 
To confirm inhibition of transcription and replication of UV-DENV, the DENV protein NS3 
which can only be detected once transcription of viral RNA occurred, was analysed by flow 
cytometry (Fig. 9c). As expected, NS3 was only expressed in DENV infected DCs whereas 
UV-DENV infected or mock treated DCs showed no NS3 expression. Interestingly, the level 
of NS3 positive DCs correlated with MAIT cell IFN-γ expression (Fig. 9d).   
Next, the impact of monocytes or other lymphocytes inducing MAIT cell activation was 
examined. Instead of using autologous PBMCs, MAIT cells were isolated and co-cultured 
with DENV infected DCs for 24 hours (Fig. 9e+f). In the absence of monocytes or other 
lymphocytes, MAIT cells were activated upon co-culture with DENV infected DCs as judged 
by IFN-γ expression (Fig. 9f). Mock treated DCs did not induce MAIT cell activation. As a 
positive control, isolated MAIT cells were stimulated with PMA/Ionomycin for 24 hours, 
which induced a strong IFN-γ response.  
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Figure 9 MAIT cell activation by DENV infected DCs is dependent on viral replication 
and infection rate but does not require the presence of other PBMC subsets. (a, b) 
PBMCs (n=3-8) were co-cultured for 24 hours with UV-inactivated DENV (UV-DENV), 
DENV, UV-inactivated mock (UV-mock) or mock treated DCs. All viruses were used at an 
MOI of 1 FFU/cell. In addition, PBMCs were incubated with DENV, UV-DENV and mock 
for 24 hours. Percentage of IFN-γ expressing MAIT cells was analysed by flow cytometry. 
(a) Representative flow cytometry plots. (c) Viral replication in DCs (n=5) was confirmed 
by intracellular staining of the DENV protein NS3. (d) Correlation of NS3 positive DENV 
infected DCs against MAIT cell IFN-γ expression by Spearman rank correlation test. (e, f) 
MAIT cells were isolated from PBMCs (n=3) and expanded before use. (f) IFN-γ expression 
of isolated MAIT cells co-cultured for 24 hours with DENV infected or mock treated 
autologous DCs. Statistical significance was determined with a Mann-Whitney test. ns > 
0.05, *P ≤ 0.05, , **P ≤ 0.01.  
91 | P a g e  
 
2.3.2 MAIT cell activation is dependent on cell proximity  
 
Activation of MAIT cells occurs either via TCR engagement to the MR1-ligand complex 
and/or via cytokines, such as IL-12 and IL-18 (Huang et al., 2005, Kjer-Nielsen et al., 2012, 
Ussher et al., 2013). To test whether cell contact or proximity is required for MAIT cell 
activation, PBMCs were cultured in a transwell system in which DCs were separated from 
autologous PBMCs (Fig. 10a+b). Activation of MAIT cells only occurred in the absence of 
a transwell membrane, where direct contact between DENV infected DCs and PBMCs was 
allowed. In contrast, when PBMCs were separated from infected DCs by a transwell 
membrane, only allowing contact with the cell-conditioned medium, no production of IFN-γ 
was observed. Similar results were obtained when incubating PBMCs with conditioned 
medium from DENV infected or mock treated DCs, which did not activate MAIT cells (Fig. 
10c+d).  
Having shown that cell contact or proximity is important for MAIT cell activation, potential 
receptor-ligand interactions were investigated. The ligand presented by MR1 is derived 
from the riboflavin synthesis pathway, which is not found in host cells or viruses (Kjer-
Nielsen et al., 2012). Consistent with this, blocking MR1 with a blocking antibody while co-
culturing PBMCs and DENV infected DCs did not alter MAIT cell activation compared to 
the isotype control (Fig. 11a+b). However, blocking MR1 resulted in complete suppression 
of IFN-γ expression by MAIT cells incubated with DCs pulsed with E.coli. 
The roles of PD-1 and NKG2D, both expressed on MAIT cells, were also investigated (Fig. 
11c-f) (Dusseaux et al., 2011, Jiang et al., 2014). PD-1 has previously been shown to 
influence MAIT cell function whereas triggering NKG2D induces effector functions in T cells 
(Jiang et al., 2014, Groh et al., 2001). However, using blocking antibody against PD-1 (Fig. 
11c+d) or NKG2D (Fig. 11e+f) did not reveal a significant difference in MAIT cell activation, 
judged by IFN-γ expression, compared to the isotype control.  
 
2.3.3 MAIT cell activation is also dependent on cytokines 
 
Since activation was TCR independent, activation of MAIT cells by cytokines was 
assessed. Previous publications demonstrated a role for IL-12, IL-15 and IL-18 in inducing 
IFN-γ expression in MAIT cells (Ussher et al., 2013, Sattler et al., 2015). In addition, Type 
I IFN and IL-2 were also included in this study due to their crucial role in viral infections and  
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Figure 10 MAIT cell activation requires cell contact or proximity to DENV infected 
DCs. Percentage of IFN-γ expressing MAIT cells from healthy individuals were analysed 
by flow cytometry, gated on live CD3+CD161++Vα7.2+ cells. (b, d) Representative flow 
cytometry plots. (a, b) PBMCs (n=8) were co-cultured with autologous DENV infected or 
mock treated DCs in presence or absence of a transwell membrane. As a positive control, 
PBMCs were stimulated with PMA/Ionomycin. (c, d) PBMCs (n=5) were co-cultured for 24 
hours with autologous DENV infected or mock treated DCs or incubated with supernatants 
from DENV infected or mock treated DCs 42 hours post infection. Data is representative 
from at least two independent experiments. Bars represent means ± s.e.m. Statistical 
significance was determined with a Mann-Whitney test. ns > 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
Abbreviations: DENV, dengue virus; Iono, ionomycin; IFN, interferon; S/N, supernatant. 
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Figure 11 Interaction between MAIT cells and DENV infected DCs is not via MR1, PD1 
nor NKG2D. Percentage of IFN-γ expressing MAIT cells, gated on live 
CD3+CD161++Vα7.2+ cells, from healthy individuals were analysed by flow cytometry and 
is shown relative to the isotype control. Mock treated DCs were used as a negative control 
(b, d, f) Representative flow cytometry plots. (a, b) PBMCs (n=3-6) were co-cultured for 24 
hours with autologous DENV or E.coli infected DCs in presence of anti-MR1 antibody or 
isotype control. (c-f) Isotype control, anti-PD1 (n=4) (c, d) or anti-NKG2D (n=3) (e, f) were 
added to the co-culture of DENV infected DCs. Data is representative from at least two 
independent experiments. Bars represent means ± s.e.m. Statistical significance was 
determined with a Mann-Whitney test. ns > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.  
Abbreviations: DENV, dengue virus; IFN, interferon. 
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T cell function (Castet et al., 2002, Liang et al., 2011, Garcia-Sastre, 2011, Boyman and 
Sprent, 2012). MAIT cell activation was examined after using blocking antibodies against 
each cytokine during co-culture of PBMCs and DENV infected DCs (Fig. 12a-d). Isotype 
controls for each antibody were used as a reference for MAIT cell activation. Blocking IL-2 
signalling or IL-15 did not significantly alter IFN-γ expression in MAIT cells (Fig. 12a+b). 
However, MAIT cell activation was significantly reduced while blocking IL-12 and/or IL-18, 
with anti-IL-18 blockade alone leading to complete suppression of IFN-γ expression. 
Additionally, measuring cytokines in the supernatant of DENV infected DCs revealed IL-18 
as the most abundant cytokine after 42 hours infection (Fig. 12e). IL-12p70 and IL-15 were 
only induced in low amounts by DENV infected DCs. Interestingly, DENV infected DCs did 
not secrete IL-18 after 24 hours of infection, corresponding to a co-culture period of 6 hours. 
Hence no MAIT cell activation was detected after 6 hours co-culture with DENV infected 
DCs (Fig. 5a). Having observed no IFN-γ expression in MAIT cells upon co-culture with 
DENV infected monocytes, M1, M2 or HepG2 cells (Fig. 6+7+8), IL-18 levels in 
supernatants after 42 hours DENV infection were analysed by ELISA (Supplementary Fig. 
4a+b). M2 and HepG2 cells did not secrete IL-18 in presence or absence of ADE. 
Interestingly, IL-18 was present in the supernatant of DENV infected M1 in the presence or 
absence of antibodies and levels of IL-18 were similar to that of DENV infected DCs.  
To explore the role of type I IFNs during MAIT cell triggering, three different reagents were 
used: a vaccine virus-encoded soluble type I IFN receptor (B18R) (Symons et al., 1995), a 
neutralising antibody against IFNαβR2 (Type I IFNR) and a selective JAK inhibitor, 
Ruxolinitib (Rux). Interestingly, IFN-γ expression by MAIT cells was strongly reduced by 
B18R and almost completely inhibited using Rux (Fig. 12c+d). In contrast, the neutralising 
antibody induced no significant reduction in MAIT cell activation compared to the isotype 
control. Measuring levels of IFN-α2 in the supernatant of DENV infected DCs after 24 or 
42 hours incubation revealed no difference in concentration compared to mock treated DCs 
(Fig. 12e).    
 
In summary, activation of MAIT cells in vitro is dependent on the presence of DENV infected 
DCs but not monocytes or lymphocytes. This activation is TCR independent but close 
proximity of MAIT cells to the infected DCs is needed to induce IFN-γ expression. 
Furthermore, the results show that secreted IL-18, IL-12 and Type I IFN from DENV 
infected DCs are crucial for MAIT cell activation.  
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Figure 12 MAIT cell activation is dependent on cytokines. (a-d) Percentage of IFN-γ 
expressing MAIT cells from healthy individuals were analysed by flow cytometry and are 
shown relative to the isotype control. Mock treated DCs were used as a negative control. 
(b, d) Representative flow cytometry plots. (a-d) Isotype control, anti-IL-2Rα, anti-IL-12, 
anti-IL-15, Type I IFNR and anti-IL-18 antibodies as well as a soluble type I IFN receptor 
(B18R) and a selective JAK inhibitor (Rux) were added to the co-culture of DENV infected 
DCs (n=3-7). (e) IL-12p70, IL-15, IL-18 and IFN-α2 levels secreted by DENV infected or 
mock treated DCs (n=4) after 24 or 42 hours were measured using a multiplex bead assay. 
Bars represent means ± s.e.m. Statistical significance was determined with a Kruskal-
Wallis test followed by Dunns’ test (a) or a Mann-Whitney test (c, e). ns > 0.05, *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Abbreviations: Rux, Ruxolinitib; hrs, hours. 
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2.4 Correlation of IL-18 Levels and MAIT Cell Activation in vivo 
 
IL-12, IL-18 and Type I IFN were identified as important cytokines for viral MAIT cell 
activation in vitro, thus the relevance of these cytokines were explored in vivo.   
First, levels of IL-18, IL-12p70 and Type I IFN were measured in plasma samples of DHF 
and DF patients during the acute and convalescent phase (conv) of DENV infection (Fig. 
13 and Supplementary Table. 2). Levels of cytokines in patient plasma samples were 
compared to those of HCs. Levels of IL-12p70 and IFN-α2 did not change between patients 
and HCs or between DHF and DF patients (Fig. 11a+b). Interestingly, levels of IL-18 were 
increased during the acute phase of infection compared to HCs. Furthermore, patients 
suffering from the severe form of dengue had higher IL-18 levels compared to patients with 
DF (Fig. 13c). 
 
 
Figure 13 Levels of IL-12p70, IL-18 and IFN-α2 
in plasma of DENV infected patients. Heparin 
plasma from healthy controls (n=7) or patients 
suffering from severe dengue (DHF, n=4-12) or 
dengue (DF, n=4-12) were analysed by multiplex. 
Plasma levels of IL-12p70 (a), IFN-α2 (b) and IL-
18 (c) were measured in plasma samples during 
the acute (day 0) and convalescent (day>10) 
phase of infection and compared to healthy 
controls. Bars represent means ± s.e.m. Statistical 
significance was determined wit a Kruskal-Wallis 
test followed by Dunns’ test (a-c). A Mann-Whitney 
test was applied to compare DHF and DF samples 
(c). ns > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001. Abbreviations: HC, healthy control; 
conv, convalescent; DF, dengue fever; DHF, 
dengue haemorrhagic fever. 
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Having observed a difference in IL-18 levels in plasma samples, additional investigations 
were conducted in a longitudinal study of patient samples to further explore the role of IL-
18 in vivo (Supplementary Table. 2). As seen before, IL-18 levels in plasma were markedly 
increased during the acute phase compared to the convalescent phase of infection and 
HCs (Fig. 14a). In addition, patients with DHF had significantly higher levels of IL-18 over 
the course of acute infection (day -3 to day 0) compared to patient with DF (Fig. 14b). IL-
18 levels peaked at a critical moment for DENV infected patients – the day of 
defervescence (day 0) and reduced to the level of HCs during the convalescent phase of 
infection. Interestingly, expression of the IL-18 receptor (IL-18R) on MAIT cells was also 
upregulated during the acute phase of infection and resolved to the level of HCs in the 
convalescent samples (Fig. 14c). As observed for IL-18, expression of IL-18R on MAIT 
cells was increased in patients with DHF compared DF patients and followed the same 
time course as that of IL-18 (Fig. 14b) as well as CD38 and PD-1 on MAIT cells (Fig. 3g+j).  
Plotting IL-18 levels in plasma samples, IL-18R and CD38 expression on MAIT cells against 
each other, revealed a strong association with increased activation of MAIT cells and 
disease severity in DENV infected patients (Fig. 14e-g).  
 
Taken together, IL-18 in plasma and IL-18R on MAIT cells were increased during the acute 
phase of infection in DENV infected patients. In addition, patients suffering from severe 
dengue showed higher levels of IL-18 and expression of IL-18R over the course of infection. 
Furthermore, levels of IL-18 in plasma as well as IL-18R and CD38 on MAIT cells during 
the acute phase of infection followed the same time course and correlated with disease 
severity. 
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Figure 14 Virally-triggered IL-18 correlates with MAIT cell activation in vivo. PBMC’s 
or plasma samples from healthy controls (n=8-10) or patients suffering from severe dengue 
(DHF, n=2-12) or dengue (DF, n=4-12) were analysed. (a, b) Plasma levels of IL-18. (c, d) 
IL-18Rα expression on MAIT cells. (a, c) Comparison between acute (day 0) and 
convalescent (day>10) phase of infection. (b, d) Comparison between DHF and DF 
patients. (e-g) Correlation of plasma levels of IL-18, MAIT cell CD38 expression and/or 
MAIT cell IL18Rα expression against each other by Spearman rank correlation test. Data 
is representative from at least two independent experiments. Bars represent means. 
Statistical significance was determined with a Kruskal-Wallis test followed by Dunns’ test 
and a Wilcoxon signed-ranks test between matched samples of the acute and conv phase 
(a, c). A Mann-Whitney test was applied to compare DHF and DF samples (b, d). ns > 
0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Abbreviations: HC, healthy control; 
conv, convalescent; DF, dengue fever; DHF, dengue haemorrhagic fever.  
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III.3 Discussion 
 
MAIT cells are an abundant human T cell population with a semi-invariant TCR determining 
bacterial specificity. It has previously been considered that MAIT cells have only a microbial 
reactivity and are not responsive to viral infection (Le Bourhis et al., 2010). However, 
analysing the role of MAIT cells during DENV infection proved that MAIT cells are also 
readily and specifically activated by this virus in vivo and in vitro. Furthermore, the 
mechanism of MAIT cell activation during DENV infection has been defined using an in 
vitro model.  
 
The in vivo data showed that there is evidence of a profound and rapid MAIT cell activation 
in response to DENV infection, which is a severe clinical setting. Of note, patients suffering 
from severe dengue (DHF) exhibited significantly higher levels of activation as judged by 
CD38 expression. This suggests that the MAIT cell response could contribute to the 
pathogenesis of dengue. Activation of MAIT cells could also be observed by upregulation 
of granzyme B and perforin, which are tightly regulated in MAIT cells (Kurioka et al., 2014). 
Due to the fact that the majority of MAIT cells express CD8 and only a small proportion of 
MAIT cells are double negative or CD4 positive, total CD8 T cells were examined in patient 
samples and healthy adults. CD8 T cells revealed increased CD38 expression during the 
course of infection, however activation peaked after patients entered the critical phase of 
infection, a day after defervescence. Furthermore, CD38 expression did not differ between 
DHF and DF patients.  
Interestingly, studies examining the kinetics of DENV specific CD8 T cells in primary or 
secondary DENV infection showed more tetramer specific CD8 T cell responses in patients 
with severe dengue compared to DF. However, this difference was only observed in 
convalescent samples as DENV specific T cell responses were absent or very low during 
the acute phase in those patients (Chau et al., 2008, Dung et al., 2010, Mongkolsapaya et 
al., 2006). Having observed a difference in activation between DHF and DF patients during 
the acute phase of infection only in MAIT cells but not in CD8 T cells reinforces the 
hypothesis that the MAIT cell response could contribute to dengue pathogenesis.   
 
MAIT cells were identified as CD161++Vα7.2+ T cells, which is a common staining approach 
(Martin et al., 2009). In 2013, Reantragoon, R. et al. created antigen loaded MR1 tetramers 
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that unequivocally identify MAIT cells. In this study, MR1 tetramers could not be used due 
to the restricted availability to date. However, previous reports comparing both detection 
methods showed that MAIT cells identified by CD161++Vα7.2+ markers included the 
majority of tetramer-positive MAIT cells (Reantragoon et al., 2013, Fernandez et al., 2014). 
Nevertheless, further studies using MR1 tetramers are needed to further establish the 
distribution of MAIT cell phenotype in dengue and any other viral infection in humans in 
more detail. 
 
Looking at MAIT cell frequencies in patients, a small decrease in circulating MAIT cells was 
observed between the acute phase and the convalescent phase of DENV infection. The 
mechanism for this is not clear. It might result from migration of MAIT cells from the blood 
to tissues or from activation-induced cell death as has been suggested for HIV infection 
(Cosgrove et al., 2013). As MR1 tetramers were not used in this study, another possibility 
could be that the observed loss of MAIT cells in virally infected patients may be explained 
by downregulation of CD161, as previously suggested (Leeansyah et al., 2013, Ussher et 
al., 2013). However, Fernandez et al. showed that in HIV-1 infected patients MR1 tetramers 
did not bind CD161-Vα7.2+ T cells (Fernandez et al., 2014).  
 
Activation of MAIT cells could also be observed by analysing PD-1 expression, which 
followed the same time course as that of CD38 expression on MAIT cells in DENV infected 
patients. In other inflammatory diseases such as HIV, active tuberculosis, lupus or chronic 
HCV, elevated levels of PD-1 on MAIT cells were also observed compared to healthy adults 
(Jiang et al., 2014, Cho et al., 2014, Saeidi et al., 2015, Barathan et al., 2016). PD-1 is 
known as a mediator of immune exhaustion and previous studies reported that PD-1 is 
highly expressed on exhausted CD8 T cells during chronic viral infections (Barber et al., 
2006, Day et al., 2006, Trautmann et al., 2006). However, in acute infections such as 
dengue, PD-1 can be transiently expressed upon immune stimulus on multiple immune 
cells, including T cells, B cells and macrophages (Hokey et al., 2008, Bally et al., 2015, de 
Alwis et al., 2016); thus indicating activation rather than exhaustion. Nevertheless, it would 
be of interest to investigate the expression of other inhibitory molecules, such as TIM-3 and 
CTLA-4 (CD152) on MAIT cells in DENV infection.      
As for CD38 expression, PD-1 was expressed at higher levels in patients suffering from 
severe dengue compared to patients with DF during the acute phase of infection. Even 
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though PD-1 expression on MAIT cells reduced in convalescent samples, DHF patients still 
showed higher PD-1 levels compared to patients with DF. Previous reports have suggested 
a genetic and epigenetic regulation of PD-1 in CD8 T cells, which maintain PD-1 expression 
even in the absence of antigenic stimulation (Utzschneider et al., 2013, Bally et al., 2016). 
Whether the level of PD-1 on MAIT cells has an impact on its function and on dengue 
pathogenesis in vivo remains to be investigated. However, blocking PD-1 in vitro with a 
blocking antibody slightly increased MAIT cell activation, as shown by IFN-γ expression. 
The same effect of PD-1 on MAIT cells was observed in PBMCs from patients with active 
tuberculosis after BCG stimulation (Jiang et al., 2014). These data might suggest that IFN-
γ production in MAIT cells is modulated to some extent by PD-1 signalling. Thus, higher 
levels of PD-1 in patients suffering from severe dengue may be a possible mechanism for 
MAIT cells to stay highly activated without causing overwhelming immunological pathology.  
Furthermore, PD-1 on MAIT cells was expressed at similar levels in HC samples and in 
patient samples during the acute phase of infection, with 30.4% and 20.6% respectively. 
However, in previous studies expression levels of PD-1 on MAIT cells in healthy adults 
were reported to be much lower, around 5% (Cho et al., 2014, Jiang et al., 2014). The 
reason for this elevated expression of PD-1 in healthy adults is not clear. In this study, HCs 
were obtained by the NHS blood service without any further donor information. Thus 
elevated PD-1 levels might result from unhealthy donors or from additional blood 
manipulation by the NHS. Interestingly, Duraiswamy et al. demonstrated that PD-1high 
expressing CD8 T cells have a different gene signature and phenotype in healthy human 
adults than in virally infected humans (Duraiswamy et al., 2011). Hence, PD-1 expression 
can represent different cell stages in distinct environmental conditions, therefore comparing 
levels of PD-1 between healthy human adults and DENV infected children should be 
interpreted with caution.   
 
The correlation between levels of IL-18 in the plasma of patients, levels of IL-18R on MAIT 
cells and MAIT cell activation suggests an important function of IL-18 in this activation 
process. The role of IL-18 in inducing IFN-γ expression in MAIT cells was also observed in 
an in vitro model, in which autologous PBMCs were co-cultured with DENV infected DCs 
in the presence of blocking antibodies against various cytokines.  
In addition to cytokine stimulation, MAIT cell activation required cell contact or cell proximity 
to DENV infected DCs, as demonstrated by the use of a transwell system or by cell 
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conditioned media from DENV infected DCs. As expected, cell contact dependent 
activation was not promoted via the interaction of MR1 with the TCR of MAIT cells as 
previous work demonstrated that ligands presented on MR1 are not found in host cells or 
viruses (Kjer-Nielsen et al., 2012). 
Next, the role of NKG2D on MAIT cells was assessed upon DENV infection. MAIT cells 
express high levels of this receptor and triggering NKG2D induces effector functions in T 
cells (Groh et al., 2001, Dusseaux et al., 2011). However, blocking NKG2D in the co-culture 
did not alter IFN-γ expression in MAIT cells. Similar result was found by Le Bourhis et al. 
looking at MAIT cell responses towards bacteria infected epithelial cells (Le Bourhis et al., 
2013). 
MAIT cells also display a strong expression of the C type lectin CD161, also known as 
NKR-P1A (Martin et al., 2009). The effect of CD161 upon interaction with its ligand LLT1 
induces distinct outcomes depending on the cell type and environmental condition. Ligation 
of CD161 on NK cells inhibits cytotoxicity and diminishes IFN-γ expression whereas on T 
cells it can be co-stimulatory and enhances IFN-γ expression (Aldemir et al., 2005, Rosen 
et al., 2005). Interestingly, the effect of CD161 on MAIT cells mimics that of NK cells, as 
triggering CD161 reduces IFN-γ production (Le Bourhis et al., 2013). In this study, the role 
of CD161 could not be investigated due to the lack of a commercially available blocking 
antibody against CD161 or LLT1. In addition, detection of LLT1 on DENV infected or mock 
treated DCs was difficult as LLT1 could not be measured with an anti-LLT1 antibody (Gift 
from C.B.Willberg) nor by RNA sequencing (data not shown). This is in opposition to 
existing literature showing upregulation of LLT1 on activated DCs upon stimulation with 
TLR3/4/8, inactivated viruses or IFN-γ (Rosen et al., 2008, Germain et al., 2011). Further 
experiments should be performed to explore the role of CD161 on MAIT cells in the context 
of DENV infection. 
It might also be that activation is not driven by a direct receptor-ligand interaction but rather 
via the formation of functional synapses between DCs and MAIT cells, as has been 
suggested for NK cell activation (Borg et al., 2004, Semino et al., 2005). In addition, Kurioka 
et al. demonstrated immunological synapses formation between CD161++CD8+ T cells, 
which are the majority of MAIT cells, and infected target cells (Kurioka et al., 2014). Thus, 
it might be possible that functional synapses are required for MAIT cell activation in 
response to DENV infected DCs in vitro. As synapse formation depends on cytoskeleton 
remodelling and lipid raft mobilisation, disruption of these processes using pharmacologic 
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agents might be used to address this hypothesis. In addition, temporal and spatial 
redistribution of IL-12 and/or IL-18 in DCs might be observed under confocal microscopy 
during the interaction of DCs with MAIT cells. 
 
Activation of MAIT cells by DENV infected DCs required viral replication in the host cell, as 
observed during co-culture with UV-DENV infected DCs. In addition, MAIT cell activation 
positively correlated with the level of productive infection in DCs. Interestingly for other 
viruses such as hepatitis C virus (HCV) and influenza A virus (IAV), viral replication was 
not required (van Wilgenburg et al., 2016). However, MAIT cell activation was induced by 
TLR sensing in APCs. Accordingly, these viruses showed a poor replication in APCs 
compared to DENV. Using a range of TLR agonists, Klenerman et al. demonstrated that 
stimulation of TLR3 and/or TLR8 in APCs was sufficient for IL-12 and IL-18 secretion, which 
induced MAIT cell activation (Billerbeck et al., 2010, Ussher et al., 2013, Jo et al., 2014). 
In the case of DENV, MAIT cells are activated by cytokines as well as cell-cell interaction. 
This could be a possible explanation why TLR sensing is not sufficient for MAIT cell 
activation in the context of DENV infection, as it needs receptor-ligand interaction which 
might only be present on the cell surface once viral replication occurs. However, further 
experiments should be performed to investigate this hypothesis. 
 
MAIT cells belong to the family of unconventional T cells and previous work showed that 
monocytes are important cells that augmented the IFN-γ response of an unconventional T 
cell, γδ T cells, upon co-culture with autologous DENV infected DCs (Tsai et al., 2015). In 
this in vitro setting, γδ T cells were activated by cytokines Type I IFN and IL-18 and the 
lack of monocytes in culture resulted in lower IL-18 levels, leading to diminished IFN-γ 
expression by γδ T cells. In contrast to γδ T cells, activation of MAIT cells did not require 
monocytes or other lymphocytes in culture during DENV infection. This could be due to the 
fact that MAIT cells might be more sensitive to IL-18 than γδ T cells as MAIT cells express 
high amounts of IL-18R (Turtle et al., 2009, Le Bourhis et al., 2010). As a consequence IL-
18 levels secreted by DCs may be sufficient for full activation. Furthermore, since activation 
of MAIT cells was not only driven by cytokines but also required cell contact or proximity to 
the infected DCs other factors might influence MAIT activation in response to DENV.   
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Interestingly, only DENV infected DCs were able to induce IFN-γ expression in MAIT cells. 
Other major target cells of DENV, such as primary human monocytes, M1 as well as M2 
failed to induce activation of MAIT cells.  
Human monocytes can be divided into three subsets based on the cell surface expression 
of CD14 and CD16 (Ziegler-Heitbrock et al., 2010, Wong et al., 2011). Discrete monocyte 
subsets express distinct patterns of cytokine secretion upon viral infection, with CD16+ 
monocytes producing more pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-18 
(Cros et al., 2010, Wong et al., 2012, Tsai et al., 2015). In this study classical monocytes 
which are defined by the lack of CD16 expression were used. Accordingly, IL-18 was not 
detected in the supernatant of DENV infected monocytes after 42 hours, which coincided 
with the lack of MAIT cell activation. Further work should be performed to analyse the effect 
of different monocyte subsets on MAIT cell activation. However, the absence of IFN-γ 
expression in MAIT cells could also be explained by low infection rates, which ranged from 
2-10 % infected cells in the presence of antibodies but was almost undetectable in the 
absence of antibodies. Previous studies have reported similar levels of infection rates 
(Boonnak et al., 2011, Sun et al., 2011, Kou et al., 2008), thus it is difficult to determine 
whether higher level of DENV infection in monocytes would induce MAIT cell activation.   
Another major target cell for DENV replication is the macrophage (Halstead, 1989, 
Halstead et al., 1977). In this study, the effect of both macrophage subsets M1 and M2 on 
MAIT cell activation was investigated. In both macrophage subsets infection rates were 
enhanced in the presence of antibodies. However, this increase was more dramatic in M2 
than M1 with a 7 and 2 fold increase respectively. This is in line with the observation that 
M2 expresses higher levels of the Fcγ receptor CD16 on the cell surface compared to M1, 
leading to increased ADE. Interestingly, Wu et al. demonstrated that DENV replicates more 
efficiently in M1 than M2 in absence of ADE (Wu et al., 2013b). This observation could not 
be reproduced in this study, in fact the opposite was noted. A reason for this discrepancy 
could be the differences in MOI used to infect macrophages. The distinct infection rates for 
M1 and M2 seen by Wu et al. was especially striking at a MOI of 30, with 15% infected M1 
compared to 3% infected M2. At an MOI of 5, this difference could still be detected but at 
much lower rate with 3.5% infected M1 and 1.5% infected M2. In this study a MOI of 1 was 
used. Thus, it would be interesting to see whether findings of Wu et al. could be reproduced 
when infecting cells at higher MOI.  
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Both Macrophage subsets did not activate MAIT cells upon DENV infection. This came as 
a surprise especially for M1 which produces IL-18 upon DENV infection as reported in this 
study and by other groups (Wu et al., 2013b, Wu et al., 2013a). The reason for the lack of 
MAIT cell activation is not clear. A possible cause could be that the required interaction 
observed between DENV infected DCs and MAIT cells is not expressed on macrophages. 
However, further experiments should be performed to investigate this hypothesis.  
 
Using a longitudinal study to measure IL-18 levels in the plasma of DENV infected patients 
revealed that levels of IL-18 follow the same time course as those of IL18R and CD38 on 
MAIT cells. This is in agreement with previous studies, which reported increased IL-18 
levels in DENV infected patients compared to healthy adults (Mustafa et al., 2001, Pohan 
et al., 2004, Chirathaworn et al., 2010, Rathakrishnan et al., 2012, Michels et al., 2015). 
However, the observed variation in IL-18 levels between DHF and DF patients remains 
controversial. This is most likely due to the lack of consistency in those studies in disease 
classification, sample sizes and time points of sample collection. In line with our findings, 
some studies observed higher serum IL-18 levels in patients with DHF compared to DF 
(Mustafa et al., 2001, Pohan et al., 2004). Mustafa et al. also showed that IL-18 levels in 
the serum of patient samples correlated with the grade of disease severity; DHF IV having 
the highest IL-18 levels with 300 pg/ml and DF the lowest with 100 pg/ml (Mustafa et al., 
2001). As mentioned before, this trend was not observed in all studies (Michels et al., 2015, 
Rathakrishnan et al., 2012, Chirathaworn et al., 2010). However, the grade of DHF from 
patients with severe dengue, if included in the analysis, was not specified. In addition, the 
day of sample collection during the acute phase of infection was either not mentioned 
(Chirathaworn et al., 2010, Rathakrishnan et al., 2012) or blood was taken on day 1 or 2 
after the day of defervescence (Michels et al., 2015), which might be too late to detect 
differences in IL-18 levels. Michels et al. analysed levels of biologically active IL-18 
between DHF and DF patients. Even though the difference between both groups was not 
significant, a trend could be observed with higher free IL-18 levels in patient suffering from 
severe dengue. A reason why significance was not reached might be the variation in the 
sample size between both groups, with 60 DF and 10 DHF samples. Thus, results from 
previous studies should be interpreted with caution.   
IL-18 binding protein (IL-18BP) is a soluble protein which binds to mature IL-18 and 
prevents its interaction with the IL-18R, thus acting as a natural inhibitor (Kim et al., 2000, 
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Arend et al., 2008). As previously reported, levels of IL-18BP were increased in the plasma 
of DENV infected patients during the acute phase of infection compared to HCs 
(Chirathaworn et al., 2010, Michels et al., 2015). Hence, in addition to measured IL-18 
levels in plasma samples, IL-18BP levels should be measured to obtain a precise readout 
for biologically active IL-18. In conclusion, the correlation between levels of IL-18, levels of 
IL18R on MAIT cells and disease severity suggests an important role for IL-18 in the 
pathogenesis of dengue, as has been proposed for other inflammatory diseases such as 
sepsis or arthritis (Wei et al., 2001, Endo et al., 2000). 
The explored mechanism for MAIT cell activation in the context of DENV infection revealed 
a central role for IL-18. However, the critical co-stimulation was not restricted to a single 
cytokine. As previously described, IL-12 was also important for the induction of IFN-γ 
expression in MAIT cells (Ussher et al., 2013). Additionally, a role for Type I IFNs in the 
activation of MAIT cells was observed depending on reagents used for blocking Type I 
IFNs. This finding is consistent with data from NK and γδ T cells, where such cytokine 
mediated activation is described (Tsai et al., 2015, Matikainen et al., 2001). In addition, 
recent findings showed an effect of Type I IFNs on MAIT cell activation in vitro and in 
response to HCV (van Wilgenburg et al., 2016, Spaan et al., 2016).   
In this study, the role of Type I IFNs was assessed using three different reagents; the 
vaccine virus-encoded, soluble type I IFN receptor (B18R), a neutralising antibody against 
the IFNαR2 (Type I IFNR) and a selective JAK1/2 inhibitor, Ruxolinitib (Rux).  Apart from 
anti-Type I IFNR, all reagents showed a significant reduction of IFN-γ expression in MAIT 
cells. Anti-Type I IFNR is an antibody which binds with high affinity to the extracellular 
domain of the IFNα receptor (Colamonici and Domanski, 1993) and even though reduction 
of IFN-γ expression was not significant, a clear trend could be observed. The effect of this 
reagent varied between donors from no impact to a strong inhibition. The reason for this is 
not clear, however increasing the amount of anti-Type I IFNR might be a useful approach 
to overcome this variation. In contrast to B18R which is specific to IFN-α/β (Alcami et al., 
2000), results obtained by the reagent Rux should be interpreted with caution. Rux is a 
Janus kinase (JAK) inhibitor with selectivity for JAK1/2. Both JAKs are crucial in the 
response to IFNs however other cytokine receptors also operate via JAK1/2. Thus, blocking 
both JAKs might have an impact on various cytokine signalling pathways in DCs  (Schindler 
et al., 2007). Furthermore, Heine et al. demonstrated that applying Rux on monocyte 
107 | P a g e  
 
derived DCs leads to reduced function and activity as well as decreased IL-12 production 
(Heine et al., 2013). 
Having observed an effect of Type I IFN on MAIT cell activation, levels of IFN-α were 
measured in supernatants of DENV infected DCs after 24 and 42 hours post infection. 
Interestingly, Type I IFN was not induced upon DENV infection. This is in contrast to 
published data which detected IFN-α at a concentration of 35 to 2000 pg/ml in the 
supernatant of DENV infected DCs after 24 or 48 hours (Ho et al., 2001, Palmer et al., 
2005, Sun et al., 2009, Lim et al., 2014, Nightingale et al., 2008). However, the use of a 
different DENV serotype (Lim et al., 2014) or strains (Nightingale et al., 2008, Ho et al., 
2001, Palmer et al., 2005, Sun et al., 2009) as well as higher MOI (Sun et al., 2009, 
Nightingale et al., 2008) could be an explanation for this discrepancy. Furthermore, in this 
study Type I IFN was measured only via the detection of IFN-α2, which is one out of 13 
IFN-α subtypes (Gibbert et al., 2013). Thus, further IFN-α subtypes should be measured to 
verify the result. Using the same viral strain and MOI than this study, Rodriguez-Madoz et 
al. reported extremely low IFN-α levels at 15 pg/ml in the supernatant of DENV infected 
DCs after 36 to 72 hours using a panspecific IFN-α ELISA (Rodriguez-Madoz et al., 2010).   
 
In conclusion, human MAIT cells are activated in response to DENV infection in vivo and 
in vitro. MAIT cell activation was driven by cytokines such as IL-18, IL-12 and Type I IFN 
as well as cell contact or proximity to the infected DCs. In addition, levels of IL-18, IL-18R 
and CD38 on MAIT cells correlated with disease severity, suggesting an important role for 
IL-18 in this process. These data extend the likely functions of these abundant human 
lymphocytes well beyond their traditional anti-microbial confines. Modulation of this cell 
subset could provide a novel opportunity to influence disease outcome in DENV and 
perhaps also other viral infections. 
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IV.1 Introduction 
 
Mucosal associate invariant T (MAIT) cells are a recently discovered subset of 
unconventional T cell that express a semi-invariant TCR composed of the invariant TCRα 
chain Vα7.2-Jα33 (Tilloy et al., 1999, Treiner et al., 2003). MAIT cells are very abundant in 
humans and account for 1-10% of T cells in peripheral blood (Martin et al., 2009). They are 
also present in the liver, skin and in a number of mucosal tissues (Martin et al., 2009, 
Dusseaux et al., 2011, Teunissen et al., 2014). The MAIT TCR engages with ligands that 
are presented by the highly conserved HLA-Ib MHC-related protein 1 (MR1) (Huang et al., 
2009). In both mouse and man, MR1 ligands include derivatives of the vitamin B9 (folate) 
and the vitamin B2 (riboflavin) synthesis pathway (Kjer-Nielsen et al., 2012). As both 
vitamin biosynthetic pathways are unique to bacteria and yeast, it has been suggested that 
MAIT cells are only restricted to microbial infections (Le Bourhis et al., 2010, Kjer-Nielsen 
et al., 2012). Several in vivo studies using MR1 knock-out and wild-type mice have 
confirmed a protective role for MAIT cells against bacterial infections, such as Klebsiella 
pneumonia, Mycobacterium bovis and Francisella tularensis (Georgel et al., 2011, 
Meierovics et al., 2013, Chua et al., 2012).    
 
The impact of MAIT cells during microbial infections is vast. Upon activation, MAIT cells 
are able to rapidly produce a diverse range of cytokines such as IFN-γ, IL-2, TNF-α and IL-
17 as well as kill infected target cells via granzyme B and perforin (Dusseaux et al., 2011, 
Le Bourhis et al., 2013, Kurioka et al., 2014). In addition, MAIT cells can reduce bacterial 
growth within macrophages in a MR1 independent but IL-12 dependent manner (Chua et 
al., 2012, Meierovics et al., 2013). MAIT cells have also been shown to induce early 
recruitment of activated T cells to the site of infection during a pulmonary Francisella 
infection in mice (Meierovics et al., 2013). Thus, early MAIT cell activation can restrict 
bacterial growth and dissemination as well as influence the subsequent adaptive immune 
response. 
 
MAIT cells have a distinct phenotypic and functional profile. They are characterised by high 
expression of the C type lectin CD161 (KLRB1 or NKR-P1A) as well as two key 
transcription factors (TFs) RORγt and PLZF (Dusseaux et al., 2011, Martin et al., 2009). 
Recent studies reported that T cells expressing CD161 share a common transcriptional 
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signature and an ‘innate-like’, TCR independent response to IL-12 and IL-18 (Fergusson 
et al., 2014). This has been confirmed by Ussher et al. demonstrating a cytokine dependent 
activation of MAIT cells via IL-12 and IL-18 (Ussher et al., 2013). RORγt is a key TF for the 
development of type 17 function (Ivanov et al., 2006, Curtis and Way, 2009). This is 
consistent with the observed anti-bacterial functions and IL-17 production by MAIT cells. In 
contrast, PLZF has been associated with the development and the ‘innate’ effector function 
of iNKT cells (Martin et al., 2009, Rahimpour et al., 2015, Savage et al., 2008, Kovalovsky 
et al., 2008). Thus, this dual transcriptional drive suggests that MAIT cells may have 
multiple functionalities depending on environmental conditions. 
 
Given the ‘innate' phenotype of MAIT cells and their responsiveness to IL-12 and IL-18, a 
recent study (also part of Chapter 3 in this thesis) investigated MAIT cell activation during 
human viral infections, including dengue virus (DENV) (van Wilgenburg et al., 2016). A 
marked activation of MAIT cells was observed during the course of several viral infections. 
DENV is a rapidly emerging pathogen causing an estimated 100 million symptomatic 
infections annually worldwide (Bhatt et al., 2013). Patients infected with DENV can be 
asymptomatic or develop illnesses ranging from a mild, flu-like syndrome to a severe and 
sometimes fatal disease. The factors contributing to differential outcome of DENV disease 
are not entirely understood which impedes the development of effective antiviral treatments 
and vaccines to date. 
Interestingly, MAIT cell activation correlated with disease severity in DENV infected 
patients suggesting that MAIT cells may contribute in the pathogenesis of dengue (van 
Wilgenburg et al., 2016). However, the impact of MAIT cell activation on human immunity 
and DENV infection has not been addressed and remains unclear. In this study, the 
influence of MAIT cells on DENV infection and production is investigated to better 
understand the consequences of MAIT cell activation on disease development.   
 
 
 
 
 
111 | P a g e  
 
IV.2 Results 
 
2.1 Activated MAIT Cells enhance DENV Infection of U937 
Cells 
 
Having observed MAIT cell activation during DENV infection, the functional impact of 
activated MAIT cells on viral replication and infection was explored in vitro. Sorted MAIT 
cells were stimulated in a TCR-independent manner with IL-12 and IL-18 for 24 hours 
(Ussher et al., 2013). MAIT cells were washed in media to remove any excess cytokines 
before they were co-cultured with a monocytic cell line, U937 cells. After overnight co-
culture, U937 cells were infected with DENV at an MOI of 5 FFU/cell in the presence of a 
monoclonal antibody against the DENV protein prM (anti-prM). Dejnirattisai et al. identified 
anti-prM as a major component promoting ADE (Dejnirattisai et al., 2010) and previous 
studies demonstrated the importance of ADE for a successful DENV infection in U937 cells 
(Kontny et al., 1988, Diamond et al., 2000) (Fig. 15a). As a negative control, U937 cells 
were incubated with antibodies in the absence of DENV. Infection rates of U937 cells were 
assessed by flow cytometry using a fluorochrome labelled antibody against the DENV non-
structural protein NS3. The percentage of infected cells was compared to that of U937 cells 
without MAIT cells and represented as fold ratios.  
The addition of stimulated MAIT cells to U937 cells showed a 1.5 fold increase in infection 
rate in U937 cells at an effector-target (E/T) ratio of 1:1 and 10:1 (Fig. 15b). This 
enhancement could not be observed at a lower E/T ratio of 1:10. To ensure that the 
observed effect on DENV infection is due to the activation of MAIT cells, U937 cells were 
co-cultured with unstimulated MAIT cells at similar ratios. As expected, unstimulated MAIT 
cells did not enhance infection rates of U937 at various E/T ratios. Next, viral production of 
U937 cells in presence of activated or rested MAIT cells was investigated (Fig. 15c).  To 
do so, supernatants of infected U937 cells were collected on day 2 post infection and viral 
loads were analysed by focus forming assay. DENV infected U937 cells in the absence of 
MAIT cells showed a weak viral production of 280 FFU/ml. Addition of IL-12 and IL-18 
stimulated MAIT cells increased viral loads up to 7x103 FFU/ml at an E/T ratio of 1:1. 
Increasing the number of activated MAIT cells by 10 fold reduced viral production back to 
103 FFU/ml. A similar viral load was obtained at an E/T ratio of 1:10. After the addition of 
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unstimulated MAIT cells at various E/T ratios the viral load remained stable. Thus, 
stimulation of MAIT cells with IL-12 and IL-18 induces responses that can enhance the 
effects of ADE on the monocytic cell line, U937 cells, in vitro.    
 
 
Figure 15 Activated MAIT cells can enhance DENV infection and production in U937 
cells. Sorted MAIT cells (CD3+CD161++Vα7.2+) were rested or activated in a TCR-
independent manner with IL-12 and IL-18 for 24 hours. Rested or stimulated MAIT cells 
were transferred on U937 cells and incubated for 18 hours before DENV infection in the 
presence or absence of a monoclonal antibody against the DENV protein prM (anti-prM). 
(a, b) Infection rate of U937 cells, gated on live CD3-CD14+ cells, was measured by flow 
cytometry 24 hours post infection using intracellular staining of the DENV non-structural 
protein NS3. (a) Representative flow cytometry plots of U937 infection rates in presence or 
absence of anti-prM. (b) Infection rates of U937 cells (n=10) in presence of anti-prM and 
presented as fold ratios relative to infected U937 cells without MAIT cells. (c) Viral 
production (n=3) was measured by focus forming assay 2 days post infection. Data are 
representative from at least two independent experiments. Bars represent means ± s.e.m. 
Statistical significance was determined with a Kruskal-Wallis test followed by Dunns’ test. 
ns > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Abbreviations: E, effector 
cell; T, target cell; DENV, dengue virus; Ab, antibody. 
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Figure 16 Activated MAIT cells can limit DENV infection and production in 
monocytes and DCs. Sorted MAIT cells were rested or activated in a TCR-independent 
manner with IL-12 and IL-18 for 24 hours. Rested or stimulated MAIT cells were transferred 
to monocytes or DCs and incubated for 18 hours before DENV infection. (a-c) Infection 
rate of monocytes (n=6) or DCs (n=6-8), gated on live CD3-CD14+ cells, were measured 
by intracellular staining of the DENV protein NS3, 24 hours post infection. (a, b) 
Representative flow cytometry plots of infection rates of monocytes (a) or DC’s (b) in the 
presence and absence of a monoclonal antibody (anti-prM). (c) Infection rates are 
presented as fold ratios relative to infected monocytes or DCs without MAIT cells. (d) Viral 
production for monocytes (n=4) and DCs (n=4) were measured by focus forming assay 3 
days post infection. Bars represent means ± s.e.m. Statistical significance was determined 
with a Kruskal-Wallis test followed by Dunns’ test. ns > 0.05, *P ≤ 0.05, **P ≤ 0.01.   
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2.2 Activated MAIT Cells inhibit DENV Infection of Primary 
Human Cells 
 
To investigate the impact of MAIT cells on primary human cells, unstimulated or IL-12 and 
IL-18 stimulated MAIT cells were co-cultured with freshly isolated primary human 
monocytes or monocyte derived DCs (DCs) (Fig. 16). As for U937 cells, unstimulated and 
stimulated MAIT cells were washed in media to remove any cytokine excess before co-
culturing with target cells. After overnight incubation, cells were infected with DENV. In the 
case of monocytes, DENV infection was performed at an MOI of 5 FFU/cell in the presence 
of a monoclonal antibody (anti-prM). In absence of anti-prM, infection rates of monocytes 
were undetectable to very low (Fig. 16a). In contrast, infection rates of DENV infection of 
DCs were not influenced by the presence or absence of antibodies as they express high 
levels of a DENV receptor called DC-SIGN (Tassaneetrithep et al., 2003) (Fig. 16b). 
Therefore, DENV infection of DCs was performed at an MOI of 1 FFU/cell in absence of 
anti-prM. Infection rates of monocytes and DCs were assessed by flow cytometry using an 
anti-NS3 antibody and represented as fold ratios relative to infected cells without MAIT 
cells (Fig. 16c).    
Activated MAIT cells reduced infection rates of monocytes at various E/T ratios. 
Interestingly, the effect of activated MAIT cells on DENV infection was the strongest at an 
E/T ratio of 1:10, showing almost a complete inhibition with a fold ratio of 0.04. Increasing 
the E/T ratio by 10 reduced the effect gradually and resolved to a 2 fold reduction at the 
highest E/T ratio. DENV infection in DCs in the presence of activated MAIT cells at various 
concentration revealed similar results as for monocytes. The strongest inhibition of DENV 
infection was observed at the lowest E/T ratio with a reduction of 75%. As previously 
observed, increased amounts of stimulated MAIT cells reduced the effect by 2 fold. Co-
culture of monocytes or DCs with unstimulated MAIT cells did not significantly alter the 
infection rate at various E/T ratios.  
Next, the impact of MAIT cells on DENV production was assessed in monocytes and DCs 
(Fig. 16d). Supernatants of infected target cells in the presence or absence of unstimulated 
or IL-12 and IL-18 stimulated MAIT cells were collected on day 3 post infection and viral 
loads were analysed by focus forming assay. DENV infected monocytes in the absence of 
MAIT cells produced around 4x104 FFU/ml of DENV. The addition of activated MAIT cells 
strongly reduced viral production to 35, 25 and 160 FFU/ml at an E/T ratio of 1:10, 1:1 and 
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10:1, respectively. Viral production of DENV infected DCs in the absence of activated MAIT 
cells resulted in a viral load of 2x105 FFU/ml. In the presence of IL-12 and IL-18 stimulated 
MAIT cells, a 2 log reduction in viral production could be observed at an E/T ratio of 1:10 
and 1:1. As previously observed, a 10 fold increase in MAIT cell concentration reduced this 
effect to 3x104 FFU/ml. Co-culture of DENV infected monocytes or DCs with unstimulated 
MAIT cells did not alter viral production at various E/T ratios. To sum up, activation of MAIT 
cells induced by cytokines inhibits DENV infection and production in primary human 
monocytes and DCs. 
  
2.3 Cell Type Specific and Dose Dependent Impact of 
Recombinant Human IFN-γ on DENV Infection 
 
IL-12 and IL-18 were important cytokines in the in vitro co-culture model to induce MAIT 
cell activation, as blocking IL-12 and/or IL-18 led to reduced IFN-γ (Fig. 12a+b). 
Furthermore, Klenerman et al. reported a TCR independent stimulation of MAIT cells via 
IL-12 and IL-18, leading to IFN-γ expression (Ussher et al., 2014a). To verify these 
observations, production of IFN-γ by MAIT cells was analysed after 24 hours stimulation 
with IL-12 and IL-18 in vitro (Fig. 17a). As expected, up to 25% of MAIT cells expressed 
IFN-γ after stimulation. Next, recombinant human IFN-γ was used to investigate whether it 
could mimic the effects of activated MAIT cells observed on DENV infection (Fig. 17 and 
Supplementary Fig. 5). Therefore instead of incubating target cells with unstimulated or IL-
12 and IL-18 stimulated MAIT cells, a 10 fold dilution of recombinant human IFN-γ was 
added, starting from 103 U/ml. As before, infection rates were assessed by flow cytometry 
using an anti-NS3 antibody and represented as fold ratios relative to infected cells without 
the addition of recombinant human IFN-γ. 
DENV infection of the monocytic cell line, U937 cells, increased gradually in the presence 
of 0.1 to 10 U/ml of recombinant human IFN-γ, leading to a 2 fold increase at 10 U/ml (Fig. 
17b and Supplementary Fig. 5). Interestingly, additional increase in the amount of added 
IFN-γ to the target cells resulted in an opposite effect and showed a 2 fold inhibition of 
DENV infection at 103 U/ml. Thus, the effect of recombinant human IFN-γ is dose 
dependent and can have an enhancing or inhibiting impact on DENV infection of U937 
cells. For primary human monocytes and DCs the addition of recombinant human IFN-γ 
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led to a reduction in DENV infection, reaching almost complete inhibition at 103 U/ml with a 
fold ratio of 0.05 and 0.07, respectively (Fig. 17c+d and Supplementary Fig. 5).  
In conclusion, recombinant human IFN-γ mimics the effect observed by activated MAIT 
cells on DENV infection. Furthermore, the addition of IFN-γ on DENV infection can have 
enhancing or inhibiting impact depending on the concentration of IFN-γ and the infected 
cell type.   
 
Figure 17 Recombinant human IFN-γ mimics the effect of activated MAIT cells on 
DENV infection. (a) Sorted MAIT cells (CD3+CD161++Vα7.2+) were rested (-) or activated 
in a TCR-independent manner with IL-12 and IL-18 for 24 hours. IFN-γ expression by MAIT 
cells was analysed by flow cytometry. (b-d) A 10 fold dilution series was performed on 
recombinant human IFN-γ starting from 103U/ml. U937 cells (n=4, b), monocytes (n=4, c) 
or DCs (n=4, d) were incubated with recombinant IFN-γ for 18 hours before DENV infection. 
A monoclonal antibody (anti-prM) was added for U937 cells and monocytes. Infection rate 
of target cells, gated on live CD3-CD14+ cells, were measured by intracellular staining of 
the DENV protein NS3, 24 hours post infection. Bars represent means ± s.e.m. Statistical 
significance was determined with a Kruskal-Wallis test followed by Dunns’ test. ns > 0.05, 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
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2.4 MAIT Cells influence the Infection Rate of DENV Infected 
Cells via IFN-γ 
 
Having observed similar effects on DENV infection from activated MAIT cells and 
recombinant human IFN-γ, the hypothesis raised whether activated MAIT cells influence 
DENV infection via IFN-γ. To assess this theory, unstimulated and IL-12 and IL-18 
stimulated MAIT cells were co-cultured with target cells at an E/T ratio of 1:1 in presence 
of a blocking antibody against IFN-γ (anti-IFN-γ) (Fig. 18 and Supplementary Fig. 6). The 
isotype antibody IgG1 was used as a reference and infection rates were represented as 
fold ratio relative to target cells co-cultured with unstimulated MAIT cells in the presence of 
the IgG1 antibody.  
First, activation of MAIT cells by IL-12 and IL-18 was confirmed using an intracellular 
staining of IFN-γ (Fig. 18a). Infection rates of U937 cells co-cultured with unstimulated 
MAIT cells were similar in presence or absence of anti-IFN-γ (Fig. 18b and Supplementary 
Fig. 6). Again, a 2 fold increase in DENV infection of U937 cells was observed after the 
addition of activated MAIT cells in the presence of the isotype control. Addition of anti-IFN-
γ reversed DENV enhancement by activated MAIT cells and resulted to similar infection 
rates of U937 cells as with unstimulated MAIT cells. 
Next, the impact of IFN-γ produced by MAIT cells was assessed in primary human 
monocytes (Fig. 18c and Supplementary Fig. 6) and DCs (Fig. 18d and Supplementary Fig. 
6) using anti-IFN-γ. For both cell types, DENV infection remained unchanged after co-
culture with unstimulated MAIT cells in presence or absence of anti-IFN-γ. Using activated 
instead of rested MAIT cells in the presence of IgG1 potently suppressed DENV infection 
to 90%. This inhibition was restored after the addition of anti-IFN-γ to the co-culture. These 
data demonstrate that DENV infection of target cells is modulated by activated MAIT cells 
via IFN-γ.      
To sum up, activated MAIT cells by IL-12 and IL-18 induced responses that can enhance 
or inhibit DENV infection of several major target cells, such as primary human DCs, 
monocytes and the monocytic cell line U937 in vitro. The effects on DENV infection by 
activated MAIT cells were driven by IFN-γ and dependent on the target cell and the amount 
of IFN-γ. These data suggest a possible mechanism for how activation of MAIT cells could 
contribute to the antiviral defence or pathogenesis during DENV infection in vivo.  
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Figure 18 Activated MAIT cells influence DENV infection via IFN-γ. (a) Sorted MAIT 
cells (CD3+CD161++Vα7.2+) were rested (-) or activated in a TCR-independent manner with 
IL-12 and IL-18 for 24 hours. IFN-γ expression by MAIT cells was analysed by flow 
cytometry. (b-d) Rested (MAIT-) or stimulated (MAIT+) MAIT cells were transferred to U937 
cells (n=3, b), monocytes (n=4, c) or DCs (n=4, d) and incubated for 18 hours before DENV 
infection in presence of an isotype control or anti-IFN-γ (αIFN-γ). Infection rate of target 
cells, gated on live CD3-CD14+ cells, were measured by flow cytometry 24 hours post 
infection using intracellular staining of the DENV protein NS3. Data are representative from 
at least two independent experiments. Bars represent means ± s.e.m. Statistical 
significance was determined with a Kruskal-Wallis test followed by Dunns’ test. ns > 0.05, 
*P ≤ 0.05.  
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IV.3 Discussion  
 
In this study, the effect of MAIT cell activation on DENV infection was assessed. MAIT cells 
were activated with IL-12 and IL-18 and co-cultured with primary human monocytes and 
DCs or with a monocytic cell line before viral infection. A marked inhibition and/or 
enhancement in DENV production as well as infection was noted in the presence of 
activated MAIT cells. The observed impact of activated MAIT cells on DENV infection was 
mediated by IFN-γ, in a dose and cell type dependent manner. 
 
To investigate the effect of activated MAIT cells on DENV infection, MAIT cells were 
stimulated with IL-12 and IL-18 for 24 hours. This stimulation method was used as MAIT 
cells were activated in an IL-12 and IL-18 dependent manner by DENV infected DCs in 
vitro. Furthermore, analysing levels of IL-18 in plasma of DENV infected patients revealed 
higher IL-18 levels in patients suffering from severe dengue compared to DF patients, 
which also correlated with higher MAIT cell activation in vivo. These data demonstrated a 
crucial role of IL-18 in vivo and in vitro in inducing MAIT cell activation. In addition, 
Klenerman et al. showed that MAIT cells become activated, as judged by IFN-γ expression, 
via the addition of exogenous human IL-12 and IL-18 in vitro (Ussher et al., 2014a). Thus, 
stimulation of MAIT cells with IL-12 and IL-18 is a straight forward method to induce 
activation and is biologically relevant in the context of DENV infection. However, it would 
be interesting to test whether MAIT cell activation by DENV infected DCs has a similar 
effect on viral production and infection. 
 
The secondary consequences of MAIT cell activation could be of significance for both 
protection and immunopathology during viral infection. So far, activation of MAIT cells was 
reported in humans infected with HIV, HCV and IAV (Fernandez et al., 2014, van 
Wilgenburg et al., 2016). However, the impact of MAIT cell activation in disease 
development for all three viral infections remains unclear. During HIV infection, MAIT cells 
exist in an activated state but are functionally exhausted at the late stage in HIV infection 
(Leeansyah et al., 2013, Fernandez et al., 2014). Furthermore, a decline in MAIT cell 
frequency in the blood of HIV infected patients was reported (Cosgrove et al., 2013, 
Fernandez et al., 2014). Due to the loss and functional exhaustion of MAIT cells, it has 
been postulated that this may contribute to microbial translocation in the intestine, thus 
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increasing the susceptibility of HIV infected patients to mucosal infections (Greathead et 
al., 2014, Cosgrove et al., 2013). However, to date there is no direct evidence confirming 
this hypothesis. 
MAIT cell activation, as shown by granzyme B expression, during acute IAV and chronic 
HCV infections was reported by Van Wilgenburg et al. (van Wilgenburg et al., 2016). The 
impact of activated MAIT cells on HCV infection was investigated in vitro using a hepatocyte 
cell line. HCV replication was limited by conditioned media from activated MAIT cells in an 
IFN-γ dependent manner. These findings suggest that a local activation of MAIT cells could 
plausibly correlate with a direct antiviral function in vivo, e.g. in the liver where elevated IL-
18 levels were detected in HCV infected patients (van Wilgenburg et al., 2016).  However, 
further experiments should be performed to investigate MAIT cell frequencies in the liver 
of HCV infected patients as well as the impact of activated MAIT cells on HCV infected 
primary human cells.     
 
Monocytes and DCs were used as target cells as they are the main cells supporting DENV 
replication in vivo and in vitro (Chen and Wang, 2002, Tassaneetrithep et al., 2003, Kyle et 
al., 2007). Immature DCs are easily infected by DENV as they express high amounts of the 
C-type lectin receptor DC-SIGN (CD209) (Tassaneetrithep et al., 2003). In addition the lack 
of FcγRs on their cell surface hinders an ADE dependent infection. Thus, DCs were used 
to investigate the effect of activated MAIT cells on DENV infection in the absence of ADE. 
The addition of activated MAIT cells or recombinant IFN-γ had an inhibitory effect on 
infection rate and viral production. This is in agreement with studies performed by Diamond 
et al. suggesting that IFN-γ inhibits infection in all ADE independent infection (Diamond et 
al., 2000).  
Most cases of severe dengue occur during secondary DENV infections with a heterologous 
DENV serotype. This is most likely due to the presence of pre-existing cross-reactive 
antibodies, which increase uptake of viruses in FcyR bearing cells such as monocytes and 
macrophages (Halstead, 1988, Dejnirattisai et al., 2010, Halstead, 2003). In addition, the 
presence of anti-DENV antibodies has been shown to enhance infection to a much greater 
extent than in the absence of antibodies, leading to a 10-30% infection rate as compared 
to a 1-3% infection rate in the absence of antibodies. Thus, freshly isolated primary human 
monocytes were used to investigate the effect of activated MAIT cells on DENV infection 
in the presence of ADE. As for DCs, the addition of activated MAIT cells or recombinant 
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IFN-γ reduced viral infection and production. The same result was obtained in a previous 
study looking at the impact of IFN-γ on monocytes (Sittisombut et al., 1995). These results 
suggest a possible anti-viral role for MAIT cells during DENV infection in the presence or 
absence of ADE.     
Lastly, the effect of activated MAIT cells on DENV infection was investigated in a monocytic 
cell line, U937. Direct infection of U937 cells with DENV results in a very low yield due to 
the lack of specific DENV receptors on the cell surface (Kontny et al., 1988, Diamond et 
al., 2000). However, the expression of FcyR makes this cell line an attractive system for 
studying ADE dependent infection. The addition of activated MAIT cells enhanced viral 
infection at various E/T ratios. Enhancement of viral production could also be observed at 
an E/T ratio of 1:1 but this effect was abolished at a higher ratio. Of note, viral titers obtained 
in this study were 2 logs lower than published ones (Kontny et al., 1988, Diamond et al., 
2000). One reason for this might be differences in the incubation period after infection, thus 
this experiment should be repeated with supernatants collected on day 3 or 4 post infection. 
The same effect of DENV enhancement could also be observed using recombinant human 
IFN-γ at lower concentrations, 1 to 100 U/ml. Interestingly, using 103 U/ml of IFN-γ resulted 
in a 2 fold suppression of DENV infection suggesting that the effect of IFN-γ on U937 cells 
is dose dependent. This might explain why enhancement in viral production was abolished 
in presence of activated MAIT cells at an E/T ratio of 10:1. It would be interesting to 
investigate whether activated MAIT cells at higher E/T ratio can mimic the suppressive 
effect of IFN-γ on U937 cells. Of note, Kontny et al. performed the same dose dependent 
assay on U937 cells using recombinant IFN-γ from 0.01 to 104 U/ml and did not observe 
inhibition of DENV infection at high IFN-γ concentrations (Kontny et al., 1988). The reason 
for this discrepancy is not clear. It might result from the use of different virus strains, 
different antibodies to induce ADE or from the source and passage of the cell line, which 
might influence their sensitivity and responsiveness to IFN as suggested by Sittisombut et 
al. (Sittisombut et al., 1995). Thus, results obtained from U937 cells should be interpreted 
with caution.  
 
Activated MAIT cells influence DENV infection of target cells via IFN-γ as determined by 
the use of a blocking antibody against IFN-γ. Previous studies published conflicting results 
about the role of IFN-γ on DENV infection using U937 cells (Kontny et al., 1988) or 
monocytes (Sittisombut et al., 1995). In 2000, Diamond et al. investigated the influence of 
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IFN-γ on DENV infection using several cell lines and demonstrated a variable effect of IFN-
γ, dependent on cell type and pathway of infection (Diamond et al., 2000). These data 
revealed a suppressive or enhancing impact of IFN-γ on ADE independent or dependent 
infection, respectively. However, DENV enhancement during ADE dependent infection was 
only observed in a subset of myeloid cells. The reason for this variance was not 
investigated in this study. Interestingly, treating U937 cells with IFN-γ before DENV 
infection increased the expression of FcγR on the cell surface, leading to enhance infection 
in the presence of antibodies (Perussia et al., 1983, Kontny et al., 1988). In contrast, using 
similar levels of IFN-γ on monocytes inhibited ADE dependent infection, even though an 
increase in FcγR expression was also observed on the cell surface (Sittisombut et al., 
1995). The cause of the discrepancy between those results is not clear. It might result from 
the fact that DENV infected monocytes in contrast to U937 cells secrete IFN-α, which has 
a strong antiviral activity and limits DENV infection (Kurane and Ennis, 1988). Thus, IFN-α 
might counteract the effect of IFN-γ on DENV infection in presence of ADE. Further 
experiments should be performed to investigate the role of IFN-α in this in vitro setting. In 
addition, ADE dependent infection following IFN-γ treatment should be tested on other 
primary human cells, such as macrophages. Another possible explanation for the 
discrepancy between the enhancing effect on U937 cells and the suppressive effect on 
monocytes during ADE dependent infection may be the distinct responsiveness of U937 
cells to IFN-γ, as suggested by Improta et al. (Improta et al., 1992). The use of a cell line 
might impact the sensitivity to external stimuli and result in a hypo-responsiveness to IFN-
γ after long-term passages compared to freshly isolated human cells. This would explain 
why the addition of higher levels of recombinant IFN-γ on U937 cells reversed its enhancing 
effect and suppressed DENV infection. However, as mentioned above this dose dependent 
effect of IFN-γ on U937 cells was not observed in a previous study (Kontny et al., 1988). 
Therefore further experiments should be performed to investigate this hypothesis.            
 
Comparing results obtained from experiments using recombinant IFN-γ and activated MAIT 
cells at higher concentrations did not manifest the same trend. Using recombinant IFN-γ 
on primary human DCs and monocytes presented a dose dependent reduction in viral 
infection and production, with almost a complete inhibition at the highest IFN-γ 
concentration tested. In contrast, the addition of activated MAIT cells at the highest E/T 
ratio slightly reversed the suppressive effect on DENV infection and production. The reason 
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for this is not clear. However, the presence of activated MAIT cells at high concentration 
might disturb the ability of the virus to infect target cells in co-culture or it might be because 
activated MAIT cells produce other factors which may compete against the antiviral effect 
of IFN-γ.  
 
In conclusion, MAIT cells are able to supress DENV infection in primary human monocytes 
and DCs in an IFN-γ dependent manner. These data suggest a protective role of activated 
MAIT cells during DENV infection. However, the observed increase of FcγR on cells by 
IFN-γ might also enhance infection via ADE, promoting pathogenesis. Thus, MAIT cells 
seem to influence disease severity in both ways depending on the number of activated 
MAIT cells present, the type of target cells and the presence of anti-DENV antibodies. 
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Chapter V 
 
RESULTS PART 3 
The Effect Of Host Genetic Variants  
On Dengue Virus Infection 
 
 
Analysis of the RNA sequencing dataset was performed in collaboration with Dr. Marta 
Imprialou & Dr. Jacques Behmoaras at Imperial College London. 
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AIM: To identify new host genomic risk factors which influence the susceptibility of 
two main target cells (DCs and macrophages) to DENV infection. 
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V.1 Introduction 
 
DENV infection is a major emerging disease in tropical and subtropical countries and cases 
of infection are increasing at an alarming rate. DENV is classified into four serotypes that 
share around 70% homology at the amino acid level. Following the bite of an infected 
mosquito (Aedes aegypti), most individuals will be asymptomatic or develop dengue fever 
(DF). However, 5-30% of patients with symptoms will develop a more severe form of the 
disease - dengue haemorrhagic fever (DHF) - which can include plasma leakage, 
thrombocytopenia and shock. Without expert clinical intervention, severe dengue can lead 
to organ failure and death.  
 
Multiple prospective cohort studies have identified secondary infections with a 
heterologous serotype as an epidemiological risk factor for severe dengue (Burke et al., 
1988, Kouri et al., 1989, Sangkawibha et al., 1984). One proposed pathogenic mechanism 
for increased risk of disease during a secondary infection is antibody dependent 
enhancement (ADE) (Halstead, 2003). However due to the fact that only a small proportion 
of antibody positive individuals who experience DENV infection actually develop severe 
dengue, other factors may also be relevant and predispose some patients to DHF (Burke 
et al., 1988).  
 
The importance of pathogen genetic variation and disease severity has been demonstrated 
in several studies (Coffey et al., 2009). DENV strains exhibit varying degrees of virulence 
with certain virus serotypes or genotypes causing more pathologic DENV disease than 
others (Fried et al., 2010, Rico-Hesse, 2007). A well-established example of this has been 
the introduction of the Asian DENV2 strain in Cuba where previously the more benign 
American DENV2 strain circulated. This was accompanied with the occurrence of an 
increase in severe cases (Rico-Hesse et al., 1997). Sequence analysis of these two 
genotypes revealed a difference of six amino acids, contributing to differences in virulence 
(Leitmeyer et al., 1999).  
 
Pathogenesis of dengue has also been linked to host genetic factors. However, in contrast 
to viral genetic determinants, studies examining the influence of host genetics on dengue 
severity are limited (Rico-Hesse, 2007). Case control studies have identified a number of 
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candidate genes associated with disease susceptibility. These include genes encoding 
HLA molecules, vitamin D receptor, DC-SIGN, TNF-α and platelet antigens (Coffey et al., 
2009). However, many of these studies have been compromised by poor design, 
inadequate sample size or unclear case definitions. The first comprehensive attempt to 
understand the effect of host genome variation on the susceptibility to DENV infection was 
obtained from a large-scale GWAS study in Vietnam. This study identified two new distinct 
loci associated with disease severity, MICB and PLCE1 (Khor et al., 2011). However, both 
loci explained no more than 2.5% of the overall heritable variance in susceptibility to severe 
dengue, suggesting that there is still a large unknown heritability that remains to be 
identified (Khor and Hibberd, 2011).  
 
Recently, a new genomic approach called systems genetics has emerged, which considers 
not only the underlying genetic variation but also intermediate phenotypes, such as 
transcripts, proteins or metabolite levels (Civelek and Lusis, 2014). Systems genetics aims 
to understand the flow of biological information that underlies a complex trait and correlates 
intermediate phenotypes with a trait of interest which shows inter-individual variability in 
populations. A transcript whose variation in expression is correlated with variation in the 
trait of interest is called a quantitative trait transcript (QTT). Recent systems genetics 
studies have demonstrated that immune cells, such as T cells, monocytes, neutrophils and 
DCs, are genetically regulated in their function (Lee et al., 2014, Ye et al., 2014, Fairfax et 
al., 2014, Naranbhai et al., 2015). For example, Lee et al. identified common alleles that 
explain inter-individual variation in pathogen sensing responses in DCs leading to altered 
susceptibility to inflammatory diseases (Lee et al., 2014). 
 
As increased viral load in DENV infected patients is associated with disease severity, it is 
crucial to better understand and identify genetic factors which influence the susceptibility 
of host cells to DENV infection. The role of host genetic factors in modulating the 
susceptibility to DENV infection remains largely unknown and has not been analysed on 
the complete host transcriptome. In this study, the impact of host genetic variants on DENV 
infection was investigated using a systems genetics approach. 
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V.2 Results 
 
2.1 DENV Infection of Primary Human Cells is Donor Specific 
 
One of the critical steps in understanding the pathogenesis of dengue disease is to identify 
and characterise factors of host cells that facilitate DENV infection during the early phase 
of infection. Due to the fact that macrophages and DCs are among the primary targets of 
DENV in vivo and in vitro, gene expression in those cells were analysed by RNA 
sequencing to identify new innate immune regulators that influence DENV infections.  
 
First, monocytes were isolated from PBMCs from healthy donors and differentiated into 
macrophages and DCs for 5 to 6 days (Fig. 19a). Macrophages were infected with DENV 
at an MOI of 1 FFU/cell in the presence or absence of a monoclonal antibody against the 
DENV protein prM (anti-prM). Dejnirattisai et al. identified anti-prM as a major component 
promoting ADE (Dejnirattisai et al., 2010). In the case of DCs, infection was performed in 
the absence of antibodies. After 24 hours incubation, infection rates of macrophages and 
DCs were assessed by flow cytometry using an antibody against the DENV protein NS3 
(anti-NS3).  
Infection rates in macrophages (Fig. 19b) and DCs (Fig. 19c) from 13 donors (1-13) showed 
a high inter-individual variability. Percentage of DENV infected macrophages in the 
presence of anti-prM ranged from 69.3% to 14.8%, with a mean of 44.78% ± 4.3. In the 
absence of antibodies, infection rates were much lower and ranged from 26.7% to 4.91%, 
with a mean of 14.58 ± 1.6. Analysing the percentage of DENV infected DC also revealed 
a strong inter-individual variability in infection rates ranging from 74.1% to 21% (mean 
56.24 ± 5.4). DCs derived from donor 8 and 9 could not be used due to technical problems. 
Comparing the top 6 donors (donor 1, 12, 4, 10, 13, 6) for ADE dependent infection in 
macrophages with donors having the highest infection rates in DENV infected DCs (donor 
4, 13, 1, 12, 2, 6) revealed similarities except for donors 2 and 10. Furthermore, to verify 
that infection rates were donor specific and not dependent on external factors, DCs from 3 
donors were infected with DENV at various times over the course of one year (Fig. 19d). 
The percentage of infected DCs did not change during this period.  
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These results demonstrated a large variability in infection rates between individuals, but no 
intra-individual variance was observed. In addition, different cell types derived from the 
same donor showed similar pattern of infection rates. These data suggest a genetic 
influence in immune cells controlling the susceptibility to dengue infection.  
 
 
Figure 19 Inter-individual variability in DENV infection in primary human DCs and 
macrophages. Primary human macrophages and DCs (n=11-13) were infected with DENV 
at an MOI of 1 FFU/cell in presence and/or absence of antibodies, respectively. Infection 
rates were measured by intracellular staining of the DENV non-structural protein NS3 using 
flow cytometry. (a) A schematic outline of DC and macrophage differentiation. (b) Infection 
rates of DENV infected macrophages in presence (+ADE) and absence (-ADE) of 
antibodies. (c, d) Infection rates of DENV infected DCs. Abbreviations: M, macrophage; 
DC, dendritic cell; CD14, monocytes; ADE, antibody dependent enhancement. 
129 | P a g e  
 
2.2 RNA Sequencing of Primary Human Macrophages and 
Dendritic Cells after DENV Infection (in collaboration with Dr. Marta Imprialou 
& Dr. Jacques Behmoaras) 
 
Having observed a possible genetic effect on DENV infection in macrophages and DCs, 
gene transcripts were identified for which variation in their expressions correlated with 
infection rates. Macrophages and DCs derived from 13 donors were generated and 
infected with DENV for 6 and 24 hours before isolating RNA. To identify gene expression 
at baseline (= before DENV infection), RNA was isolated from uninfected macrophages 
and DCs in the presence and/or absence of anti-prM. In this study, the interest was focused 
on the very early phase of DENV infection which might only be influenced by the human 
host genetic. Thus, RNA sequencing (RNA-seq) was performed on samples obtained from 
DENV infected or uninfected (= mock) DCs as well as from DENV+anti-prM infected and 
mock+anti-prM treated macrophages after 6 hours incubation (Fig. 20).  
 
An average coverage of 50 million reads per sample was achieved (Fig. 21a). To identify 
the mapping percentage of each sample, RNA-seq reads were aligned to the human (hg19) 
reference genome showing a coverage of over 80% (Fig. 21b). In addition, using standard 
tools provided in the FastQC software, the quality of sequencing and mapping was 
confirmed looking at lane effects and technical covariates (Supplementary Fig. 7-9). 
Transcript levels for each gene were then normalised to their read counts and gene length 
using Cufflinks 2.1.1. In total, the RNA-seq dataset represented 22643 expressed 
transcripts. After normalising genes to their read counts, transcripts with fewer than 5 reads 
were eliminated from the study which led to a total of 10238 expressed transcripts. 
To investigate whether cluster of gene expression profiles could be detected in DCs and 
macrophages, a principal component analysis was performed (Fig. 21c). Interestingly, two 
distinct patterns of gene transcript profiles could be observed relative to the cell type. Thus, 
even though DCs and macrophages were generated from the same donor, infection with 
DENV led to distinct genes expression in both cell types.  
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Figure 20 An overview study to identify host genomic risk factors for DENV infection 
in DCs and macrophages using systems genetics. Primary human macrophages and 
DCs were infected with DENV at an MOI of 1 FFU/cell in presence and/or absence of 
antibodies (α-prM), respectively. To identify expression levels of gene transcripts at 
baseline, cells were treated with mock in presence or absence of antibodies. After 6 and 
24 hours incubation, RNA was extracted from DENV infected and mock treated DCs and 
macrophages. At the same time, infection rates of DENV infected cells were measured by 
intracellular staining of the DENV non-structural protein NS3 using flow cytometry. RNA 
obtained after 6 hours incubation was processed and analysed using the TruSeq® Stranded 
mRNA kit (Illumina) followed by ultra-high-throughput RNA-sequencing with HiSeq 2500 
(Illumina). Correlation between expression levels of gene transcripts and infection rates 
were analysed using Pearson’s correlation. Abbreviations: MDM, macrophage; DC, 
dendritic cell; DENV, dengue virus; RNA seq, RNA sequencing. 
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Figure 21 Read counts, principal component analysis and mappability to human 
genome. (in collaboration with Dr. Marta Imprialou & Dr. Jacques Behmoaras) RNA-seq 
was performed on the whole transcriptome of DCs (green) and macrophages (purple) 
derived from 13 healthy individuals. (a) Read counts per gene were calculated for each 
sample using HTseq version 0.6.1. (b) Raw reads were mapped to the reference human 
genome (hg19_ens_GRCh37) using tophat 2.0.11. (c) Capture of clusters in the gene 
expression profiles obtained by RNA-seq using principal component analysis. Each donor 
represents one data point or bar. Abbreviations: M, macrophage; DC, dendritic cell; RNA 
seq, RNA sequencing; PC, principal component. 
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2.3 Identification of Potential Host Genomic Risk Factors which 
might influence DENV Infection in Primary Human Dendritic 
Cells  
 
Inter-individual variation in the early (6 hours) host response to DENV infection was 
characterised in primary human DCs from 11 donors. Infection rates from those 11 donors 
(Fig. 22a) were treated as a continuous trait and a QTT analysis was performed to 
investigate whether inter-individual variation of gene transcripts correlate with the variation 
in infection rates. Of the 10238 expressed transcripts, 398 and 376 QTTs significantly 
(P<0.01; false discovery rate (FDR) = 0.25) correlated with infection rates in DCs before 
and after DENV infection, respectively. To identify host genomic risk factors that might 
influence DENV infection, transcripts which correlated with the continuous trait at baseline 
(= before DENV infection) were selected and ranked from the most to the least significant 
gene (Fig. 22b + Supplementary Table 3). Of the 398 QTTs, 93 of them showed a strong 
Pearson correlation factor of ρ2 > 0.7. Interestingly, a transmembrane protein (TMEM206) 
was one of the genes showing the most significant correlation with infection rate (Fig. 23). 
TMEM206 is expressed on the cell surface. Therefore, it might have an impact on viral 
attachment and/or entry, as demonstrated for DC-SIGN (CD209) (Tassaneetrithep et al., 
2003). After DENV infection, expression of TMEM206 in all 11 donors continued to show a 
strong correlation with the corresponding infection rates (P = 0.002 and ρ2 = 0.65). Another 
gene of interest was a fatty acid binding protein (FABP3), which had a correlation factor of 
ρ2 > 0.7 before and after DENV infection. Of note, previous studies reported an important 
role for fatty acids during DENV replication in vitro (Heaton et al., 2010, Lorizate and 
Krausslich, 2011). This result hints that donors with increased FABP3 levels in DCs might 
better promote viral infection, leading to higher infection rates. A strong correlation with 
infection rates was also observed for other gene transcripts such as EWS RNA-binding 
protein (EWSR1, (Oakland et al., 2013)), growth factor receptor bound protein (GAB1, 
(Zheng et al., 2010)) and peroxisome proliferator-activated receptor (PPARα, (Hu et al., 
2012, Guidotti et al., 1999)), for which some implications in viral infections have already 
been reported (Fig 22b + Supplementary Fig. 10). Interestingly, not all gene transcripts 
showed similar expression pattern before and after DENV infection.  
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Figure 22 Significant QTTs associated with infection rates in DENV infected DCs. 
Correlating mRNA expression levels obtained by RNA-seq with infection rates in DCs 
established a list of 398 and 376 QTTs before and after DENV infection, respectively. (a) 
Infection rates of DENV infected DCs derived from 13 healthy donors. Infection rates were 
measured by intracellular staining of the DENV non-structural protein NS3 using flow 
cytometry. (b) The table shows the top 20 QTTs that correlate with infection rates at 
baseline in DCs. Genes marked in red are discussed in Results and/or Discussion. 
Abbreviations: DC, dendritic cell; DENV, dengue virus; QTT, quantitative trait transcript; 
NA, not applicable. 
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Figure 23 Association between 
increased TMEM206, FABP3 and 
BRD9 mRNA expression at 
baseline and elevated infection 
rates in primary human DCs. RNA 
transcripts were analysed in DCs 
(n=10) before and after DENV 
infection using RNA-seq. At the 
same time, infection rates were 
measured by intracellular staining of 
the DENV protein NS3 using flow 
cytometry. Infection rates were 
treated as a continuous trait and 
correlation between expression 
levels of gene transcripts and the 
continuous trait were analysed by 
Pearson’s correlation. Each donor 
represents one data point. 
Abbreviations: TMEM206, 
Transmembrane Protein 206; 
FABP3, fatty acid binding protein 3. 
 
Variation in the expression level of the bromodomain (BRD9) which is involved in chromatin 
remodelling and transcription, positively correlated with the percentage of infection at 
baseline (Fig. 23). However, the presence of DENV resulted in the abolishment of this 
correlation, suggesting that DENV influences expression of some genes. To investigate the 
functional interaction networks of proteins, all 398 gene transcripts were analysed using 
the online database resource Search Tool for the Retrieval of Interacting Genes (STRING; 
Supplementary Fig. 11) (Szklarczyk et al., 2015).  Even though some proteins showed no 
connection with one another a number of them were highly connected, indicating that genes 
act on common networks and pathways. In addition, analysing significantly enriched 
biological processes in this dataset revealed a strong association with various metabolic 
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pathways. Interestingly, biological processes of viral transcription, viral process and viral 
gene expression were also significantly represented in this dataset (data not shown).  
 
In conclusion, 93 gene transcripts were identified showing a strong correlation between 
inter-individual variation of transcript levels and their corresponding infection rates. Thus, 
with the help of systems genetics a list of genes was identified which might influence the 
susceptibility of DCs to DENV infection. Furthermore, some genes in this dataset have 
already been reported to play a role in viral replication and/or infection, based on the online 
database STRING analysis as well as published studies. These findings are a first step in 
identifying host genomic risk factors for DENV infection in DCs.  
 
2.4 Identification of Potential Host Genomic Risk Factors which 
might influence DENV Infection in Primary Human Macrophage  
 
ADE is an important factor promoting dengue pathogenesis. Furthermore, increased viral 
load is associated with disease severity. Macrophages are one of the major target cells for 
ADE dependent infection. Therefore, identifying genomic factors which might influence 
DENV infection in those cells is crucial to better understand dengue pathogenesis. 10238 
gene transcripts were analysed in macrophages from 13 healthy donors before and after 
DENV infection in the presence of anti-prM (Fig. 24a). Inter-individual variation in the 
expression level of various gene transcripts were plotted against the infection rates of 
macrophages from those 13 donors. As before, infection rates were treated as a continuous 
trait and correlation was assessed by QTT analysis. In total, 44 and 19 QTTs significantly 
(P<0.01) correlated with the infection rate in macrophages before and after DENV infection, 
respectively. To identify host genomic risk factors that might influence DENV infection, 
transcripts which correlated with the continuous trait at baseline (= before DENV infection) 
were selected and ranked from the most to the least significant gene (Fig. 24b + 
Supplementary Table 4). Interestingly, many genes were involved in cell metabolism such 
as iron and calcium homeostasis as well as in the citric acid cycle, which is important for 
generating energy in the cell. However, of the 44 genes only 3 of them showed a strong 
Pearson correlation factor of ρ2 > 0.7: the mitochondrial translational release factor 
(MTRF1L), the 3-Hydroxybutyrate Dehydrogenase (BDH2) and the inflammasome  
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Figure 24 Significant QTTs associated with ADE dependent DENV infection rates in 
macrophages. Correlating mRNA expression levels obtained by RNA-seq with infection 
rates in macrophages established a list of 44 and 19 QTTs before and after DENV infection, 
respectively. (a) Infection rates of DENV infected macrophages derived from 13 healthy 
donors. Infection rates were measured by intracellular staining of the DENV non-structural 
protein NS3 using flow cytometry. (b) The table shows the top 20 QTTs that correlate with 
infection rates at baseline in macrophages. Genes marked in red are discussed in Results 
and/or Discussion. Abbreviations: MDM, macrophage; DENV, dengue virus; ADE, antibody 
dependent infection; QTT, quantitative trait transcript; NA, not applicable. 
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component NLRP3 (Fig. 25). Levels of MTRF1L negatively correlated with the infection 
rates at baseline, indicating that MTRF1L in macrophages might promote resistance to 
DENV infection and/or replication. In contrast, a positive correlation was observed for 
BDH2 and NLRP3. For all three gene transcripts, the strong correlation between 
expression levels and the continuous trait was abolished after DENV infection. 
Interestingly, in 2006 Pontillo et al. reported the beneficial role of a genetic variant in NLRP3 
against human papilloma virus persistence and infection (Pontillo et al., 2016). In addition, 
other genes in this dataset have also been reported to influence viral infection and/or 
replication, such as the chromodomain helicase (CHD3, (Arbuckle and Kristie, 2014, 
Terhune et al., 2010)), the Iron-sulfur cluster assembly enzyme (ISCU, (Tsang et al., 2016)) 
and the heat shock protein 40 (DNAJC18, (Taguwa et al., 2015)) (Fig 24b + Supplementary 
Fig. 12). Due to the fact that macrophages were infected in an ADE dependent manner, 
gene expressions of various FcR was investigated. Interestingly, only one gene in this 
family, FcεR1γ, showed a significant correlation with DENV infection rates (Fig. 25). 
However, at baseline no correlation could be observed. FcεR1γ is a component of various 
FcγRs. Thus, expression of this gene might have an impact on ADE.  
As for DCs, functional protein-protein interaction networks were investigated in this dataset 
using the online database STRING (Supplementary Fig. 13). Only two interaction networks 
could be observed, indicating that genes in this dataset do not act in common pathways. 
In addition, no significantly enriched biological processes were identified (data not shown).  
In conclusion, to identify host genomic risk factors that might influence DENV infection, 
transcripts which correlate with the continuous trait at baseline were selected. In total, inter-
individual variation of 44 genes were identified to significantly correlate with the infection 
rate in macrophages. However, no common pathways and networks were identified in this 
dataset. Even though Pearson’s correlation was only strong in 3 genes, 5 out of the 44 
gene transcripts have already been reported to influence viral infection and/or replication 
in host cells. These findings are a first step in identifying host genomic risk factors for ADE 
dependent DENV infection in macrophages.  
 
To sum up, viral load in DENV infected patients is a critical factor related to disease severity 
as patients with severe dengue express 1-2 log higher viral loads in plasma as compared 
to patients with DF. Thus, identifying host factors which can influence the susceptibility of 
target cells to DENV infection are crucial to better understand dengue pathogenesis. In this 
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study, primary human DCs and macrophages were used as they are the main target cells 
for DENV infection. Furthermore, genes influencing ADE dependent or independent 
infection were able to be assessed using both cell types. In DCs and macrophages, 
expression levels of 93 and 3 genes showed a strong correlation with the inter-individual 
variation in infection rates, respectively. Some of these genes have already been reported 
to play a role during viral infection and/or replication. Thus, using a systems genetics 
approach a list of genes was obtained which might result in the discovery of unknown host 
genomic risk factors to DENV susceptibility.  
 
Figure 25 Association between 
MTRF1L, BDH2, NLRP3 and 
FcεR1γ mRNA expression levels 
and infection rates in primary 
human macrophages. RNA 
transcripts were analysed in 
macrophages (n=12-13) before and 
after DENV infection using RNA-seq. 
At the same time, infection rates were 
measured by intracellular staining of 
the DENV non-structural protein NS3 
using flow cytometry. Infection rates 
were treated as a continuous trait and 
correlation between expression 
levels of gene transcripts and the 
continuous trait were analysed by 
Pearson’s correlation. Each donor 
represents one data point. 
Abbreviations: DENV, dengue virus; 
MTRF1L, mitochondrial translational 
release factor 1 like; BDH2, 3-
Hydroxybutyrate dehydrogenase 
type 2; NLRP3, NLR family; FcεR1γ, 
Fc epsilon receptor gamma.   
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V.3 Discussion  
 
In this study, a systems genetics approach was used to identify new host genomic risk 
factors which influence the susceptibility of immune cells to DENV infection, in order to 
better understand dengue pathogenesis. Consistent with other studies, an inter-individual 
variability of infection rates was observed in DCs and macrophages, both important target 
cells for DENV. Furthermore, it is widely accepted that increased viral load in DENV 
infected patients is associated with disease severity (Vaughn et al., 2000). These 
observations raise the question of whether the susceptibility of DENV infection, e.g. 
infection rates in target cells, is genetically determined and influenced by genetic variants. 
To address this, correlations between variations in gene expressions and infection rates 
were investigated using RNA-seq and QTT analysis. This is the first attempt to link the 
susceptibility of primary human immune cells to DENV infections with inter-individual 
variation in gene expression.     
 
Macrophages and DCs are among the primary targets of DENV. Myeloid DCs are localised 
in the epidermis and dermis of the host and are immediately encountered by DENV 
following the bite of an infective mosquito (Wu et al., 2000). Wu et al. showed that monocyte 
derived DCs and human skin DCs were susceptible for DENV infection and were therefore 
likely to be the primary targets for DENV infection (Wu et al., 2000). Furthermore, the 
recruitment of monocytes to the site of infection and the subsequent differentiation to DCs 
increases the targets of DENV infection in the dermis (Schmid and Harris, 2014). Thus, 
DCs are important target cells for DENV replication during the initial phase of infection and 
identifying genetic variants which influence DENV infection are crucial to better understand 
the interplay between host and DENV.  
Macrophages were used to identify genes that influence ADE dependent infection, as they 
are the main target for such infection in vivo and in vitro (Halstead and O'Rourke, 1977b, 
Halstead, 1988). Furthermore, ADE has been postulated to play an important role during 
secondary DENV infection and is associated with disease severity (Whitehorn and 
Simmons, 2011). Therefore, identifying host genomic factors which influence ADE 
dependent DENV infection is crucial to better understand dengue pathogenesis. 
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To identify new host genomic risk factors for DENV infection, RNA-seq was performed on 
DCs and macrophages derived from 13 healthy donors before and after infection. An 
important factor which influences the quality of the analysis is the library size, which is the 
number of sequenced reads for a given sample. In general, identification and quantification 
of transcripts will be more precise as samples are sequenced to a deeper level. In this 
study an average of 50 million reads per sample was obtained, which has been shown to 
be sufficient for optimal data analysis (Mortazavi et al., 2008). However some samples, 
especially DCs from donor 2 and 4, presented very low read counts of only 10 million reads. 
This might be due to technical or biological variability. Nevertheless previous studies 
showed that as few as 5 million mapped reads are sufficient to quantify accurately medium 
to highly expressed genes in most eukaryotic transcriptomes (Conesa et al., 2016). Thus 
even though some samples displayed a low read count, data could still be included in the 
analysis without apprehension.    
The quality of the analysis is also influenced by the biological variation and technical noise, 
which can be introduced during experimental procedures. To minimise such variations, 
RNA isolation and sequencing from macrophages and DCs derived from all donors was 
performed at the same time to avoid batch-related effects. However, DC and macrophage 
differentiation and infection was performed for each donor separately. Although the same 
unique batch of cytokines and DENV was used throughout the whole study, biases could 
have been introduced into the resulting data. To control experimental batch-related effects 
in the future, U937 derived macrophages should be cultured, infected and analysed in 
parallel.     
After normalising transcript levels for each gene to their read counts and length, gene 
transcripts were plotted against infection rates. This resulted in a list of QTTs that 
significantly correlated with the phenotype. Significance was confirmed using P values 
below 0.01 and FDRs. FDR is defined as the expected proportion of false positives among 
the declared significant results. In this study FDRs were very high with 0.25 and 0.84 for 
DCs and macrophages, respectively. This is likely due to the limited sample size (n=11-
13). Thus, to overcome elevated levels of FDRs more individuals should be included in this 
study. In the case of macrophages, the presence of anti-prM might additionally reduce 
changes in gene expressions, leading to higher FDRs (unpublished observations from 
J.Behmoaras). Furthermore, Ayala-Nunez et al. showed a considerable delay in the fusion 
time of DENV+anti-prM versus DENV to macrophages (Ayala-Nunez et al., 2016). This 
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may suggest that stronger changes in gene transcripts might be visible at later time point 
than 6 hours. To investigate whether the presence of antibodies impedes differential 
expression of gene transcripts, the RNA signature of macrophages treated with mock or 
DENV in the absence of anti-prM should be analysed.  
 
Using a systems genetics approach in DCs and macrophages two sets of QTTs were 
obtained; before and after DENV infection. In this study, the focus lay on the identification 
of genetic variants which influence DENV infection. Therefore, QTTs before DENV infection 
(= baseline) correlating with the infection rate were selected and analysed. Caution should 
be taken when analysing QTTs which were identified after DENV infection, as it is difficult 
to dissect if differential expression of a gene is caused by viral load or vice versa. Thus, 
analysing QTTs that correlate with infection rate at baseline eliminates this problem. 
However it is important to keep in mind that some gene transcripts, which only become 
expressed once immune cells are stimulated or infected, might be missed in this analysis.   
 
High viral load in DENV infected patients has been associated with disease severity and to 
date no study has investigated the relationship between host genetic variation of the 
complete transcriptome and DENV infection. So far, most studies have focused to identify 
allelic variants of gene loci which associate with disease severity. Findings included genes 
encoding HLA molecules (Vejbaesya et al., 2009, Stephens et al., 2002), blood antigens 
(Stephens, 2010) and cell receptors, such as the vitamin D receptor and FcγR (Loke et al., 
2002). Interestingly, Sakuntabhai et al. observed a strong association between the G allele 
of the variant in the DC-SIGN promoter region and disease severity in DENV infected 
patients (Sakuntabhai et al., 2005). DC-SIGN is a major dengue receptor on human DCs 
and is important for DENV attachment and entry (Tassaneetrithep et al., 2003). A further 
study in 2011 showed that the same SNP in the DC-SIGN promoter region (rs4804803) 
was associated with increased cell surface expression on DCs from individuals with AG 
genotype compared to AA genotype (Wang et al., 2011). These findings indicate that 
disease outcome and DENV infection in DCs may be partly related to the activity of DC-
SIGN and the degree of DC-SIGN expression. Interestingly, in this project the inter-
individual variation of DC-SIGN expression only showed a weak but not significant 
correlation with infection rates in DCs (Supplementary Fig. 10). This might be due to the 
limited sample size or due to the fact that DCs were derived from individuals with the same 
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genotype, therefore expressing similar levels of DC-SIGN. Genomic DNA obtained from 
those donors should be genotyped to clarify this point. In addition, levels of DC-SIGN 
mRNA might not correlate with protein levels or expression levels on the cell surface. 
However, our study also suggests that other genetic factors might have a stronger effect 
than DC-SIGN on DENV susceptibility in DCs. This is in line with published studies 
reporting similar levels of viral replication in DCs from individuals with AG and AA 
genotypes, even though the former expressed elevated levels of DC-SIGN on the cell 
surface (Wang et al., 2011). Interestingly, a difference in viral replication between both 
individuals could be observed after 48 and 72 hours post infection, suggesting that the 
initial phase of DENV infection is not primarily driven by genetic variants of DC-SIGN. Thus 
other genetic variants might play a role in the susceptibility of DCs to DENV infection.  
 
Infection rates of DCs and macrophages were treated as a continuous trait and correlations 
between gene expression levels and the continuous trait were investigated. For DCs, a 
total of 398 QTTs significantly correlated with the infection rate at baseline. Of those, 93 
QTTs showed a strong Pearson correlation factor of ρ2 > 0.7. Interestingly, some genes 
(marked red in Fig. 22b) have already been reported to play a role during viral infection, 
suggesting that the obtained list is biologically relevant. For example, a study in 2010 
demonstrated that GAB1 inhibits vesicular stomatitis virus replication in mouse embryonic 
fibroblasts (Zheng et al., 2010). This is in line with findings obtained in this study, as 
expression levels of GAB1 negatively correlated with the infection rate, suggesting that 
GAB1 might have the same effect on DENV replication (Supplementary Fig. 10). In 
addition, EWSR1 and PPARα have been reported to be required for efficient HCV and HBV 
viral replication in human liver cell lines (Huh-7.5 and HepG2) and in vivo (Hu et al., 2012, 
Oakland et al., 2013, Guidotti et al., 1999). Again similar observation could be detected for 
EWSR1 during DENV infection, as the QTT manifest a positive correlation with the infection 
rate in DCs. However, the gene transcript PPARα negatively correlated with the infection 
rate in this study, suggesting an opposite effect. During HBV infection, the transcription 
factor PPARα is required for controlling the pregenomic RNA synthesis from the viral DNA 
genome (Tang and McLachlan, 2001). Pregenomic RNA is then used as a template for 
viral replication. Due to the fact that DENV already contains a RNA genome, no DNA 
transcription is needed. Published studies also reported that PPARα plays a critical role in 
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regulating lipid metabolism in host cells, thus PPARα might have a different role during 
DENV infection (Berger and Moller, 2002, Heaton et al., 2010, Lee et al., 2008).  
Analysis of gene transcripts in macrophages resulted in a total of 44 QTTs, which 
significantly correlated with the infection rate at baseline. Interestingly, fewer QTTs with 
higher p values and FDRs were detected in macrophages compared to DCs. In addition 
QTTs obtained from macrophages were distinct to those obtained from DCs. The reason 
for this difference is not clear. It might be because different cell types were used or because 
of the presence of anti-prM antibodies. To investigate whether the presence of anti-prM 
impedes the expression of gene transcripts, macrophages treated with mock or DENV 
without antibodies should be sequenced. Nevertheless, as observed for DCs some QTTs 
have already been reported to play an important role in viral replication and in the viral life 
cycle (marked red in Fig. 24b). For example, CHD3 has been shown to repress herpes 
simplex virus infection (Arbuckle and Kristie, 2014) but also facilitate HCMV replication 
(Terhune et al., 2010) as well as helping IAV during export and propagation (Hu et al., 
2015). Here, a positive correlation between CHD3 expression and infection rate was 
observed, suggesting a beneficial role during DENV infection (Supplementary Fig. 12). 
Other genes of interests were ISCU and DNAJC18, for which enhancing effects on viral 
replication and/or infection were reported (Taguwa et al., 2015, Tsang et al., 2016). 
Interestingly, Taguwa et al. demonstrated a crucial role of DNAJC18 during DENV entry 
into human cells as knock down of DNAJC18 completely abolished viral production 
(Taguwa et al., 2015). This is in agreement with results obtained in this study as DNAJC18 
and ISCU positively correlated with the infection rate.  
The fact that some QTTs in DCs and macrophages have already been reported to influence 
viral replication and/or infection confirms QTTs obtained in this study as biologically 
relevant. These findings might lead to the identification of new host genomic risk factors for 
DENV infection.             
 
Macrophages were used to identify genes that influence ADE dependent infection and 
previous studies reported a correlation between levels of FcγR on the cell surface and 
infection rate in a monocytic cell line (Kontny et al., 1988). Therefore, expression levels of 
genes encoding FcRs were investigated in macrophages before and after DENV infection. 
Interestingly, only one gene of the FcR family, FcεR1γ, showed a significant correlation 
with the infection rate. The γ chain of the IgE receptor is also used for other FcRs. Thus, 
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differential expression of this gene might have an impact on the expression of FcγR on the 
cell surface. However, a negative correlation was observed after DENV infection, which 
stands in contradiction with the published study. Due to the fact that correlation of FcεR1γ 
was not detected at baseline it is very likely that downregulation of this gene occurs in 
DENV infected cells depending on the viral load. This suggests that the level of DENV 
infection influences gene expression rather than the other way around. Thus, in this study 
expression levels of FcRs did not appear to have an effect on ADE dependent infection in 
macrophages. 
 
In conclusion, a genetic approach was used to identify new host genomic risk factors which 
influence DENV infection in two major target cells, DCs and macrophages. A total of 398 
and 44 QTTs were identified which showed a strong correlation with the inter-individual 
variation in infection rates in DCs and macrophages, respectively. Even though a limited 
sample size was used in this initial study, the biological relevance of these datasets were 
verified based on the online database resource STRING and published reports, which 
already demonstrated the influence of some genes on viral infection and/or replication. 
Furthermore, two distinct protein-protein networks were observed based on the 398 QTTs 
found in DCs, further validating the dataset obtained from this analysis. To acquire more 
information about those QTTs, on-going investigations are being performed which include 
genotyping and RNA interference of selected QTTs in human primary DCs and 
macrophages in vitro. This might result in the discovery of unknown host genomic risk 
factors for DENV susceptibility in two major target cells.  
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VI.1 Introduction 
 
Dengue virus (DENV) is the most widespread arthropod-borne virus in the world. Current 
estimates suggest there are around 390 million people infected each year of which 100 
million will have an apparent infection (Bhatt et al., 2013). Furthermore, the global incidence 
of DENV infection has been shown to be increasing year on year. It is commonly accepted 
that variation in host genetics and viral determinants as well as an aberrant immune 
response during the early phase of infection play an important role in dengue pathogenesis 
(Yacoub et al., 2013). However, there are still many unknown factors which impede the 
creation of an effective drug or vaccine. In this thesis, the influence of host genetics and of 
a recently discovered immune cell, called mucosal-associated invariant T (MAIT) cells, on 
DENV infection were investigated. Identifying new host genomic risk factors which 
influence the susceptibility of immune cells to DENV infection as well as understanding the 
role of this highly abundant immune cell during DENV infection are crucial to better 
understand dengue pathogenesis and may help generate therapeutic agents in the future. 
 
VI.2 The Role of MAIT cells during DENV Infection 
 
MAIT cells are an abundant human T cell population with a semi-invariant TCR determining 
bacterial specificity. This study, in collaboration with van Wilgenburg, demonstrated for the 
first time a viral reactivity of this unique cell type during various viral infections (DENV, IAV 
and HCV) in vitro and in vivo and identified the mechanism of activation (van Wilgenburg 
et al., 2016).  
Here, the role of MAIT cells during DENV infection was investigated and a specific 
activation of MAIT cells by DENV was demonstrated in vivo and in vitro. MAIT cells became 
activated via cytokines, especially IL-18 and required cell contact to the infected DCs. The 
required interaction could not be identified in this thesis. However, it might also be that 
activation is not driven by a direct receptor-ligand interaction but rather via the formation of 
functional synapses between DCs and MAIT cells, as has been suggested for NK cell 
activation (Borg et al., 2004, Semino et al., 2005). In addition, Kurioka et al. demonstrated 
immunological synapses formation between CD161++CD8+ T cells, which are the majority 
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of MAIT cells, and infected target cells (Kurioka et al., 2014). Thus, it might be possible that 
functional synapses are required for MAIT cell activation in response to DENV infected DCs 
in vitro. As synapse formation depends on cytoskeleton remodelling and lipid raft 
mobilisation, disruption of these processes using pharmacologic agents might be used to 
address this hypothesis. In addition, temporal and spatial redistribution of IL-12 and/or IL-
18 in DCs might be observed under confocal microscopy during the interaction of DCs with 
MAIT cells. 
 
The data presented for MAIT cells are correlative – however probing a non-redundant role 
in animal models is not straightforward. Humans and mosquitoes are the only natural hosts 
that support DENV infection, which makes working with an animal model more challenging. 
Although no perfect DENV animal model exists yet, the use of mouse-brain adapted DENV 
strains, immunocompromised mice and mouse human-chimeras have helped to better 
understand dengue pathogenesis (Guabiraba and Ryffel, 2013). However, due to the fact 
that mice are not natural hosts for DENV, findings should be interpreted with caution. 
Furthermore, the MAIT cell population in mice is a very small minority compared to the 
frequencies of iNKT cells, which in humans is reversed with MAIT cell frequencies 1-2 logs 
higher than that of iNKT cells (Billerbeck et al., 2010). MAIT and iNKT cells have 
overlapping functions and innate cytokine responsiveness (Reilly et al., 2010). 
Interestingly, the role of iNKT cells during experimental DENV infection in mice has been 
addressed and showed a critical role for iNKT cells in the pathogenesis of severe dengue 
(Renneson et al., 2011): given similar molecular mechanisms of activation apply, and 
similar effector functions are induced, it seems reasonable to extrapolate from this that 
MAIT cell activity could play a parallel role in human infection. Emerging models with 
increased MAIT cell frequencies in mice or other animal models may help address this 
question (Cui et al., 2015).  
 
Investigating MAIT cell activation in vivo revealed a marked increase in CD38 expression 
during the acute phase of infection which was more pronounced in patients with severe 
dengue. In addition using an in vitro co-culture model, a positive correlation between MAIT 
cell activation and IFN-γ expression was observed. Thus, MAIT cells in patients developing 
severe dengue might secrete more IFN-γ and other cytokines which may contribute to the 
excessive cytokine production in those patients. The cytokine storm occurs early on in the 
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disease and has been nominated to play a central role in the mechanistic process of 
vascular permeability (Appanna et al., 2012). Which cell types are responsible for 
promoting this cytokine storm is still not fully understood. The fact that MAIT cells are very 
abundant in humans and differences in activation were observed during the very early 
instant after infection, in contrast to CD8 and CD161++ T cells, makes them potentially a 
crucial player in promoting immunopathogenesis in DENV infected patients.  
 
Upon activation via DENV infected DCs, MAIT cells predominantly secret IFN-γ in vitro. 
Whether the same pattern of cytokine production applies in vivo during acute DENV 
infection should be investigated in the future. The role of IFN-γ during DENV infection is 
controversial with some studies showing that IFN-γ levels were higher in severe dengue 
and some showing that it was lower  (Bozza et al., 2008, Priyadarshini et al., 2010, 
Chakravarti and Kumaria, 2006). This discrepancy is probably due to the timing of sample 
collection during the acute phase of infection. However, time course studies show that IFN-
γ level peaks at an early time point and this increased level was observed in patients with 
severe dengue having plasma leakage (Libraty et al., 2002). 
Interestingly, Sittisombut et al. and Kontny et al. showed that IFN-γ increases ADE 
dependent DENV infection of Fc-bearing cells by increasing FcγR expression on the cell 
surface of target cells (Kontny et al., 1988, Sittisombut et al., 1995). A similar phenomenon 
was observed in this study using activated MAIT cells with a monocytic cell line, U937 cells. 
Finally, it has been shown previously that IFN-γ enhances activation and maturation as well 
as amplify the production of cytokines (IL-12 and IL-18) and IFN-γ inducible chemokines 
(CXCL9/10/11) in DENV infected DCs (Dejnirattisai et al., 2008, Libraty et al., 2001, 
Vankayalapati et al., 2001). CXCL10 recruits CXCR3 expressing cells, including activated 
and memory T cells as well as MAIT cells, and levels of CXCL10 in DENV infected patients 
have been associated with disease severity (Dejnirattisai et al., 2008, Meierovics et al., 
2013). Additionally, levels of CXCL10 followed the same time course as that of the 
activation markers, CD38 and PD-1, on MAIT cells. Thus, early activation of MAIT cells 
may drive viral infection as well as maturation and cytokine production of DENV infected 
DCs, recruiting activated T cells and MAIT cells to the site of infection and further stoking 
a bonfire of T cell activation and cytokine production. Combining previous reports with our 
in vivo and in vitro data suggests that early activation of MAIT cells might influence the 
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subsequent immune response and play a pathogenic role, depending on the magnitude of 
MAIT cell activation, during DENV infection. 
However, using an in vitro co-culture model of primary human cells and activated MAIT 
cells demonstrated suppression of DENV infection and production via IFN-γ. This indicates 
that MAIT cells may also have an anti-viral impact on DENV infection. Whether the same 
effect can be observed in vivo or in a more complex experimental setting is still unclear and 
should be further investigated. An anti-viral and protective effect of IFN-γ during DENV 
infection has been demonstrated in mice (Fagundes et al., 2011, Shresta et al., 2004). 
Fagundes et al. showed that early IFN-γ production, mainly secreted by NKT and NK cells, 
was induced by IL-12 and IL-18. Furthermore, blockade of IL-18 resulted in a complete 
inhibition of IFN-γ, greater DENV replication and enhanced disease manifestation, 
resembling the response seen in infected IFN-γ−/− mice (Fagundes et al., 2011). However, 
it is important to keep in mind that IFN-γ alone does not determine the outcome of the 
disease as demonstrated in DENV infected Jα18-/- mice, which lack iNKT cells (Renneson 
et al., 2011). Those mice were resistant to severe DENV infection even though IFN-γ levels 
were severely reduced in tissues and plasma compared to wild-type mice.  
At this stage no final conclusion can be made on the role of MAIT cells during DENV 
infection. The data suggest that MAIT cells might potentially have a ‘yin yang’ effect on 
dengue infection. The outcome of the disease is most likely determined by a balance of 
multiple factors, of which MAIT cells might contribute either way depending on 
environmental conditions as well as the magnitude of MAIT cell activation and frequency.  
 
It has been shown that aside from secreting pro-inflammatory cytokines MAIT cells also kill 
bacterially infected cells in a MR1-dependent manner (Le Bourhis et al., 2013, Kurioka et 
al., 2014). In this study, an increase in granzyme B and perforin expression in MAIT cells 
was observed in vivo during the acute phase of infection. Furthermore, MAIT cells 
upregulated CD107a expression upon co-culture with DENV infected DCs in vitro. This 
raised the question as to whether MAIT cells might be able to kill DENV infected cells and 
thereby may influence disease outcome in another way. This possibility was quickly 
investigated using various cytotoxic assays such as lactate dehydrogenase (LDH), 
fluorometric assessment of T lymphocyte antigen specific lysis (FATAL) (Sheehy et al., 
2001, Kurioka et al., 2014) and DELFIA® EuDTA (Tsai et al., 2015). The cytotoxic potential 
of MAIT cells was assessed using DENV infected or mock treated DCs as target cells and 
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either allogeneic sorted MAIT cells or in the case of FATAL autologous CD8 T cells as 
effector cells. Effector cells were either stimulated overnight with IL-12 and IL-18 or left 
unstimulated. In all three assays, the strongest killing was observed against mock treated 
DCs rather than DENV infected DCs (data not shown). The reason for this is not clear and 
it might have resulted from faults in experimental procedures. Further experiments should 
be performed to clarify this point. In future experiments, freshly sorted autologous MAIT 
cells will be used as effector cells and DCs as well as other cells will be used as target 
cells.  
 
Over 80% of severe dengue cases occur during secondary infections with a different DENV 
serotype than that which caused a given primary infection (Kouri et al., 1989). One 
proposed pathogenic mechanism contributing to disease severity during a secondary 
infection is ADE. As MAIT cells were more activated in patients suffering from severe 
dengue, the effect of ADE on MAIT cell activation was investigated. Interestingly, cells 
which were permissive for ADE, monocytes and macrophages, did not activate MAIT cells 
in vitro. The reason for this is not clear. It might result from low infection rates in monocytes 
and macrophages or missing factors in the in vitro experimental setting. Further 
experiments should be performed to investigate it. Furthermore, FcR ligation has been 
shown to modulate patterns of cytokine production in macrophages, with complete 
abrogation of IL-12 transcription after FcγR ligation (Grazia Cappiello et al., 2001, 
Sutterwala et al., 1997). IL-12 is required for MAIT cell activation (Ussher et al., 2013, van 
Wilgenburg et al., 2016), thus FcR ligation might impede MAIT activation due to a lack of 
IL-12. In addition, Germain et al. showed induction of LLT1 expression on NK cells upon 
FcγR crosslinking (Germain et al., 2011). LLT1 is a ligand for the highly expressed C type 
lectin CD161 on MAIT cells and previous studies have demonstrated an inhibitory effect on 
MAIT cells upon interaction (Le Bourhis et al., 2013). Whether upregulation of LLT1 can 
also be observed on monocytes and/or macrophages upon FcR ligation has to be 
investigated. 
 
In this study, a crosstalk between DCs and MAIT cells has been demonstrated. The 
question remains where this interaction could occur in vivo. MAIT cells have been recently 
found in the dermis and epidermis of healthy skin (Li et al., 2016, Teunissen et al., 2014). 
Following the bite of a DENV infective mosquito, myeloid DCs which are localised in the 
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epidermis and dermis are immediately encountered by DENV and become the primary 
targets for the virus (Wu et al., 2000). Furthermore, the recruitment of monocytes to the 
site of infection and their subsequent differentiation to DCs increases the targets for DENV 
infection in the dermis (Schmid and Harris, 2014). Also, secretion of CXCL10 by DENV 
infected DCs may recruit more MAIT cells from the peripheral blood to the infected site. 
Thus, skin MAIT cells may be part of the first line of immune response against DENV.   
Alternatively, the DC/MAIT cell cross talk could occur in inflamed and infected tissues, such 
as the liver. The involvement of the liver in DENV infection has been well document and 
elevated liver enzyme levels, indicating liver damage, have been detected in most DENV 
infected patients (Samanta and Sharma, 2015). In addition, the presence of DENV in the 
liver has been confirmed in vitro as well as in biopsies and autopsies of fatal cases (Huerre 
et al., 2001, Thongtan et al., 2004). The repertoire of chemokine receptors expressed on 
circulating blood MAIT cells (CCR6 and CXCR6) suggests that they efficiently home to the 
liver and previous reports showed that MAIT cells represent up to 45% of liver T cells (Tang 
et al., 2013). Whether liver DCs become infected with DENV needs to be further 
investigated but it is possible that MAIT cells and DCs interact in the hepatic sinusoid, 
leading to liver MAIT cell activation and promoting inflammation, as has been suggested 
for patients with severe sero-negative acute liver failure (Toubal and Lehuen, 2016, Jeffery 
et al., 2016).   
 
VI.3 The Effect of Host Genetic Variants on DENV Infection 
 
Viral load in DENV infected patients is a critical factor related to disease severity as patients 
with severe dengue have viral loads that are 1-2 logs higher than patients with DF (Vaughn 
et al., 2000). However, factors contributing to this enhancement are still not fully 
understood. Therefore, identifying host factors which influence the susceptibility of target 
cells to DENV infection are crucial to better understand dengue pathogenesis. Using a 
systems genetics approach, primary human DCs and macrophages were used to identify 
new host genomic risk factors for ADE independent or dependent infection. Infection rates 
of DENV infected cells were treated as a continuous trait and a QTT analysis was 
performed to investigate whether inter-individual variation of gene transcripts at baseline 
correlated with variation in infection rates. In total 398 and 44 QTTs showed a significant 
correlation with the inter-individual variation of infection rates in DCs and macrophages, 
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respectively. Interestingly, some of these genes have already been reported to influence 
viral infection and/or replication. Furthermore, in the case of DCs two distinct protein-
protein networks were observed based on the 398 QTTs. All in all this suggests that results 
obtained in this study are truly positive and biologically relevant. Thus, using a systems 
genetics approach a list of genes was obtained which might result in the discovery of 
unknown host genomic risk factors to DENV susceptibility.  
 
This study is the first attempt to investigate genetic variants which influence the 
susceptibility of target cells to DENV infection on the whole transcriptome. However, to 
identify new host genomic risk factors for DENV infection more experiments should be 
performed.  
First, QTTs which have been reported to influence viral replication or infection in other viral 
diseases as well as genes encoding surface receptors should be further investigated using 
RNA interference. To do so, primary human DCs and macrophages will be transfected with 
gene-specific siRNA using either transient transfection (e.g. DharmaFECT) or 
electroporation before DENV infection. Infection rates in each condition will be compared 
to cells transfected with non-targeting siRNA.  
Next, genomic DNA from each donor should be genotyped to identify the genetic basis of 
differentially expressed gene transcripts in individuals. RNA and DNA sequencing data will 
be used to link transcript abundance from selected QTTs to genotype, to discover new 
SNPs and to map expression quantitative trait loci (eQTL) using Bayesian variable 
selection approaches. However to do so, the number of individuals should be increased 
(n>50) to detect correlations between genotype and expression level of gene transcripts.  
Furthermore, cytokine levels in supernatants of DENV infected DCs and macrophages 
should be investigated. Previous studies reported an influence of host genetic 
polymorphisms on cytokine productions in primary human cells as well as a link between 
viral infection and cytokine secretion (Boonnak et al., 2011, Westendorp et al., 1997, Chen 
and Wang, 2002). In addition expression levels of the gene transcript NLRP3 showed a 
strong positive correlation with the infection rate in macrophages, which might indicate an 
enhanced inflammasome activation leading to increase IL-18 and IL-1β secretion. Due to 
the fact that enhanced cytokine levels and viral load are important factors influencing 
dengue pathogenesis, investigating cytokine levels in this experimental setting would 
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provide us with useful information about the complex interplay between host genetics, 
cytokine production and viral infection.   
Finally, DENV production should also be measured in addition to infection rates in DCs and 
macrophages. So far in this study, QTTs were selected based on their correlation with 
infection rates, which were measured by flow cytometry using an anti-NS3 antibody. 
However, measuring viral production in the supernatant of DENV infected DCs and 
macrophages would be of interest as infection rates and production might not always 
correlate (unpublished data from our group). Furthermore, to assess whether viral 
production is genetically determined, multiple measurements should first be performed on 
the same donors over the course of one year.  
 
VI.4 Conclusions 
 
The pathogenesis of DENV infection is multifactorial, involving the complex interplay 
between host genetic and viral factors as well as the immune response against DENV. In 
this thesis, the influence of host genetics and MAIT cells on DENV infection was 
investigated.  
For the first time, activation of MAIT cells during DENV infection has been demonstrated in 
an IL-12 and IL-18 dependent manner. Furthermore, activation of MAIT cells and levels of 
IL-18 in DENV infected patients correlated with disease severity, suggesting a pathogenic 
role of MAIT cells during DENV infection.   
Next, a first attempt was conducted to identify new host genomic risk factors which 
influence the susceptibility of immune cells to DENV infection. Using a systems genetics 
approach, a list of QTTs which correlated with infection rates of two primary target cells - 
DCs and macrophages - was determined. The fact that some genes have been previously 
reported to influence viral replication and/or infection confirms the validity and the 
biologically relevance of this list. However, more experiments would have to be performed 
to discover new innate immune regulators for DENV infection.  
These results help broaden our knowledge on dengue pathogenesis and provide new 
information on host genetic factors and immune cells influencing DENV infection. This may 
prove helpful in the development of new therapeutic agents as well as predictive indicators 
for disease severity.   
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VI.5 Future Directions 
 
In this thesis, the mechanism of MAIT cell activation was investigated. This activation was 
driven by cytokines but also required cell contact or proximity. The required interaction 
could not be identified. Further work should be performed to investigate other receptor 
ligand interactions such as CD161-LLT1 or CD26-caveolin. However, it might also be 
possible that functional synapses are required for MAIT cell activation in response to DENV 
infected DCs in vitro. As synapse formation depends on cytoskeleton remodelling and lipid 
raft mobilisation, disruption of these processes using pharmacologic agents might be used 
to address this hypothesis. Furthermore, temporal and spatial redistribution of IL-12 and/or 
IL-18 in DCs might be observed under confocal microscopy during the interaction of DCs 
with MAIT cells. 
In addition to producing large amounts of cytokines, MAIT cells have also a cytotoxic 
potential. Upon co-culture with DENV infected DCs, an increase in granzyme B/perforin 
and degranulation was observed. However, whether MAIT cells are able to kill DENV 
infected DCs was not investigated. This possibility should be further analysed using freshly 
sorted autologous MAIT cells and DENV infected or mock treated DCs. 
Due to the recent outbreak of another flavivirus in South and Central America, the role of 
MAIT cells during Zika virus infection should also be investigated. Interestingly, a recent 
study demonstrated the presence of MAIT cells in the female genital mucosa (Gibbs et al., 
2016).  
 
A first attempt was conducted to identify new host genomic risk factors which influence the 
susceptibility of immune cells to DENV infection. However, the reproducibility of the RNA-
seq dataset should be validated in an independent experiment.  
In addition to measuring infection rates in target cells, viral production in the supernatant 
of DENV infected DCs and macrophages should also be analysed. Comparing QTTs 
correlating with infection rates or viral load will give us additional information. Furthermore, 
to assess whether viral production is genetically determined, multiple measurements 
should be performed on the same donors over the course of one year.  
Last, the effect of selected host genes on viral infection or production should be 
investigated in more detail using RNA interference.   
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Chapter VIII 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1 Summary of DENV-infected patients enrolled in the study. 
Clinical characteristics of 20 DENV infected patients suffering from dengue fever (DF) or 
dengue haemorrhagic fever (DHF1-4). DHF is divided into four grades according to the 
disease severity: patients with DHF1 and 2 having increased vascular permeability and 
patients with DHF3 and 4 developing shock due to severe plasma loss. Blood samples 
were obtained from these individuals at several time points during the acute and 
convalescent phase of infection. Laboratory confirmation of DENV infection and the 
serotype (DENV1-4) were determined by RT-PCR detection of DENV nucleic acid. 
Abbreviations: DENV, dengue virus; DHF, dengue haemorrhagic fever; DF, dengue fever. 
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Supplementary Table 2 Summary of plasma samples from DENV infected patients 
enrolled in the study. Clinical characteristics of 24 DENV infected patients suffering from 
dengue fever (DF) or dengue haemorrhagic fever (DHF1-4). DHF is divided into four grades 
according to the disease severity: patients with DHF1 and 2 having increased vascular 
permeability and patients with DHF3 and 4 developing shock due to severe plasma loss. 
Plasma samples were obtained from these individuals at several time points during the 
acute and convalescent phase of infection. Laboratory confirmation of DENV infection and 
the serotype (DENV1-4) were determined by RT-PCR detection of DENV nucleic acid. 
Abbreviations: DENV, dengue virus; DHF, dengue haemorrhagic fever; DF, dengue fever. 
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Supplementary Table 3 List of all QTTs at baseline 
which significantly correlate with the infection rate in 
DENV infected DCs. RNA transcripts at baseline were 
analysed in DCs (n=10) using RNA-seq. Infection rates 
of DENV infected DCs were measured by intracellular 
staining of the DENV non-structural protein NS3 using 
flow cytometry. Infection rates were treated as a 
continuous trait and correlation between expression 
levels of gene transcripts and the continuous trait were 
analysed by Pearson’s correlation. A total of 398 QTTs 
were identified with a p value<0.01. 
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Supplementary Table 4 List of all QTTs at 
baseline which significantly correlate with 
the infection rate in DENV infected 
macrophages in the presence of 
antibodies. Expression levels of RNA 
transcripts at baseline were analysed in 
macrophages (n=13) using RNA-seq. 
Infection rates of DENV infected macrophages 
in presence of antibodies were measured by 
intracellular staining of the DENV non-
structural protein NS3 using flow cytometry. 
Infection rates were treated as a continuous 
trait and correlation between expression levels 
of gene transcripts and the continuous trait 
were analysed by Pearson’s correlation. A 
total of 44 QTTs were identified with a p 
value<0.01. 
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Supplementary Figure 1 Expression levels of CD38 and PD-1 on MAIT cells during 
acute DENV infection in vivo. PBMC’s from healthy controls (n=5-10), patients suffering 
from severe dengue (DHF, n=2-10), dengue (DF, n=4-10) were analysed by flow cytometry. 
(a, c) Comparison between acute (day 0) and convalescent (day>10) phase of infection. 
(b, d) Comparison between DHF and DF patients. (a, b) Expression level of CD38 on MAIT 
cells. (c, d) Expression level of PD-1 on MAIT cells. Statistical significance was determined 
with a Kruskal-Wallis test followed by Dunns’ test and a Wilcoxon signed-ranks test 
between matched samples of the acute and conv phase (a, c). A Mann-Whitney test was 
applied to compare DHF and DF samples (b, d). Bars represent means. ns > 0.05, *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Abbreviations: HC, healthy controls; conv, 
convalescent; DENV, Dengue Virus; DF, dengue fever; DHF, dengue haemorrhagic fever. 
 
 
 
 
 
 
185 | P a g e  
 
 
Supplementary Figure 2 CD8 T cells activation during acute DENV infection in vivo. 
PBMC’s from healthy controls (n=5-10), patients suffering from severe dengue (DHF, n=2-
10), dengue (DF, n=4-10) were analysed by flow cytometry. (a, c, e) Comparison between 
acute (day 0) and convalescent (day>10) phase of infection. (b, d, f) Comparison between 
DHF and DF patients. (a-b) Percentage of CD38 expression by CD8 T cells. (c-d) 
Percentage of Granzyme B expression in CD8 T cells. (e-f) Percentage of Perforin 
expression in CD8 T cells. Statistical significance was determined with a Kruskal-Wallis 
test followed by Dunns’ test and a Wilcoxon signed-ranks test between matched samples 
of the acute and conv phase (a, c, e). Bars represent means. ns > 0.05, *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Abbreviations: HC, healthy controls; conv, convalescent; 
DENV, Dengue Virus; DF, dengue fever; DHF, dengue haemorrhagic fever; GrB, 
Granzyme B. 
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Supplementary Figure 3 Degranulation and PD-1 expression on MAIT cells upon co-
culture with DENV infected DCs in vitro. MAIT cells from healthy individuals were 
analysed by flow cytometry, gated on live CD3+CD161++Vα7.2+ cells. PBMCs were co-
cultured for 24 hours with DENV infected or mock treated autologous monocyte derived 
DCs. (a, b) Proportion of MAIT cells expressing PD-1 (n=3). As a negative control, MAIT 
cells were stained with the corresponding isotype control (b) Representative flow cytometry 
plots. (c, d) Proportion of MAIT cells (n=3) degranulating, as judged by CD107a expression. 
(d) Representative flow cytometry plots. All data are representative from at least two 
independent experiments. Bars represent means ± s.e.m. (b, d) Statistical significance was 
determined with a Mann-Whitney test. ns > 0.05. Abbreviations: DENV, Dengue Virus. 
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Supplementary Figure 4 IL-18 levels in supernatants of DENV infected DC, M1, M2, 
monocytes and HepG2 cells. IL-18 levels were measured using an IL-18 ELISA and 
supernatants were harvested after 42 hours infection. M1 (n=3) and M2 (n=3) were infected 
with DENV at an MOI of 1 FFU/cell in presence and absence of antibodies. DCs (n=4) and 
HepG2 cells (n=4) were infected at an MOI of 1 FFU/cell in absence of antibodies. 
Monocytes (n=3) were infected with DENV at an MOI of 5 FFU/cell in presence and 
absence of antibodies. (a) Standard curve of IL-18. (b) Level of IL-18 in supernatants of 
DENV or mock treated cells. Bars represent means ± s.e.m. (b) Statistical significance was 
determined with a Mann-Whitney test. ns > 0.05, *P ≤ 0.05. Abbreviations: ND, not 
determined; DENV, Dengue Virus; Ab, antibody; CD14, monocytes; M1, M1 like 
macrophage; M2, M2 like macrophage; DC, dendritic cell. 
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Supplementary Figure 5 Recombinant human IFN-γ mimics the effect of activated 
MAIT cells on DENV infection. Representative flow cytometry plots of diluted recombinant 
human IFN-γ, 103 to 0’1 U/ml with U937 cells, monocytes or DCs following DENV infection. 
Infection rate of target cells, gated on live CD3-CD14+ cells, were measured by flow 
cytometry 24 hours post infection using intracellular staining of the DENV non-structural 
protein NS3. Gates for NS3 were set according to the negative control: cells treated with 
mock in presence of recombinant human IFN-γ (data not shown).   
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Supplementary Figure 6 Activated MAIT cells influence DENV infection via IFN-γ. 
Representative flow cytometry plots of rested (MAIT-) or stimulated (MAIT+) MAIT cells co-
cultured with U937 cells, monocytes or DCs following DENV infection in presence of an 
isotype control or anti-IFN-γ (αIFN-γ). Infection rate of target cells, gated on live CD3-CD14+ 
cells, were measured by flow cytometry 24 hours post infection using intracellular staining 
of the DENV non-structural protein NS3.  
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Supplementary Figure 7 No lane effect during RNA sequencing. (in collaboration with 
Dr. Marta Imprialou & Dr. Jacques Behmoaras) RNA-seq of DCs and macrophages derived 
from 13 healthy individuals were pooled together (6 donors/lane) and a total of 4 lanes were 
sequenced. Lane effects were investigated using principal component analysis. The 
principal components are orthogonal linear combinations of the 10238-dimensional gene 
expression profiles across the 24 samples (13 macrophages and 11 DCs). Clusters of gene 
expression profiles derived from each donor and cell type were analysed relative to lanes. 
Each point represents one sample and each colour represents a different lane. As all 
principal components clearly show, no lane effect can be observed as samples do not 
cluster by colour. Abbreviations: PC, principal component; RNA-seq, RNA sequencing.  
 
191 | P a g e  
 
 
Supplementary Figure 8 No technical covariates: mappability does not correlate with 
principal components. (in collaboration with Dr. Marta Imprialou & Dr. Jacques 
Behmoaras) RNA-seq of DCs (red, n=11) and macrophages (blue, n=13) derived from 
healthy individuals. Gene expression profiles of all 24 samples were plotted against 
principal components and the percentage of mapped reads for each donor. There is no 
correlation between high mappability and gene expression profiles in DCs and 
macrophages. Abbreviations: PC, principal component; RNA-seq, RNA sequencing.  
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Supplementary Figure 9 No technical covariates: percentage of properly paired 
reads does not correlate with principal components. (in collaboration with Dr. Marta 
Imprialou & Dr. Jacques Behmoaras) RNA-seq of DCs (red, n=11) and macrophages (blue, 
n=13) derived from healthy individuals. Gene expression profiles of all 24 samples were 
plotted against principal components and the percentage of properly paired reads in each 
donor. There is no correlation between the percentage of properly paired reads and gene 
expression profiles in DCs and macrophages. Abbreviations: PC, principal component; 
RNA-seq, RNA sequencing.  
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Supplementary Figure 10 Association between CD209, GAB1, PPARα and EWSR1 
mRNA expression levels and infection rates in primary human DCs. RNA transcripts 
were analysed in DCs (n=10-11) before and after DENV infection using RNA-seq. At the 
same time, infection rates were measured by intracellular staining of the DENV non-
structural protein NS3 using flow cytometry. Infection rates were treated as a continuous 
trait and correlation between expression levels of gene transcripts and the continuous trait 
were analysed by Pearson’s correlation. Each donor represents one data point. 
Abbreviations: DENV, dengue virus; CD209, Dendritic Cell-Specific ICAM-3-Grabbing Non-
Integrin 1; GAB1, GRB2 Associated Binding Protein 1; PPARα, Peroxisome Proliferator 
Activated Receptor; EWSR1, EWS RNA Binding Protein 1. 
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Supplementary Figure 11 Interaction network of all 398 QTTs in DCs using STRING 
9.1. RNA transcripts at baseline were analysed in DCs (n=10) using RNA-seq. Infection 
rates of DENV infected DCs were treated as a continuous trait and correlation between 
expression levels of gene transcripts and the continuous trait were analysed by Pearson’s 
correlation. A total of 398 QTTs were identified with a p value<0.01. 
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Supplementary Figure 12 Association between CHD3, ISCU and DNAJC18 mRNA 
expression levels and infection rates in primary human macrophages. RNA 
transcripts were analysed in macrophages (n=12-13) before and after DENV infection using 
RNA-seq. At the same time, infection rates were measured by intracellular staining of the 
DENV non-structural protein NS3 using flow cytometry. Infection rates were treated as a 
continuous trait and correlation between expression levels of gene transcripts and the 
continuous trait were analysed by Pearson’s correlation. Each donor represents one data 
point. Abbreviations: DENV, dengue virus; CHD3, chromodomain helicase DNA binding 
protein 3; ISCU, iron-sulfur cluster assembly enzyme; DNAJC18, DnaJ heat shock protein 
family (Hsp40) member C18.  
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Supplementary Figure 13 Interaction network of all 44 QTTs in macrophages using 
STRING 9.1. RNA transcripts at baseline were analysed in macrophages (n=12) using 
RNA-seq. Infection rates of DENV infected macrophages in presence of antibodies were 
treated as a continuous trait and correlation between expression levels of gene transcripts 
and the continuous trait were analysed by Pearson’s correlation. A total of 44 QTTs were 
identified with a p value<0.01. 
 
